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Background: Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided
prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy.
Multiparametric magnetic resonance imaging (mpMRI) used as a triage test might allow men to avoid
unnecessary TRUS-guided biopsy and improve diagnostic accuracy.
Objectives: To (1) assess the ability of mpMRI to identify men who can safely avoid unnecessary biopsy,
(2) assess the ability of the mpMRI-based pathway to improve the rate of detection of clinically significant
(CS) cancer compared with TRUS-guided biopsy and (3) estimate the cost-effectiveness of a mpMRI-based
diagnostic pathway.
Design: A validating paired-cohort study and an economic evaluation using a decision-analytic model.
Setting: Eleven NHS hospitals in England.
Participants: Men at risk of prostate cancer undergoing a first prostate biopsy.
Interventions: Participants underwent three tests: (1) mpMRI (the index test), (2) TRUS-guided biopsy
(the current standard) and (3) template prostate mapping (TPM) biopsy (the reference test).
Main outcome measures: Diagnostic accuracy of mpMRI, TRUS-guided biopsy and TPM-biopsy measured
by sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) using primary
and secondary definitions of CS cancer. The percentage of negative magnetic resonance imaging (MRI)
scans was used to identify men who might be able to avoid biopsy.
Results: Diagnostic study – a total of 740 men were registered and 576 underwent all three tests.
According to TPM-biopsy, the prevalence of any cancer was 71% [95% confidence interval (CI) 67% to
75%]. The prevalence of CS cancer according to the primary definition (a Gleason score of ≥ 4 + 3 and/or
cancer core length of ≥ 6 mm) was 40% (95% CI 36% to 44%). For CS cancer, TRUS-guided biopsy
showed a sensitivity of 48% (95% CI 42% to 55%), specificity of 96% (95% CI 94% to 98%), PPV of
90% (95% CI 83% to 94%) and NPV of 74% (95% CI 69% to 78%). The sensitivity of mpMRI was 93%
(95% CI 88% to 96%), specificity was 41% (95% CI 36% to 46%), PPV was 51% (95% CI 46% to 56%)
and NPV was 89% (95% CI 83% to 94%). A negative mpMRI scan was recorded for 158 men (27%). Of
these, 17 were found to have CS cancer on TPM-biopsy. Economic evaluation – the most cost-effective
strategy involved testing all men with mpMRI, followed by MRI-guided TRUS-guided biopsy in those patients
with suspected CS cancer, followed by rebiopsy if CS cancer was not detected. This strategy is cost-effective
at the TRUS-guided biopsy definition 2 (any Gleason pattern of ≥ 4 and/or cancer core length of ≥ 4 mm),
mpMRI definition 2 (lesion volume of ≥ 0.2 ml and/or Gleason score of ≥ 3 + 4) and cut-off point 2
(likely to be benign) and detects 95% (95% CI 92% to 98%) of CS cancers. The main drivers of cost-
effectiveness were the unit costs of tests, the improvement in sensitivity of MRI-guided TRUS-guided biopsy
compared with blind TRUS-guided biopsy and the longer-term costs and outcomes of men with cancer.
Limitations: The PROstate Magnetic resonance Imaging Study (PROMIS) was carried out in a selected
group and excluded men with a prostate volume of > 100 ml, who are less likely to have cancer. The
limitations in the economic modelling arise from the limited evidence on the long-term outcomes of men
with prostate cancer and on the sensitivity of MRI-targeted repeat biopsy.
Conclusions: Incorporating mpMRI into the diagnostic pathway as an initial test prior to prostate biopsy
may (1) reduce the proportion of men having unnecessary biopsies, (2) improve the detection of CS prostate
cancer and (3) increase the cost-effectiveness of the prostate cancer diagnostic and therapeutic pathway.
The PROMIS data set will be used for future research; this is likely to include modelling prognostic factors
for CS cancer, optimising MRI scan sequencing and biomarker or translational research analyses using the
blood and urine samples collected. Better-quality evidence on long-term outcomes in prostate cancer under
the various management strategies is required to better assess cost-effectiveness. The value-of-information
analysis should be developed further to assess new research to commission.
Trial registration: Current Controlled Trials ISRCTN16082556 and NCT01292291.
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Plain English summary
The only way to tell whether or not a man has prostate cancer is to examine samples of the prostateunder a microscope. These are normally obtained using needles inserted via the rectum, guided by
ultrasound imaging. This is called transrectal ultrasound (TRUS)-guided biopsy. However, the ultrasound
locates only the prostate and cannot show the cancer, so the needles may miss the cancer.
Transrectal ultrasound-guided biopsy may detect small, slow-growing cancers that would never develop far
enough to cause problems. Detecting and treating these has no benefit and exposes men to unnecessary pain
and side effects caused by TRUS-guided biopsy. It also creates unnecessary expense for the health service.
This study aimed to find out whether or not a magnetic resonance imaging (MRI) scan can show which
men need a TRUS-guided biopsy and which do not. It also assessed whether or not using MRI would
improve the detection of cancers that need treatment. Participants volunteered to undergo an extra
procedure that takes samples from right across the prostate, as a reference to assess the accuracy of
TRUS-guided biopsy and MRI.
We found that using a MRI scan to decide whether or not a biopsy is needed reduces the number of men
who have unnecessary biopsies. It may also improve the detection of cancers that need treatment so that
fewer are missed. Economic modelling showed that using MRI to decide who should have a TRUS-guided
biopsy and to guide the biopsy would be a cost-effective use of NHS resources, providing certain
conditions were fulfilled.
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Scientific summary
Background
Increasing numbers of men are being referred for prostate biopsy with suspected prostate cancer in the
UK, mainly as a result of the increased use of serum prostate-specific antigen (PSA) testing in healthy men.
Many of the cancers currently diagnosed are clinically non-significant (CNS) (i.e. are unlikely to have any
clinical impact on the individual during his remaining life). If left unchecked, the existing diagnostic
pathway will result in a further rise in the number of CNS cases identified and in the associated costs and
harms of treatment, without necessarily reducing the risk of dying from the disease.
The standard diagnostic procedure is transrectal ultrasound (TRUS)-guided biopsy. Unlike procedures in
other solid cancers, this technique is ‘blind’ to the location of the suspect lesion, because ultrasonography
serves only to locate the prostate and cannot differentiate between cancerous and non-cancerous tissue.
The unguided placement of the needles means that CNS cancers may be detected and clinically significant
(CS) cancers may be missed.
A diagnostic method more specific to CS prostate cancer could reduce the unnecessary harms and costs
associated with overdiagnosis and overtreatment of CNS cancers.
Objectives
The purpose of the PROstate Magnetic resonance Imaging Study (PROMIS) was to trial the use of
multiparametric magnetic resonance imaging (mpMRI) in the diagnosis of prostate cancer. The main
objectives were to:
l assess the ability of mpMRI to identify men who can safely avoid unnecessary biopsy
l assess the ability of a diagnostic pathway incorporating mpMRI to improve detection of CS cancer
compared with TRUS-guided biopsy
l use economic modelling to identify the most efficient and cost-effective diagnostic strategy in men with
suspected localised prostate cancer from the perspective of the UK NHS.
Methods
Diagnostic study
PROMIS was a validating paired-cohort study in men at risk of prostate cancer undergoing a first prostate
biopsy, conducted at 11 NHS hospitals in England. To compare the diagnostic accuracy of mpMRI (the index
test) and TRUS-guided biopsy (the current standard), both were individually compared with a reference
standard: template prostate mapping (TPM) biopsy. All participants underwent all three tests (mpMRI,
TPM-biopsy and TRUS-guided biopsy). Multiparametric magnetic resonance imaging was carried out first.
TPM-biopsy followed by TRUS-guided biopsy was carried out as a combined biopsy procedure (CBP) at a
subsequent visit. The CBP was carried out for the purposes of the study only and is not proposed for use in
clinical practice. Each test was conducted blind to the results of the other tests and was reported
independently of them.
The eligible population was adult men at risk of prostate cancer who had been advised to have a prostate
biopsy and had a serum PSA level of ≤ 15 ng/ml within the previous 3 months, had a suspected stage of
≤ T2 on a rectal examination (i.e. organ confined) and were fit for general/spinal anaesthesia. Men with a
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PSA level of > 15 ng/ml were excluded as the higher prevalence of prostate cancer in this subgroup means
that mpMRI is unlikely to be used as a triage test in these men.
Multiparametric magnetic resonance imaging was carried out according to a standardised protocol in
which T1-weighted, T2-weighted, diffusion-weighted (apparent diffusion coefficient maps and long-b
scan) and dynamic gadolinium contrast-enhanced imaging was acquired using a 1.5-T scanner and a
pelvic phased array. Radiologists used a standard reporting form to derive a 1–5 score on the Likert
scoring system to indicate the suspicion level for CS cancer. TRUS-guided biopsies were taken as per
international guidelines and incorporated 10–12 core biopsies. TPM-biopsy was carried out in accordance
with a standardised protocol.
The primary definition of CS cancer in this trial used a histological target condition on TPM-biopsy that
incorporated the presence of a Gleason score of ≥ 4 + 3 and/or a cancer core length of ≥ 6 mm in any
location. This was chosen because nearly all physicians would agree that any man with this burden of
cancer would require treatment. A secondary definition was also investigated: cancer core length of
≥ 4 mm and/or a Gleason score of ≥ 3 + 4. The primary magnetic resonance imaging (MRI) outcome
measure (i.e. the threshold against which the Likert scores were given) was defined as a prostate cancer
volume of ≥ 0.2 ml and/or a Gleason score of ≥ 3 + 4. Two analyses were carried out: (1) using a Likert
score of ≥ 3 to indicate a positive MRI result (primary analysis) and (2) using a cut-off point of ≥ 4.
The primary outcome measure was the diagnostic accuracy of mpMRI, TRUS-guided biopsy and TPM-
biopsy as measured by sensitivity, specificity, positive predictive value (PPV) and negative predictive value
(NPV) using the primary definition of CS cancer. The same parameters using combinations of alternative
definitions of disease for each test were investigated as secondary outcomes. The other outcomes reported
were inter-rater agreement between tests and serious adverse events (SAEs). Information on health-related
quality of life (HRQoL) was collected using the EuroQol-5 Dimensions, three-level version questionnaire
after each test and at the final visit and was used in the economic evaluation.
The primary analysis was based on all evaluable data, excluding men without all three test results and any
data rejected by the quality control/quality assurance process. For each comparison, 2 × 2 contingency
tables were used to calculate the diagnostic accuracy estimates with 95% confidence intervals (CIs).
McNemar’s tests were used for the head-to-head comparisons of sensitivity and specificity between
mpMRI and TRUS-guided biopsy. Because the PPVs and NPVs are dependent on disease prevalence, a
generalised estimating equation logistic regression model was used to compare these values for mpMRI
and TRUS-guided biopsy against those for TPM-biopsy.
Economic evaluation
The economic analysis aimed to identify the most efficient and cost-effective diagnostic strategy in men
with suspected localised prostate cancer from the perspective of the UK NHS. It considered all feasible
combinations of TRUS-guided biopsy, mpMRI and TPM-biopsy, within the various definitions and cut-off
points for CS cancer.
The efficient diagnostic strategies were those that detected the most men with CS cancer (i.e. sensitivity)
per £1 spent on testing. The cost-effective strategies were those that achieved the most health benefits,
expressed as quality-adjusted life-years (QALYs), per £1 spent over the patients’ expected lifetime.
The cost-effective strategies were identified for the values of health opportunity cost, also known as
cost-effectiveness thresholds, typically used in the UK NHS (i.e. £13,000, £20,000 and £30,000 per QALY).
The cost-effective strategy for a given health opportunity cost is the strategy that achieves the most health
benefits net of the health displaced given its additional costs.
A new decision-analytic model was developed to combine the information generated in PROMIS with
external evidence as appropriate. For the short term, the model calculates the proportion of CS cancers
detected by each strategy and the costs and HRQoL consequences of the tests. The model assumed that
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biopsies, both TRUS-guided and TPM, detect only cancer, either CS or CNS, if cancer is present. Therefore,
the specificity of each strategy is always perfect.
For the long term, the model calculates the health outcomes and costs of men with no cancer and low-risk,
intermediate-risk and high-risk cancer, by diagnostic classification (no cancer, CNS cancer and CS cancer).
Men classified as having CS cancer were assumed to receive radical treatment [radical prostatectomy (RP)],
whereas men classified as having CNS cancer were monitored in secondary care (active surveillance) and
men classified as having no cancer were followed in primary care. Therefore, the model calculates the
health outcomes and costs of diagnosis and treatment of the men with CS cancer who were correctly
identified, as well as misdiagnosis and delayed treatment of men with CS cancer who were not identified.
Results
Diagnostic study
A total of 740 men were registered to the trial, of whom 164 subsequently withdrew before completing
all three tests. Most withdrawals took place before the combined biopsy and the most common reason for
withdrawal was the discovery of a large prostate volume (> 100 ml). A total of 576 men were included in
the final analysis.
The prevalence of any cancer as assessed by the reference test, TPM-biopsy, was 71% (95% CI 67% to
75%). The prevalence of CS cancer according to the primary definition (a Gleason score of ≥ 4 + 3 and/or
cancer core length of ≥ 6 mm) was 40% (95% CI 36% to 44%). TRUS-guided biopsy showed sensitivity
for CS cancer of 48% (95% CI 42% to 55%) and specificity of 96% (95% CI 94% to 98%). The PPV
was 90% (95% CI 83% to 94%) and the NPV was 74% (95% CI 69% to 78%). The sensitivity of mpMRI
for CS cancer was high at 93% (95% CI 88% to 96%) and the NPV was 89% (95% CI 83% to 94%).
However, its specificity was 41% (95% CI 36% to 46%), with a PPV of 51% (95% CI 46% to 56%).
A negative mpMRI scan was recorded for 158 men (27%). Of these, 17 men were found to have CS
cancer on TPM-biopsy.
We considered the implications of using mpMRI in clinical practice by comparing the current standard
strategy (TRUS-guided biopsy for all men) with two alternative strategies: (1) mpMRI would be used as a
triage test and only men with a suspicious mpMRI result (Likert score of ≥ 3) would go on to biopsy and
(2) the remainder would receive active surveillance or would be discharged. Under the worst-case scenario,
a standard TRUS-guided biopsy would be carried out but mpMRI would not be used to direct it. Under the
best-case scenario, the TRUS-guided biopsies would be guided by the mpMRI findings and it would be
assumed that targeted biopsies would achieve a similar diagnostic accuracy to that of TPM-biopsy. For both
of these scenarios, 158 out of 576 men (27%) would avoid a primary biopsy, because they would be
categorised by mpMRI as having either no cancer or CNS cancer, but 17 men in this group would have a
CS cancer missed. For the worst-case scenario, an absolute reduction in the overdiagnosis of CNS cancers
might be seen, with 28 out of 576 fewer cases (5%) [relative reduction of 31% (95% CI 22% to 42%)
compared with the current standard]. Under the best-case scenario, overdiagnosis might be increased to
21% [i.e. there would be 31 out of 576 more cases (5%)]. However, it might also lead to 102 out of 576
more cases (18%) of CS cancer being detected compared with the standard pathway of TRUS-guided
biopsy for all.
Agreement between radiologists for the detection of CS cancer according to the primary definition was
80%. This corresponded to a Cohen’s kappa statistic of 0.5, indicating moderate agreement.
There were 44 reports of SAEs during the study, including 10 cases of sepsis (of which nine occurred after
CBP, equating to a post-CBP risk of 1.5%). As emphasised earlier, CBP is not proposed for use in
clinical practice.
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Economic evaluation
Multiparametric magnetic resonance imaging, TRUS-guided biopsy and TPM-biopsy can plausibly be used
in 32 different combinations to diagnose prostate cancer. These were evaluated for different diagnostic
definitions and cut-off points, forming 383 diagnostic substrategies. Strategies using the secondary
TRUS-guided biopsy definition (definition 2) and primary mpMRI definition (definition 2) detected more
CS cancers. Of the 383 substrategies, 14 were efficient in that they detected the most CS cancers per
£1 spent. Of these, four substrategies detected ≥ 80% of CS cancers. These substrategies involved mpMRI,
either as the first or the second test, and up to two biopsies.
In the base case, the cost-effective strategy at the health opportunity costs of £13,000, £20,000 and
£30,000 per QALY gained involves testing all men with mpMRI using definition 2 and cut-off point 2 for
CS cancer (a less restrictive definition than used in the primary outcome of PROMIS, leading to more
men receiving a biopsy, but fewer CS cancers being missed by the initial MRI) and using MRI-targeted,
TRUS-guided biopsy and definition 2 to detect CS cancer and rebiopsying those men in whom CS cancer
was not detected. This strategy detects 95% of CS cancers (95% CI 92% to 98%), achieves 8.72
discounted QALYs (95% CI 8.40 to 9.04 discounted QALYs) and costs £5367 (95% CI £4947 to £5876).
This sequence of tests constitutes the proposed PROMIS strategy, albeit using the TRUS-guided biopsy
definition 1 and mpMRI cut-off point 3. At this definition and cut-off point, this strategy detects 82% of
CS cancers (95% CI 75% to 87%), achieves 8.65 discounted QALYs (95% CI 8.35 to 8.95 discounted
QALYs) and discounted costs of £5027 (95% CI £4609 to £5512). The standard care strategy without
mpMRI is TRUS-guided biopsy in all men and rebiopsy for those in whom CS cancer was not detected,
both using definition 1. This strategy detects 52% of CS cancers (95% CI 45% to 61%), achieves 8.49
discounted QALYs (95% CI 8.19 to 8.80 discounted QALYs) and has discounted costs of £4603 (95% CI
£4174 to £5044). The strategy recommended by the National Institute for Health and Care Excellence
involves TRUS-guided biopsy in all men. Men in whom CS cancer using definition 1 is not detected receive
mpMRI. Men with suspected CS cancer on mpMRI using definition 2 and cut-off point 3 receive a second
TRUS-guided biopsy, evaluated using definition 1. This detects 85% of CS cancers (95% CI 78% to 91%),
achieves 8.66 discounted QALYs (95% CI 8.36 to 8.97 discounted QALYs) and has discounted costs of
£5173 (95% CI £4755 to £5664).
Sensitivity analysis suggests that the main drivers of cost-effectiveness are the unit cost of each test, the
improvement in sensitivity of MRI-targeted, TRUS-guided biopsy compared with blind TRUS-guided biopsy
and the cost-effectiveness of radical treatment and active surveillance.
Conclusions
The current standard, TRUS-guided biopsy, performs poorly as a diagnostic test for CS prostate cancer. Our
findings suggest that if mpMRI were used as a triage test prior to biopsy in all men with an elevated serum
PSA level then one-quarter of men might safely avoid a biopsy, thus reducing the problem of unnecessary
biopsies in men with a low risk of harbouring CS cancer. A negative mpMRI result infers a high probability of
no CS cancer. Triage with mpMRI might also reduce the diagnosis of CNS cancers and improve the detection
of CS cancers compared with the current standard of TRUS-guided biopsy for all men with suspected localised
prostate cancer. However, the lower specificity and PPV of mpMRI demonstrates that a biopsy, with the
needles deployed based on the mpMRI findings, is still needed in those men with suspicious mpMRI findings.
The economic evaluation used the results from PROMIS alongside external evidence to ascertain the value
of using these tests in sequence to support treatment decisions (when patients diagnosed with CS
cancers would be referred for RP). It found that a strategy starting with mpMRI for all men and up to two
TRUS-guided biopsies in men with suspected CS cancer using the most sensitive definitions (definition 2
and cut-off point 2) detects the most CS cancers per £1 spent and is cost-effective. These findings are
sensitive to the costs of the tests and the assumptions made on the long-term management of men with
unidentified cancers.
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Chapter 1 Introduction
Rationale
There are approximately 40,000 new cases of prostate cancer annually in the UK. The reported incidence
has doubled in the last 15 years, mainly as a result of the increased use of serum prostate-specific antigen
(PSA) testing in healthy men. As a result, prostate cancer has become the most commonly diagnosed
cancer in men.1 Many, if not most, prostate cancers that are currently detected are clinically non-significant
(CNS) (i.e. would have no clinical impact during the man’s remaining life expectancy). Although the UK has
no formal population-based PSA screening programme, the rising numbers of cases in the UK are primarily
the result of increased awareness and incidental PSA testing. The existing diagnostic pathway will, if left
unchecked, result in a further rise in the number of CNS cases identified and in the associated costs and
harms of treatment, without necessarily reducing the risk of dying from the disease.
This position is exemplified in two large randomised controlled trials (RCTs) of population-based prostate
cancer screening using serum PSA testing compared with standard practice. First, a large RCT of prostate
cancer screening in the USA2 showed no evidence of a survival benefit when comparing an annual screening
strategy (with an approximately 85% rate of screening) with usual care, which included quite considerable rates
of PSA testing (approximately 46–52%). Second, the European Randomized Study of Screening for Prostate
Cancer3 showed a modest reduction in the risk of death from prostate cancer in men who were screened every
4 years, from 8.2% to 4.8% [risk ratio 0.8, 95% confidence interval (CI) 0.65 to 0.98] at 9 years’ follow-up.
The number of participants needed to screen was 1410 and the number needed to treat was 48 to prevent
one death from prostate cancer over a 10-year period.4 This benefit was maintained up to 13 years’ follow-up.5
Once diagnosed, the lack of benefit for radical treatment of CNS cancer compared with a strategy of
monitoring has been exemplified in three RCTs. First, the Scandinavian Prostate Cancer Group – 4 (SPCG-4)
trial6 randomised men who were clinically diagnosed (not from screening). Most of these men had clinically
significant (CS) medium- to high-risk cancers and radical prostatectomy (RP) showed a survival benefit at
long-term follow-up compared with watchful waiting (a less active form of surveillance than that used in
the modern era).6 Treatment conferred significant harms for patients.7 Second, the Prostate Cancer
Intervention versus Observation Trial (PIVOT)8 randomised men diagnosed early through PSA screening in
the USA between watchful waiting and RP and found no cancer-specific survival benefit, although subgroup
analyses showed that men with high-risk disease did survive longer with treatment and there was a possible
benefit, albeit marginal, for those with intermediate-risk cancers. Most recently, the Prostate Testing for
Cancer and Treatment (ProtecT) trial in the UK9 found that, in 1643 men with localised prostate cancer
detected as a result of PSA-based screening, there was no statistically significant difference in prostate-specific
or all-cause mortality at 10 years in men assigned to active surveillance, surgery or radiotherapy; however,
rates of disease progression and metastasis were higher with active surveillance. Commentators were
quick to voice their concern that overdiagnosis, and hence overtreatment and associated morbidity,
would increase further if PSA screening was adopted more widely.10,11 However, if a diagnostic method
was available that was more specific to clinically significant prostate cancer, the beneficial effect of screening
and subsequent treatment on mortality could be retained, but overdiagnosis and overtreatment would
be minimised.
Current clinical pathway
At present, a man is judged to be at risk of harbouring prostate cancer if he has any of the following:
a raised serum PSA level (present in the majority of cases), an abnormal digital rectal examination (DRE),
a positive family history of prostate cancer or a specific ethnic risk profile.12 The diagnostic pathway of
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1
interest to this work relates to men with signs and symptoms that are suspicious of prostate cancer
who have been referred for confirmatory diagnostic testing. In these men, prostate cancer, if present, is
typically localised. Men with signs and symptoms of locally advanced cancer or metastatic cancer are often
managed in a different manner with staging whole-body scans and the institution of systemic therapy with
or without confirmatory prostate biopsy.
Men in whom there is diagnostic uncertainty are currently advised to have a transrectal ultrasound
(TRUS)-guided prostate biopsy.13 Men with a negative TRUS-guided biopsy result are advised to consider
multiparametric magnetic resonance imaging (mpMRI) (using T2- and diffusion-weighted imaging) to
determine whether or not another biopsy is needed. Between 59,000 and 80,000 men have a TRUS-guided
biopsy in the UK each year,14 although this is likely to be an underestimate considering that three to four
TRUS-guided biopsies are usually carried out to diagnose one man with cancer.
Men diagnosed with localised prostate cancer in England are managed according to their risk of
progression (Table 1). The risk of progression is assessed on the basis of their serum PSA concentration,
Gleason score and clinical stage. PSA is a protein produced by the prostate gland; an elevated PSA
level is a sign that cancer may be present. The Gleason pattern classifies prostate cells obtained in the
TRUS-guided biopsy by level of differentiation, which is related to the degree of aggressiveness of prostate
cancer. Cancer cells can be classified from Gleason grade 1 (well differentiated and lower risk) to Gleason
grade 5 (poorly differentiated and higher risk).13 The Gleason score is the sum of the grades of the two
most common types of cells. For example, if the man’s most common cells are Gleason grade 3 and
Gleason grade 4, the Gleason pattern is 3 + 4 = 7. The clinical stage is assessed by the urologist by DRE
with or without imaging scans, although the majority of men diagnosed with prostate cancer also undergo
pelvic and prostate magnetic resonance imaging (MRI) after the biopsy.
The 2014 National Institute for Health and Care Excellence (NICE) clinical guideline13 recommends that
men with low-risk prostate cancer are offered active surveillance, as described in Table 2. Men with
intermediate- or high-risk cancer should be offered active treatment. In men with intermediate-risk cancer,
the 2014 NICE clinical guideline recommends RP or radical radiotherapy but considers active surveillance or
high-dose-rate brachytherapy with external-beam radiotherapy as possible options. Men with high-risk
cancer should be offered RP, radical radiotherapy or high-dose-rate brachytherapy with external-beam
radiotherapy. Interestingly, the NICE guidance also recommends prostate MRI as a baseline test at the
commencement of active surveillance. Under the current NICE guidance and clinical practice, therefore,
almost all men who have a TRUS-guided biopsy are recommended to undergo MRI after biopsy.
TABLE 1 Risk groups for localised prostate cancer
Risk PSA level (ng/ml) Gleason score Stage
Low < 10 AND ≤ 6 AND T1–T2a
Intermediate 10–20 OR 7 OR T2b
High > 20 OR 8–10 OR ≥ T2c
Notes
T1, the tumour is too small to be seen on a scan or felt during examination of the prostate; T2a, the tumour is in only half
of one of the lobes of the prostate gland; T2b, the tumour is in more than half of one of the lobes; T2c, the tumour is in
both lobes but is still inside the prostate gland; T3, the tumour has broken through the capsule of the prostate (locally
advanced); and T4, the tumour has spread to other organs nearby.
Information drawn from NICE.13
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The current clinical pathway and potential for imaging
Men undergo prostate biopsy in the absence of accurate imaging that can visualise a suspicious lesion,
as ultrasonography is used to identify the prostate, not the suspect lesion. The result is that biopsies are
taken ‘blindly’ from areas of the gland. Although protocols stipulate that the biopsies should sample certain
regions in a fanlike manner, studies have shown that this is often not the case and that the biopsies are
clustered.15 This results in a random, rather than systematic, deployment of the needle. This approach
(Figure 1) contrasts markedly with that used for other cancers, in which the physician either visualises
(e.g. using endoscopy) or images (e.g. using mammography) a suspect lesion in order to guide a biopsy
needle to it.
The use of mpMRI prior to TRUS-guided biopsy could offer several important advantages:
l less overdiagnosis – in that fewer CNS prostate cancers are detected by avoiding unnecessary biopsy of
men who do not have CS cancer
l less overtreatment – as fewer CNS prostate cancers are detected
l increased detection of CS prostate cancers – by directing biopsies to areas of the prostate that appear
abnormal on mpMRI
l improved characterisation of individual cancers – as a result of more representative biopsy sampling
l reduced complications (including sepsis and bleeding) – as fewer men are biopsied and fewer biopsies
are taken in men who are biopsied.
In addition, a revised diagnostic pathway based on the findings of the PROstate Magnetic resonance
Imaging Study (PROMIS) also has the potential to offer a more cost-effective use of NHS resources. This is
explored in the accompanying economic evaluation.
Limitations of transrectal ultrasound-guided biopsy
l Overdetection of CNS prostate cancer: men who undergo TRUS-guided biopsy have a 25% chance of
being diagnosed with prostate cancer.17 This compares with a lifetime risk of 6–8% for symptomatic
prostate cancer, illustrating the overdiagnosis of harmless cancers in men who undergo TRUS-guided
biopsies (Figure 2).18
TABLE 2 The active surveillance protocol
Timing Testsa Frequency
Enrolment in active surveillance mpMRI if not previously carried out Not applicable
Year 1 PSA level Every 3–4 monthsb
PSA kinetics Throughout active surveillancec
DRE Every 6–12 monthsd
Prostate rebiopsy At 12 months
Year 2 and beyond PSA level Every 3–6 monthsb
PSA kinetics Throughout active surveillancec
DRE Every 6–12 monthsd
a Reassess with mpMRI if there is concern about clinical or PSA level changes at any time during active surveillance.
b PSA level testing may be carried out in primary care.
c May include PSA doubling time and velocity.
d Should be carried out by a health-care professional with expertise and confidence in carrying out DRE.
Note
Information drawn from NICE.13
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l Underdetection of CS prostate cancer: TRUS-guided biopsies have an estimated false-negative rate of
30–45%, although the true false-negative rate is unknown as few studies have applied a detailed
reference test to those men who have a negative TRUS-guided biopsy.19,20 Although the clinician takes
10–12 biopsies in a manner that attempts to obtain representative tissue within the peripheral zone
(Figure 3, left-hand image), several parts of the gland are not well sampled (a systematic error). The
anterior part of the gland may be missed as a result of its greater distance from the rectum (Figure 3,
middle and right-hand image). Tissue in the midline is missed as a result of efforts to avoid the urethra,
whereas the apex of the prostate is often difficult to access by the transrectal route.
l Inaccurate risk stratification: TRUS-guided biopsies can be unrepresentative of the true burden of
cancer as a result of random sampling error (Figure 4). Either the size or the grade of cancer may be
underestimated if the cancer tissue obtained in a TRUS-guided biopsy is not representative.21 Figure 4
illustrates how accurate estimation of tumour size will depend on hitting the centre of a lesion. At
present, because these lesions are not visualised, this relies purely on chance. However, improved risk
stratification is likely if MRI results can be used to guide deployment of needles in biopsies.
Equally, the pathological status derived from TRUS-guided biopsies can be unreliable if the test is
reapplied, for instance in active surveillance, not only in discriminating clinically important cancer from
clinically unimportant prostate cancer but also in attributing a non-cancer status from a cancer status,
in approximately one-quarter of men subject to serial testing.22
l Side effects: TRUS-guided biopsy is associated with a number of complications, the most important
being urinary tract infection (in 1–8% of cases), which can result in life-threatening sepsis (in 1–4% of
cases). Haematuria (in 50% of cases), haematospermia (in 30% of cases), pain/discomfort (in most
cases), dysuria (in most cases) and urinary retention (in 1% of cases) can also be expected.23–27
Current pathway Proposed pathway
Cancer
(significant)
Biopsy
Reduced number
of biopsies
Reduced number
of ‘cancer’ diagnoses
Reduced treatment
Suspected
prostate cancer
Suspected
prostate cancer
mpMRI
in all men
TRUS-guided biopsy
in all men
Cancer of
any grade or size
Insignificant cancer
(surveillance)
Treatment
No biopsy
required
Treatment
No cancer
Surveillance
FIGURE 1 Current and proposed diagnostic pathway for prostate cancer. Note that the proposed future pathway is
not the pathway taken by patients in the Prostate Magnetic Resonance Imaging Study. Reproduced from El-Shater
Bosaily et al.16 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction
in any medium, provided the original author and source are credited.
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Multiparametric magnetic resonance imaging in diagnosing
prostate cancer
The available evidence suggests that MRI can achieve both sensitivity and specificity of between 70% and
90% for the detection of CS prostate cancer.28 However, a systematic review of the literature29 found the
quality of the initial studies evaluating MRI to be disappointing.30 They repeatedly showed low sensitivity
and specificity as well as high interobserver variability, even when using high-resolution endorectal MRI.31–37
Much has changed since these early reports, including an appreciation of the impact of post-biopsy
changes on MRI; technological improvements such as increasing magnetic field strength (from 0.5 T to
1.5 T and 3.0 T); shorter pulse sequences enabling faster image acquisition; and the introduction of
functional imaging in the form of diffusion weighting (DW) and dynamic contrast enhancement (DCE).
The main types of magnetic resonance images available are those produced by T2 weighting, DW and
DCE. Multiparametric approaches (mpMRI, combining these three sequences together) have also been
investigated.38–48 Although their samples are small, single-centre case series have found an advantage of
using two or three magnetic resonance sequences rather than just one. A recent systematic review49
incorporating studies that reported after PROMIS started has demonstrated the following ranges in accuracy
metrics in studies using mapping biopsies and radical whole-mount prostatectomy specimens (often in
retrospective case series): sensitivity, 73–95%; specificity, 28–87%; positive predictive value (PPV), 34–93%;
and negative predictive value (NPV), 3–98%. However, no studies prior to PROMIS have prospectively
evaluated the clinical validity of mpMRI in the population of interest (men at risk of harbouring prostate
cancer who have not had a prior prostate biopsy) against an accurate and appropriate reference standard
within a multicentre study in a double-blinded fashion.
FIGURE 2 Overdetection of CNS prostate cancer.
FIGURE 3 Underdetection of CS prostate cancer.
FIGURE 4 Inaccurate risk stratification.
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Limitations of the magnetic resonance imaging literature
There are important limitations of previous studies investigating the diagnostic accuracy of MRI for
prostate cancer:
l Biopsy artefact: studies mostly evaluate MRI after biopsy; however, the biopsy procedure can affect
what is seen on MRI, which can result in an increase in false-positive or false-negative results.
l Limited application: studies mostly evaluate only the peripheral zone of the prostate, ignoring up to
one-third of prostate cancers.
l Segmentation: when each region of interest is segmented to achieve a sufficient number of data sets,
increasing the power of the analysis and accuracy by incorrectly treating each region of interest
as independent.
l Poor reference standard: most studies use RP, leading to selection bias as those undergoing surgery
tend to have burdens of cancer that are distinct from men with an abnormal PSA level, and patients
choosing other treatments can never be evaluated.50 Co-registration of a magnetic resonance image to
a RP specimen is challenging because of shrinkage (10–20%), distortion, tissue loss as a result of
‘trimming’ (10%), orientation and absent perfusion.
These deficiencies, which mean that there is a discernible lack of level 1 evidence on the accuracy of
mpMRI, probably account for the limited acceptance of MRI in contemporary prostate cancer
diagnostic pathways.51
The optimal reference standard: template prostate mapping
Template prostate mapping (TPM) biopsy was selected as the reference test for this study as it meets
the required specification for our defined population when using 5-mm sampling52 (Figure 5).
TPM-biopsy:
l Produces a histological map of the entire prostate in three dimensions.52–55
l Has an estimated sensitivity and a NPV in the order of 95% for CS cancers when assessed against RP.56–58
l Avoids selection bias because all men exposed to the index test can be exposed to the reference standard.
l Has a similar side-effect profile to that of TRUS-guided biopsy, with three important differences.
TPM-biopsy:
¢ carries a significantly lower risk of urosepsis (< 0.5%), as the needles do not traverse the rectal
mucosa23 (urosepsis is the most serious complication of TRUS-guided biopsy)
¢ confers a higher risk of self-limiting failure to void urine (5%) as a result of greater gland swelling;
the risk is 5% compared with 1–2% associated with TRUS-guided biopsy55,59,60
¢ requires general or spinal anaesthesia.
Although the accuracy of TPM-biopsy is high in the diagnosis of prostate cancer, it is not currently
recommended as standard practice as it requires general anaesthesia and theatre time and so cannot be
used routinely in the tens of thousands of men undergoing TRUS-guided biopsy.61
Template prostate mapping biopsy is carried out in accordance with a set protocol and so can be
conducted blind to any clinical or imaging data. Mapping using 5-mm sampling is obtained using core
needles inserted via a brachytherapy grid fixed on a stepper placed against the perineum with the patient
under general anaesthesia in the lithotomy position. In most prostates, two biopsies at each grid point are
required to sample the full craniocaudal gland length.
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Aims and objectives
The purpose of PROMIS was to assess the clinical validity (sensitivity, specificity, PPV and NPV) of mpMRI
for the detection of CS prostate cancer and compare these accuracy metrics with those of TRUS-guided
biopsy.
In particular, PROMIS aimed to evaluate whether or not mpMRI improves the ability to detect, as well as
rule out, CS prostate cancer in a group of men at risk of harbouring prostate cancer, who have not had
a previous biopsy and who would normally be advised to undergo a prostate biopsy as part of standard
care. PROMIS was designed to determine whether or not it is appropriate for men with a risk factor for
harbouring CS cancer to first undergo mpMRI to select who should have a prostate biopsy and who might
safely forgo a first prostate biopsy. In other words, we sought to determine whether or not mpMRI could
be used as a triage test prior to a first biopsy (see Figure 1).62
The main objectives of the trial were to:
l Assess the ability of mpMRI to identify men who can safely avoid unnecessary biopsy.
l Assess the ability of the mpMRI-based pathway to improve the rate of detection of CS cancers
compared with TRUS-guided biopsy, by evaluating the diagnostic accuracy of both mpMRI (the index
test) and TRUS-guided biopsy (standard test) against an accurate reference standard, TPM-biopsy.
l Estimate the cost-effectiveness of a mpMRI-based diagnostic pathway. Using data from the main study
and the wider literature, the study considered the implications of alternative diagnostic strategies for
NHS costs and men’s quality-adjusted survival duration.
FIGURE 5 Illustration of a TPM-biopsy procedure. Reproduced from El-Shater Bosaily et al.16 © 2015 The Authors.
Published by Elsevier Inc. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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Chapter 2 Methods
Study design
This chapter is partially reproduced from El-Shater Bosaily et al.16 © 2015 The Authors. Published by
Elsevier Inc. This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.
org/licenses/by/4.0/. The protocol is also available at www.ctu.mrc.ac.uk/research/documents/cancer_
protocols/promis_protocol_v4 (accessed 12 December 2017).
The PROMIS study was a prospective validating paired-cohort study representing level 1b evidence for
diagnostic studies.63 The population of interest was men at risk of prostate cancer who are usually
recommended to undergo a first prostate biopsy within standard care. The study was conducted at 11 NHS
hospitals in England. To compare the diagnostic accuracy of mpMRI (the index test) and TRUS-guided biopsy
(the current standard), both must be individually compared with a reference standard, TPM-biopsy. Therefore,
all participants in the study underwent all three tests (mpMRI, TPM-biopsy and TRUS-guided biopsy), with
TPM-biopsy followed by TRUS-guided biopsy carried out as a combined biopsy procedure (CBP). The trial
schema is shown in Figure 6. Each test was conducted blind to all of the other test results and reported
independently of the other tests.
Start: 0
End: usually
< 4 months
End of study follow-up
Results of all tests given to patients
Patients to follow standard care according to outcomes of tests
Visit 4
Visit 3 (as soon as possible after MRI, up to a maximum of 3 months after MRI)
Combined prostate biopsy procedure:
First: TPM-biopsy
Second: TRUS-guided biopsy
Visit 2 Index test: mpMRI
(Report initially kept blind from patient and clinicians)
Registration
Visit 1
Eligible
Patient identified with clinical suspicion of prostate cancer
FIGURE 6 Trial schema. Reproduced from El-Shater Bosaily et al.16 © 2015 The Authors. Published by Elsevier Inc.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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A patient and public representative (Robert Oldroyd) was involved in the study, in all aspects relating to
the design, the writing of the patient information and consent process, the conduct throughout the study
as a member of the Trial Management Group, the critical review of the results and the dissemination of the
results to both clinician and patient audiences. He contributed to the Trial Management Group deliberations
on the study concept and design for the duration of the trial, at both face-to-face meetings and during
teleconferences. As a lay member of the Nottingham 1 Research Ethics Committee (REC) from 2006 until
2015, he contributed expertise on ethics issues, including elements of the project proposal presented to the
London–Hampstead REC, which he attended with Mark Emberton in March 2011. As a former prostate
cancer patient, he voiced initial concerns about the patient volunteer burden in the study. He rewrote the
patient information sheet (reducing the initial 28 pages to 14 pages) to make it more acceptable to the REC
and revised the consent form. He commented fully on aspects of the study report, clarifying some sections to
make them more accessible to lay readers. He spoke about PROMIS at the Nottingham Prostate Cancer UK
conference in March 2017.
PROMIS was designed to overcome several shortcomings that are associated with other studies reported
in the literature. These shortcomings prompted the following decisions to be made around the design
of PROMIS:
l All patients were biopsy naive and underwent mpMRI prior to any biopsy, so there was no biopsy artefact.
l mpMRI was evaluated for all anatomical zones of the prostate including peripheral and transition zones.
l The study was powered so that the primary outcome was derived using the whole prostate as the
sector of analysis rather than segmented sectors of the prostate.
l The study used an accurate reference test that can be applied to all men at risk.
The study was also designed to avoid or minimise a number of biases that are inherent in the
current literature:
l Spectrum and selection biases were avoided by recruiting men at risk of prostate cancer and applying
all tests to all of the men.
l Work-up bias was eliminated by ensuring that patients and clinicians remained blinded to all imaging
test results until the biopsies were carried out and reported.
l Reviewer/reporter bias was avoided by ensuring that the radiologist was blinded to the reference test
and the pathologist was blinded to the imaging. The radiology report was submitted prior to the biopsies.
l Incorporation bias was minimised by ensuring that TPM-biopsies and TRUS-guided biopsies followed a
standard accepted protocol.
Patient eligibility
Patients were eligible for registration into the study if they fulfilled all of the inclusion criteria and none of
the exclusion criteria (Box 1). Men with a PSA level of > 15 ng/ml were excluded as the higher prevalence
of prostate cancer in this subgroup means that mpMRI is unlikely to be used as a triage test in these men.
Men whose prostate volume on mpMRI was found to be > 100 ml were withdrawn from the study. Men
were required to give written informed consent before participating.
Ethics considerations
The study was carried out in accordance with the principles of the Declaration of Helsinki64 and the UK
Research Governance Framework version 265 and received UK REC approval on 16 March 2011 from the
London–Hampstead REC. PROMIS has been registered on ClinicalTrials.gov (NCT01292291).
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Test procedures
The index test: multiparametric magnetic resonance imaging
In PROMIS, mpMRI was standardised to the minimal requirements advised by a European consensus
meeting,66 the European Society of Urogenital Radiology67 and the British Society of Urogenital Radiology
guidelines.68 T1-weighted, T2-weighted, diffusion-weighted [apparent diffusion coefficient (ADC) maps
and long-b scan] and dynamic gadolinium contrast-enhanced imaging was acquired using a 1.5-T scanner
and a pelvic phased array (Table 3).
Endorectal coils were not used as there is no consensus on their role in minimal scanning requirements.66
Magnetic resonance spectroscopy was not included because evidence from a large prospective multicentre
study at the time showed no benefit of spectroscopy for localisation of prostate cancer compared with
T2-weighted imaging alone.69 We decided to use only 1.5-T scanners as these were more widely available
in the UK health-care setting and most studies in the literature had reported the accuracy of mpMRI results
based on 1.5-T scanners alone.
Quality assurance and reporting
A robust quality control process was used to maintain the quality of scans and ensure uniformity across all
centres. All MRI scanners and individual mpMRI scans underwent quality control checks by an independent
commercial imaging clinical research organisation appointed through open tender (IXICO plc, London, UK).
Prior to site initiation, the lead radiologist (Alexander Kirkham) reviewed a number of prostate MRI scans
from each centre and gave iterative feedback on improving scan quality.
BOX 1 Inclusion and exclusion criteria
Inclusion criteria
l Men aged ≥ 18 years who are at risk of prostate cancer and have been advised to have a prostate biopsy.
l Serum PSA level of ≤ 15 ng/ml within the previous 3 months.
l Suspected stage ≤ T2 on rectal examination (organ confined).
l Fit for general/spinal anaesthesia.
l Fit to undergo all protocol procedures including a TRUS-guided biopsy.
l Signed informed consent.
Exclusion criteria
l Treated using 5-alpha-reductase inhibitors at time of registration or during the prior 6 months.
l Previous history of prostate biopsy, prostate surgery or treatment for prostate cancer (interventions for
benign prostatic hyperplasia/bladder outflow obstruction are acceptable).
l Evidence of a urinary tract infection or history of acute prostatitis within the last 3 months.
l Contraindication to MRI (e.g. claustrophobia, a pacemaker, an estimated glomerular filtration rate of
≤ 50 ml/minute).
l Any other medical condition precluding procedures described in the protocol.
l Contraindications for MRI (history of hip replacement surgery, metallic hip replacement or extensive pelvic
orthopaedic metal work).
Reproduced from El-Shater Bosaily et al.16 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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During the study, scans deemed to be of insufficient quality were repeated prior to biopsy. In addition,
a standardised operating procedure for mpMRI reporting was adopted in line with the recommendations
of the European consensus meeting66 and the European Society of Urogenital-Radiology prostate MRI
guidelines.67 This was convened before publication of the more recent Prostate Imaging Reporting and
Data System (PI-RADS) mpMRI reporting consensus.67 Subsequent comparisons of the Likert and PI-RADS
reporting schemes have yielded similar results.70,71
At each centre, mpMRI scans were reported by dedicated urological radiologists who had undergone
centralised training provided by the lead centre [University College London Hospital (UCLH)]. Radiologists
were provided with clinical details including PSA levels, DRE findings and any other risk factors such as a
family history of prostate cancer.
Images were reported in sequence, with T2-weighted images reported first, T2-weighted and diffusion-
weighted images reported together and then a third report issued for T2-weighted with diffusion-weighted
and dynamic contrast-enhanced scans together. The reporting form is shown in Figure 7. Future analyses
will investigate whether or not both diffusion-weighted and dynamic contrast-enhanced images are required.
As DCE requires a contrast agent (with its need for intravenous access, medical supervision and contrast-
related risks) and an additional 10–15 minutes of scan time, it will be useful to determine whether or not this
additional resource use and cost is necessary.
A five-point Likert scoring system66,67,72 was used to indicate the probability of cancer (1, highly likely to
be benign; 2, likely to be benign; 3, equivocal; 4, likely to be malignant; 5, highly likely to be malignant).
The prostate was divided into 12 regions of interest and each region was scored from 1 to 5. In addition,
each lesion was identified and scored separately and the longest axial diameter, lesion volume, ADC value
and contrast enhancement curve type were recorded.73–76 From these observations, an overall score of
1–5 (using the same definitions) was assigned to the whole prostate. This was carried out for ‘any cancer’
and for definitions 1 and 2 of CS cancer (see Definitions of clinically significant prostate cancer).
TABLE 3 Multiparametric magnetic resonance imaging scan specification
TR TE
Flip
angle, ° Plane
Slice
thickness
[mm (gap)]
Matrix
size
Field of
view (mm)
Time from
scan
T2 TSE 5170 92 180 Axial, coronal,
sagittal
3 (10%) 256 × 256 180 × 180 3 minutes
54 seconds (ax)
VIBE at multiple
flip angles for
T1 calculation
(optional)
VIBE fat sat 5.61 2.52 15 Axial 3 192 × 192 260 × 260 Continue for
≥ 5 minutes
30 seconds
after contrast
Diffusion (b= 0,
150, 500, 1000)
2200 Minimum
(< 98)
Axial 5 172 × 172 260 × 260 5 minutes
44 seconds
(16 averages)
Diffusion
(b = 1400)
2200 Minimum
(< 98)
Axial 5 172 × 172 320 × 320 3 minutes
39 seconds
(32 averages)
VIBE, volumetric interpolated breath-hold examination.
Note
Reproduced from El-Shater Bosaily et al.16 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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For the primary outcome, an overall score of ≥ 3 was used to indicate a suspicious scan in relation to CS
cancer (i.e. a positive mpMRI score). This reflects the level at which further tests (e.g. biopsy) would be
considered if mpMRI were to be introduced into the diagnostic pathway in the future. To assess
interobserver agreement, 132 scans from the lead site were rereported by a blinded second radiologist
based at that site. The values used in the analyses were those from the original reporter.
FIGURE 7 Multiparametric magnetic resonance imaging reporting form.
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The results of the mpMRI could be unblinded by the radiologist if the mpMRI revealed an enlarged prostate
volume of > 100ml, which would be impossible to sample every 5 mm because of the interference of the
bony pelvic arch. This might have reduced the number of ‘negative’ prostate results in the final analyses. The
mpMRI could also be unblinded if there was evidence of stage T4 prostate cancer or involved lymph nodes
or colorectal/bladder invasion. This might have had a detrimental impact on the performance characteristic
of mpMRI, as such tumours were more likely to be detected. The presence of other cancers such as bladder
or colorectal cancers was also a criterion for withdrawal. Withdrawal was deemed appropriate in these men
as expedited referral for biopsy and treatment was required. These withdrawals were unlikely to have an
impact on the primary or secondary outcomes.
The standard test: transrectal ultrasound-guided biopsy
Transrectal ultrasound-guided biopsy of the prostate was carried out after the TPM-biopsy (see The reference
test: transperineal template prostate mapping biopsy), under the same general/spinal anaesthesia. This was
to ensure that the results for the reference test (i.e. TPM-biopsy) were obtained in an optimal fashion in a
biopsy-naive gland that had not undergone swelling and distortion. It also theoretically minimised the risk of
infection as the potential for faecal contamination was restricted to the end of the procedure. The surgeon
carrying out the biopsy procedure was blind to the mpMRI results so that suspicious areas would not
be targeted during the TRUS-guided biopsy and the fidelity of the TPM-biopsy reference test was maintained.
TRUS-guided biopsies were taken as per international guidelines77 and incorporated 10–12 core biopsies.
Each core was identified and potted separately. The TPM-biopsies and TRUS-guided biopsy sets from
individual patients were sent to different pathologists to minimise review bias and work-up bias.
The reference test: transperineal template prostate mapping biopsy
Centres were selected for their prior experience in carrying out TPM-biopsies and training was provided to
all centres to enable them to conduct TPM-biopsies in accordance with the PROMIS protocol.
Definitions of clinically significant prostate cancer
Disease significance was defined using criteria that have been previously developed and validated for use
with TPM-biopsy for the detection of primary Gleason grades of ≥ 478 and of a cancer core length that is
predictive of the presence of lesions of ≥ 0.5 ml.79–82 Gleason scoring was based on the most frequent
pattern and not on the highest grade detected on histological analysis.
The primary definition of CS prostate cancer used a histological target condition on TPM-biopsy that
incorporated the presence of a Gleason score of ≥ 4 + 3 and/or a cancer core length of ≥ 6 mm of any
Gleason score, in any location (definition 1). This was chosen as the primary outcome on the basis that few
physicians would disagree that any man with this burden of cancer would require treatment. A secondary
definition of CS disease was also used (a cancer core length of ≥ 4 mm and/or a Gleason score of ≥ 3 + 4;
definition 2). A further definition of clinical significance (any Gleason pattern of ≥ 7) was added at the
request of reviewers at The Lancet and this was treated as an exploratory definition (definition 3).
Monitoring of adverse events
The expected side effects of combining the TPM-biopsy and TRUS-guided biopsy procedures were
discussed with patients before registration. The rate of serious adverse events (SAEs) was monitored
weekly by an independent Trial Steering Committee.
METHODS
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Outcome measures
The primary outcome measures were the diagnostic accuracy of mpMRI, TRUS-guided biopsy and
TPM-biopsy using the primary mpMRI and histology definitions, as measured by sensitivity, specificity, PPV
and NPV. The same parameters using combinations of alternative definitions of disease for each test were
investigated as secondary outcomes. The other outcomes reported were inter-rater agreement between
tests and adverse events (AEs).
Magnetic resonance imaging outcome measures
For the primary outcomes, a MRI score of ≥ 3 to indicate a positive MRI result (primary analysis) was used.
MRI scores of 1 or 2 were used to identify a group of men who might be able to avoid biopsy. Other
reporting thresholds and radiological criteria were recorded and will form exploratory tertiary analyses in
subsequent reports.
Translational research objectives
PROMIS was an ideal setting for assessing the utility of biomarkers (from urine and blood) to identify men
with CS prostate cancer. It was, to our knowledge, the first time that a broad spectrum of men at risk
have been evaluated using an optimal biopsy technique that accurately characterises the presence, size
and grade of prostate cancer. A comprehensive bank of tissue samples (serum, plasma, germline DNA,
urine) was collected from men prior to biopsy, to enable urinary and serum biomarkers to be analysed with
respect to the detection of CS prostate cancer on TPM-biopsy. The results of these analyses will be
reported at a later date.
Sample size
Power calculations were performed in relation to (1) the precision of the estimates for the accuracy of
mpMRI relative to TPM-biopsy in terms of the primary definition of CS cancer, (2) a head-to-head
comparison of mpMRI with TRUS-guided biopsy and (3) an assumed underlying prevalence of CS cancer of
15% according to the primary definition.19,20,83,84 For the less stringent definition (definition 2), it was
assumed that 25% of participants would have CS prostate cancer as detected by the reference standard.
The largest sample size obtained from the power calculations around (1) and (2) in the previous paragraph
was 714 (see protocol16); this was considered to be the maximum number of men required to have all
three tests (mpMRI, TPM-biopsy and TRUS-guided biopsy), based on the assumption that mpMRI and
TRUS-guided biopsy are uncorrelated.
Assuming a specificity of 77%, in order to demonstrate that the lower 95% CI is ≥ 70%, we would
require 407 cases of CNS prostate cancer. This is equivalent to a total of 479 men for definition 1 and
543 men for definition 2. Assuming a sensitivity of 75%, in order to demonstrate that the lower 95% CI
for sensitivity is ≥ 60%, we would require 97 cases of CS prostate cancer. This is equivalent to a total of
647 men for definition 1 and 388 for definition 2. These estimates of sensitivity and specificity were
considered realistic based on current unpublished and published literature.85,86
It was assumed that TRUS-guided biopsy detects 48% of CS prostate cancers83,87 and that mpMRI would
detect ≥ 70%; these were conservative estimates. Using McNemar’s test for paired binary observations,88 in
order to show an absolute increase in the proportion of CS cancers detected of ≥ 22% (from 48% to 70%)
with a power of 90% and a two-sided alpha of 5%, a total of 107 cases are required. This is equivalent
to a total study population of 714 men for definition 1 and 428 men for definition 2. Table 4 shows the
required sample size for McNemar’s test for different levels of agreement between mpMRI and TRUS-guided
biopsy. The shaded regions reflect the scenario in which virtually all cancers are detected by either mpMRI or
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TRUS-guided biopsy, in which there is extremely low agreement between mpMRI and TRUS-guided biopsy.
This is very unlikely but is included for completeness.
The independent Trial Steering Committee carried out an a priori interim review after 50 participants had
received all three tests. Although a higher than anticipated prevalence of any cancer was observed, no
changes to the target sample size were recommended.
Statistical analysis
All statistical analyses were carried out in accordance with a statistical analysis plan agreed before the data
were inspected. Stata® version 13.0 (StataCorp LP, College Station, TX, USA) was used to carry out the
analyses. The primary analysis was based on all evaluable data, excluding men without all three test results
and any data that were rejected as part of the external mpMRI quality control/quality assurance process.
For each comparison, 2 × 2 contingency tables were used to present the results and calculate the diagnostic
accuracy estimates with 95% CIs. Given the paired nature of the test results, McNemar’s tests were used
for the head-to-head comparisons of sensitivity and specificity between mpMRI and TRUS-guided biopsy.
Because the PPV and NPV are dependent on disease prevalence, a generalised estimating equation (GEE)
logistic regression model was used to compare the PPV and NPV for mpMRI and TRUS-guided biopsy
against those for TPM-biopsy.89,90
The sensitivities, specificities and predictive values were calculated for mpMRI based on the overall
radiological score for mpMRI [assigned to definition 2 on the mpMRI case report form (CRF)] and definition
1 for CS cancer on TPM-guided biopsy.
The format of the 2 × 2 table is shown in Table 5. Specificity = d/(c + d), where d = the number of men
testing negative on mpMRI and negative for CS cancer on TPM-biopsy and c = the number of men testing
positive on mpMRI and negative for CS cancer on TPM-biopsy. The NPV = d/(b + d), where d = the number
of men testing negative on mpMRI and negative for CS cancer on TPM-biopsy and b = the number of
men testing negative on mpMRI who test positive for CS cancer on TPM-biopsy. Sensitivity = a/(a + b),
TABLE 4 Required sample size for McNemar’s test for different levels of agreement between mpMRI and
TRUS-guided biopsy
mpMRI results
TRUS-guided biopsy result
(for true cases)a
Required
number
of casesb
Required sample sizeNegative Positive
–ve +ve –ve +ve
Prevalence of 15%
(definition 1)
Prevalence of 25%
(definition 2)
Sensitivity = 70% 0.29 0.23 0.01 0.47 48 321 192
0.25 0.27 0.05 0.43 66 441 264
Independence
assumptionc
0.156 0.364 0.144 0.336 107 714 428
0.05 0.47 0.25 0.23 153 1021 612
0.01 0.51 0.29 0.19 170 1134 680
a Sensitivity of TRUS-guided biopsy = 48% in all cases.
b For 90% power and two-sided 5% significance.
c Assumes that results of mpMRI and TRUS-guided biopsy are independent for each individual.
Note
The shaded rows reflect the scenario in which virtually all cancers are detected by either mpMRI or TRUS-guided biopsy,
and so there is extremely low agreement between mpMRI and TRUS-guided biopsy. This does not make clinical sense and
is very unlikely but is included for completeness.
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where a = the number of men testing positive on mpMRI and positive for CS on TPM-biopsy and b = the
number of men testing negative on mpMRI who have CS cancer on TPM-biopsy. The PPV = a/(a + c),
where a = the number of men testing positive on mpMRI and positive for CS on TPM-biopsy and c = the
number of men testing positive on mpMRI who do not have CS cancer on TPM-biopsy.
For the comparison of TRUS-guided biopsy and mpMRI, McNemar’s test was used to compare the agreement
between mpMRI (radiological score of ≥ 3 assigned to definition 2 on the mpMRI CRF) and TRUS-guided
biopsy (definition 1) in the subset of men found to have CS prostate cancer on TPM-biopsy according to
definition 1. For the secondary analysis, all analyses that were carried out for definition 1 were repeated for
definition 2 and, at the request of The Lancet reviewers, for any Gleason score of ≥ 7.
Exploratory analyses will be performed in the future to evaluate the impact on the sensitivity, specificity
and predictive values of mpMRI when each of the 12 regions of interest are correlated between mpMRI
and TPM-biopsy. Agreement between mpMRI and TPM-biopsy in identifying CS cancer in the same region
will be based on a nearest neighbourhood approach.91 Sensitivity to this approach will be tested by also
presenting results according to complete match (the most stringent rule) and using a left/right rule (the less
stringent rule). The sensitivity, specificity and predictive values of each of the individual MRI reporting
sequence combinations, namely T2, T2 + DW and T2 + DW + DCE, will inform additional important tertiary
analyses in subsequent publications.
Odds ratios (ORs) represent the odds of each test correctly detecting the presence or absence of disease.
For specificity and NPV, the coding logic was reversed as the correct test result is a negative test result.
Ratios are presented for TRUS-guided biopsy relative to mpMRI, so ratios of > 1 favour TRUS-guided biopsy
and ratios of < 1 favour mpMRI.
TABLE 5 2 × 2 tables to demonstrate the accuracy of mpMRI with respect to TPM-biopsy
TPM-biopsy
mpMRI
+ve –ve Total
+ve a b a + b
–ve c d c + d
Total a+ c b+ d
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Chapter 3 Results
The main results of PROMIS have been published by Ahmed et al.
92 Sections of this chapter have been
reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Recruitment and screening
A total of 740 participants were registered to the trial from 11 NHS hospitals in England. Recruitment took
place between May 2012 and November 2015. Details of the screening and participating centres are given
in Appendix 1.
Flow of participants through the study
Figure 8 shows the flow of participants through the study. Of the 740 men registered, 164 subsequently
withdrew from the study before completing all three tests. Reasons for withdrawal are presented in
Registrations
(n = 740) Withdrew before MRI was performed
(n = 17)
• Ineligible, n = 1
• Large prostate, n = 1
• Clinical reasons, n = 5
• No longer wished to participate, n = 10
• Large prostate, n = 21
• Large prostate, n = 1
• Ineligible, n = 1
• Original MRI found to be incomplete, n = 1
• Theatre complications, TRUS-guided biopsy 
   not completed, n = 1
• Ineligible, n = 2
• Unblinded, n = 2
• Large prostate, a volume of > 100 ml, n = 46
• T4 or nodal disease, n = 5
• Clinical reasons, n = 15
• No longer wished to participate, n = 42
• Other, n = 10
Withdrew before CBP
(n = 122)
Withdrew during CBP
(n = 21)
Withdrew after CBP
(n = 4)
MRI completed
(n = 723)
CBP attempted
(n = 601)
CBP completed
(n = 580)
Men with all three tests
completed in accordance with 
protocol (n = 576; 572 attended
final study visit)
FIGURE 8 Participant flow through the study. Reproduced from Ahmed et al.92 © 2015 The Authors. Published by
Elsevier Inc. This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
DOI: 10.3310/hta22390 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 39
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Table 6. Most withdrawals took place before the combined biopsy was carried out; the most common
reason for withdrawal was the discovery of a large prostate volume (> 100 ml), which was a mandatory
withdrawal criterion. A total of 576 men were included in the final analysis. For the analysis set, the
median (range) time between mpMRI and the combined biopsy was 38 days (1–190 days). The median
(range) time between registration and the end-of-study visit was 111 days (31–421 days).
Baseline characteristics
Table 7 summarises the baseline characteristics for the 576 men who were included in the final analysis
and the 164 men who withdrew after registration. The group of participants who withdrew had a similar
age and PSA level to the included group, but were slightly less likely to report a family history of
prostate cancer.
Cancer prevalence by template prostate mapping biopsy
The prevalence of any cancer as assessed by the reference test, TPM-biopsy, was 71% (95% CI 67% to
75%). The prevalence of CS cancer according to the primary definition (a Gleason score of ≥ 4 + 3 and/or
a cancer core length of ≥ 6 mm) was 40% (95% CI 36% to 44%). The prevalence of CS cancer according
to the secondary definition (a Gleason score of ≥ 3 + 4 and/or a cancer core length of ≥ 4 mm) was 57%
(95% CI 53% to 62%). Using the exploratory definition of any Gleason pattern of ≥ 7, the prevalence of
CS cancer was 53% (308/576).
Cancer prevalence according to each definition as detected by TPM-biopsy is summarised in Table 8,
together with the number of cancers that were identified to have perineural or lymphovascular
involvement. A summary of the cancer grades according to TPM-biopsy pathology results is given in
Appendix 1.
TABLE 6 Reasons for and timing of study withdrawals
Reason
Timing of withdrawal
Before MRI Before CBP During CBP After CBP Total
Ineligible 1 2 0 1 4
Unblinded 0 2 0 0 2
Large prostate 1 46 21 1 69
Stage T4 or nodal disease 0 5 0 0 5
Clinical reasonsa 5 15 0 1 21
Did not want biopsy 4 17 0 0 21
Did not want to wait: sought
private medical treatment
1 4 0 0 5
No longer wished to participate 5 21 0 0 26
Other 0 10 0 1 11
Total 17 122 21 4 164
a Various reasons including cardiovascular events, renal/urological problems and other cancers.
Note
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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TABLE 7 The baseline characteristics of the 576 men included in the final analysis and the 164 men who withdrew
Characteristic [missing data, n] Men included in the final analysis (N= 576) Withdrawals (N= 164)
Mean (SD) age, years [0] 63.4 (7.6) 64.5 (7.5)
Ethnicity, n (%) [1]
White 502 (87) 136 (83)
Mixed 6 (1) 2 (1)
Asian or Asian British 16 (3) 5 (3)
Black or black British 39 (7) 16 (10)
Other 12 (2) 4 (3)
Family history of prostate cancer, n (%) [7]
Yes 127 (22) 27 (17)
No 442 (78) 130 (83)
BMI (kg/m2), mean (SD) [62] 27.8 (4.4) 28.6 (5.2)
PSA level (ng/ml), mean (SD) [range] [0] 7.1 (2.9) [0.5–15.0] 7.1 (2.7) [1.0–14.7]
BMI, body mass index; SD, standard deviation.
Note
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
TABLE 8 Prevalence of cancer and CS cancer found by TPM-biopsy
Prevalence TPM-biopsy (N= 576), n (%) [95% CI]
Any cancer 408 (71) [67 to 75]
PNI 156
LVI 3
CS cancer, primary definition (Gleason score of ≥ 4+ 3 and/or cancer
core length of ≥ 6mm)
230 (40) [36 to 44]
PNI 133
LVI 3
CS cancer, secondary definition (Gleason score of ≥ 3 + 4 and/or cancer
core length of ≥ 4mm)
331 (57) [53 to 62]
PNI 155
LVI 3
CS cancer, exploratory definition (Gleason score of ≥ 7) 308 (53) [49 to 58]
PNI 152
LVI 3
LVI, lymphovascular invasion; PNI, perineural invasion.
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Diagnostic accuracy of transrectal ultrasound-guided biopsy compared
with template prostate mapping biopsy (primary outcome)
The diagnostic accuracy results for TRUS-guided biopsy compared with TPM-biopsy are shown in Table 9
and Figure 9. Cancer was detected in 286 out of 576 men (50%, 95% CI 45% to 54%), of whom 65 had
perineural invasion and one had lymphovascular invasion. CS cancer according to the primary definition
was detected in 124 out of 576 men (22%, 95% CI 18% to 25%), of whom 48 had perineural invasion
and one had lymphovascular invasion.
A summary of the cancer grades according to TRUS-guided biopsy pathology results is given in Appendix 1.
Appendix 1 also provides two case illustrations showing the correlation of TRUS-guided biopsy and mpMRI
with TPM-biopsy, one for a man harbouring CS cancer and one for a man with no cancer.
TABLE 9 Diagnostic accuracy of the detection of CS cancer for TRUS-guided biopsy compared with TPM-biopsy
TRUS-guided biopsy
TPM-biopsy, n
CS cancer (+) NC or CNS cancer (–) Total
CS cancer (+) 111 13 124
NC or CNS cancer (–) 119 333 452
Total 230 346 576
NC, no cancer.
Notes
Sensitivity = 48% (95% CI 42% to 55%); PPV= 90% (95% CI 83% to 94%).
Specificity = 96% (95% CI 94% to 98%); NPV= 74% (95% CI 69% to 78%).
Standard test (TRUS)
(n = 576)
No cancer or CNS cancer
(n = 452)
Significant cancer
on TPM-biopsy
(n = 111)
No cancer or 
CNS cancer 
on TPM-biopsy
(n = 13)
CS cancer
on TPM-biopsy
(n = 119)
No cancer or 
CNS cancer 
on TPM-biopsy
(n = 333)
CS cancer
(n = 124)
FIGURE 9 Diagnostic accuracy of the detection of CS cancer for TRUS-guided biopsy compared with TPM-biopsy.
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Diagnostic accuracy of multiparametric magnetic resonance imaging
compared with template prostate mapping biopsy (primary outcome)
Multiparametric magnetic resonance imaging results
In the group of 576 men included in the final analysis, the mean volume of the prostate was 48ml [standard
deviation (SD) 20 ml]. Six men had a prostate volume of > 100ml as they had been entered into the trial before
this threshold was adopted as an exclusion criterion mid-way through the study. The Trial Management Group
decided that these six men should remain in the study as they had been fully sampled using TPM-biopsy.
The distribution of mpMRI scores is presented in Table 10. Agreement between mpMRI and TRUS-guided
biopsy for the detection of CS cancer is shown in Appendix 1.
The diagnostic results for mpMRI compared with TPM-biopsy are shown in Table 11 and Figure 10. The
sensitivity of mpMRI for CS cancer was 93% (95% CI 88% to 96%) and the NPV was 89% (95% CI 83%
to 94%). The specificity of mpMRI was 41% (95% CI 36% to 46%), with PPV being 51% (95% CI 46%
to 56%). The proportion of CS disease by mpMRI score is shown in Figure 11.
A negative mpMRI result was recorded for 158 men (27%). Of these, 17 were found to have CS cancer on
TPM-biopsy (see Table 15 and Figure 10). All 17 had Gleason grade 3 + ≤ 4, and core lengths of between
6 mm and 12 mm (Table 12). Of the 119 significant cancers missed by TRUS-guided biopsy, 13 had a
Gleason score of 4 + 3, 99 had a Gleason score of 3 + 4 and 7 had a Gleason score of 3 + 3 (see
Table 12).
Head-to-head comparison of the diagnostic accuracy of multiparametric
magnetic resonance imaging and transrectal ultrasound-guided biopsy
compared with template prostate mapping biopsy (primary outcome)
Multiparametric magnetic resonance imaging was more accurate than TRUS-guided biopsy in terms of
both sensitivity (93% compared with 48%, respectively; McNemar’s test ratio 0.52, 95% CI 0.45 to 0.60)
and NPV (89% compared with 74%, respectively; GEE model estimate for OR 0.34, 95% CI 0.21 to 0.5;
p < 0.0001). A total of 119 significant cancers were missed by TRUS-guided biopsy, of which 13 had a
Gleason score of 4 + 3, 99 had a Gleason score of 3 + 4 and 7 had a Gleason score of 3 + 3 (see Table 12).
However, compared with mpMRI, TRUS-guided biopsy showed better specificity (41% compared with 96%,
respectively; McNemar’s test ratio 2.34, 95% CI 2.08 to 2.68; p < 0.0001) and a better PPV (51% compared
with 90%; GEE model estimate for OR 8.2, 95% CI 4.7 to 14.3; p < 0.0001].
TABLE 10 Distribution of MRI scores across all 576 men
Primary MRI score Participants, n (%)
1: highly likely benign 23 (4)
2: likely benign 135 (23)
3: equivocal 163 (29)
4: likely malignant 120 (21)
5: highly likely malignant 135 (23)
Total 576 (100)
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TABLE 11 Diagnostic accuracy of the detection of CS cancer for mpMRI compared with TPM-biopsy
mpMRI
TPM-biopsy, n
CS cancer (+) NC or CNS cancer (–) Total
CS cancer (+) 213 205 418
NC or CNS cancer (–) 17 141 158
Total 230 346 576
CNS, clinically non-significant; NC, no cancer.
Notes
Sensitivity = 93% (95% CI 88% to 96%); PPV= 51% (95% CI 46% to 56%).
Specificity = 41% (95% CI 36% to 46%); NPV= 89% (95% CI 83% to 94%).
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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FIGURE 10 Diagnostic accuracy of the detection of CS cancer for mpMRI compared with TPM-biopsy. Pie charts
represent actual mpMRI scores from 1 to 5. Reproduced from Ahmed et al.92 © The Authors. Published by Elsevier
Inc. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Clinical implications of introducing multiparametric magnetic resonance imaging into
the diagnostic pathway
We considered the implications of using mpMRI in clinical practice by comparing a strategy of an initial
TRUS-guided biopsy for all men (standard care) with two alternative strategies. In both alternative strategies,
mpMRI would be used as a triage test and only men with a suspicious mpMRI result (i.e. a Likert score of ≥ 3)
would go on to have a biopsy (Table 13), with the remainder receiving active surveillance or being discharged.
In the first alternative strategy – the worst-case scenario – a standard TRUS-guided biopsy would be carried out
but mpMRI would not be used to direct needle deployment. The TRUS-guided biopsy results for each patient
have been used to calculate overdiagnosis. In the second alternative strategy – the best-case scenario – the
TRUS-guided biopsy needle deployment would be guided by the mpMRI findings and the results presented
assume that such targeted biopsies would achieve similar diagnostic accuracy to that of TPM-biopsy.93,94 We
expect the actual scenario to lie somewhere between these best- and worst-case scenarios.
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TABLE 12 Histological characteristics on TPM-biopsy of CS cases missed by mpMRI and TRUS-guided biopsy
Gleason grade
Number of cases missed (range of maximum cancer core length, mm), by trial arm
mpMRI (N= 17) TRUS-guided biopsy (N= 119)
3+ 3 1 (8) 7 (6–11)
3+ 4 16 (6–12) 99 (6–14)
4+ 3 0 13 (3–16)
Note
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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For both of these scenarios, 158 out of 576 men (27%) might avoid a primary biopsy because they would
have a non-suspicious mpMRI result with a low (1 in 10) probability of harbouring significant cancer. For
the worst-case scenario, an absolute reduction in the overdiagnosis of CNS cancers might be seen, with
28 out of 576 (5%) fewer cases (relative reduction of 31%, 95% CI 22% to 42%) than with the current
standard. However, in this worst-case scenario, important information on tumour location would not be
used, resulting in the number of CS cancers that are detected being 1% lower than in standard care.
Under the best-case scenario, overdiagnosis might increase to 21% [i.e. there would be 31/576 (5%)
more cases]. However, this figure is based on the probability of detecting CNS cancers on TPM-biopsy and,
therefore, is an overestimation. Nonetheless, if the mpMRI information was used for biopsy deployment in
this scenario, it might also lead to 102 out of 576 (18%) more cases of CS cancer being detected than in
the standard pathway of TRUS-guided biopsy for all (see Table 13). We envisage that, in practice, the
actual impact of including mpMRI in the pathway would lie somewhere between the best- and
worst-case scenarios.
Diagnostic accuracy of transrectal ultrasound-guided biopsy and
multiparametric magnetic resonance imaging for other definitions of
clinically significant cancer
In total, 203 out of 576 cases (35%, 95% CI 31% to 39%) had CS cancer on TRUS-guided biopsy
according to the secondary definition [University College London (UCL) definition 2: Gleason grade of
≥ 3 + 4 and/or any grade of cancer length of ≥ 4 mm]. Table 14 presents the definitions and prevalence
according to TPM-biopsy. Of these 203 cases with UCL definition 2 disease, 63 had perineural invasion
and one had lymphovascular invasion. For the exploratory definition (any Gleason pattern of ≥ 7), 151 out
of 576 cases (26%, 95% CI 23% to 30%) had CS disease. Of these 151 cases with disease with a
Gleason grade of ≥ 7, 54 had perineural invasion and one had lymphovascular invasion.
Diagnostic accuracy results for the secondary and exploratory definitions of CS cancer are shown in
Table 14. Table 15 shows the histological characteristics of cancers missed by TRUS-guided biopsy and
mpMRI for all histological definitions.
TABLE 13 Potential clinical implications of the introduction of mpMRI as a triage test
Outcome
Strategy
TRUS-guided
biopsy-only
pathway
mpMRI triage followed by
non-directed TRUS-guided
biopsy (worst-case
scenario)a
mpMRI triage followed by
MRI-directed TRUS-guided
biopsy (best-case
scenario)b
Primary biopsy carried out, n (%)
[95% CI]
576 (100) [99 to 100] 418 (73) [69 to 76] 418 (73) [69 to 76]
Overdiagnosis (CNS cancer
detected), n (%) [95% CI]
90 (16) [13 to 19] 62 (11) [8 to 14] 121 (21) [18 to 25]
Significant cancer correctly
detected, n (%) [95% CI]
111 (19) [16 to 23] 105 (18) [15 to 22] 213 (37) [33 to 41]
a Worst-case scenario, in which mpMRI is not used to direct subsequent TRUS-guided biopsies and the TRUS-guided
biopsy results for each patient have been used to calculate overdiagnosis.
b Best-case scenario, in which mpMRI is used to direct subsequent biopsies with the same accuracy as that of TPM-biopsy.
Note
For all percentages, the denominator used is the total number of cases (N = 576).
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 15 Histological characteristics on TPM-biopsy of cases missed by mpMRI and TRUS-guided biopsy using the
three definitions of CS prostate cancer
Definition of clinical
significance
Missed cases, n
mpMRI TRUS-guided biopsy
Primary (N= 230) 17
l Gleason 3+ 3 with core length
8 mm, n= 1
l Gleason 3+ 4 with core lengths
6–12mm, n= 16
l Gleason 4+ 3, n = 0
119
l Gleason 3 + 3 with core lengths 6–11mm, n= 7
l Gleason 3 + 4 with core lengths 6–14mm, n= 99
l Gleason 4 + 3 with core lengths 3–16mm, n= 13
Secondary (N = 331) 44
l Gleason 3+ 3 with core lengths
4–8mm, n = 6
l Gleason 3+ 4 with core lengths
1–12mm, n= 38
l Gleason 4+ 3, n = 0
132
l Gleason 3 + 3 with core lengths 4–11mm, n= 18
l Gleason 3 + 4 with core lengths 1–14mm, n= 104
l Gleason 4 + 3 with core lengths 3–16mm, n= 10
Exploratory (Gleason
score of ≥ 7) (N = 308)
38
l Gleason 3+ 4 with core lengths
1–12mm, n= 38
l Gleason 4+ 3, n = 0
159
l Gleason 3 + 4 with core lengths 1–14mm, n= 146
l Gleason 4 + 3 with core lengths 3–16mm, n= 13
Note
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
TABLE 14 Diagnostic accuracy of TRUS-guided biopsy and mpMRI in the detection of CS prostate cancer using
alternative secondary definitions of CS cancer
TPM-biopsy
definition
of clinical
significance
Prevalence
of disease on
TPM-biopsy,
n (%) [95% CI]
Test
attribute
mpMRI, %
(95% CI)
TRUS-guided
biopsy, %
(95% CI) Test ratioa (95% CI) p-value
Secondary (Gleason
score of ≥ 3 + 4
and/or cancer score
lenght of ≥ 4 mm)
331 (57)
[53 to 62]
Sensitivity 87 (83 to 90) 60 (55 to 65) 0.69 (0.64 to 0.76) < 0.0001
Specificity 47 (40 to 53) 98 (96 to 100) 2.11 (1.85 to 2.41) < 0.0001
PPV 69 (64 to 73) 98 (95 to 100) 22.7 (8.6 to 59.9) < 0.0001
NPV 72 (65 to 79) 65 (60 to 70) 0.70 (0.52 to 0.96) 0.025
Exploratory [any
Gleason pattern of
≥ 7 (≥ 3+ 4)]
308 (53)
[49 to 58]
Sensitivity 88 (84 to 91) 48 (43 to 54) 0.55 (0.49 to 0.62) < 0.0001
Specificity 45 (39 to 51) 99 (97 to 100) 2.22 (1.94 to 2.53) < 0.0001
PPV 65 (60 to 69) 99 (95 to 100) 40.8 (10.2 to 162.8) < 0.0001
NPV 76 (69 to 82) 63 (58 to 67) 0.53 (0.38 to 0.73) < 0.0001
a McNemar’s test to compare sensitivity and specificity presents the ratio of proportions.
Notes
GEE logistic regression models to compare PPV and NPV present ORs.
All ratios presented as TRUS-guided biopsy relative to mpMRI.
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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Interobserver and intraobserver variability in the reporting of
multiparametric magnetic resonance imaging scores
Blinded, double reporting was available for the mpMRI scans of 132 men. For this group, agreement between
radiologists in the detection of CS cancer according to the primary definition was 80% (Table 16). This
corresponded to a Cohen’s kappa statistic of 0.5 [moderate agreement according to the Landis and Koch
classification,95 in which agreement is graded as excellent (κ ≥ 0.80), good (κ = 0.60–0.79), moderate
(κ = 0.40–0.59), poor (κ = 0.20–0.39) or very poor (κ < 0.20)]. Cohen’s kappa statistics indicate how much
better the agreement is over the agreement that would have occurred by chance (the expected agreement).
We propose to carry out further analyses on interobserver and intraobserver variability and all of the mpMRI
scans have been archived for future training and quality assurance purposes.
Agreement between radiologists for prostate volume measurements by mpMRI is shown in Figure 12,
using the Bland–Altman method, which plots the difference between measurements against the average
of the measurements. The average prostate volume was 48 ml. Overall, the mean difference between
volumes was +1.3 ml (95% CI –0.04 ml to +2.69 ml]. The plot indicates that the interobserver
reproducibility between radiologists for prostate volume measurement was approximately ±15 ml. There
was a tendency for poorer agreement with larger volumes and this association was significant according to
Pitman’s test, as well as simple linear regression.
There was no difference in diagnostic accuracy between the lead radiology site (UCLH, responsible for
training all other sites) and the other sites (see Appendix 1 for comparison).
Health-related quality of life
Participants filled in EuroQol-5 Dimensions, three-level version (EQ-5D-3L) questionnaires at enrolment,
after undergoing mpMRI, after undergoing the CBP and at the end of the study, which was, on average,
42 days after the CBP. As part of the economic evaluation, the EQ-5D-3L profiles were converted into
preference-based index scores using the UK tariff.96 The index scores after each test were compared with
the values at enrolment. There was no evidence of a change in index score between post mpMRI and
TABLE 16 Assessment of interobserver variability for mpMRI in 132 random cases that were double reported by a
second expert urological radiologist, for definition 2 of CS cancer
Radiologist 1
Number of cases by mpMRI score
Radiologist 2
1 2 3 4 5 Total
1 0 4 1 0 0 5
2 0 19 15 0 0 34
3 0 9 33 5 0 47
4 0 1 10 7 5 23
5 0 0 0 1 22 23
Total 0 33 59 13 27 132
Notes
Bold indicates perfect agreement between radiologists; green indicates agreement in terms of our primary outcome cut-off
point; blue indicates disagreement in terms of our primary outcome cut-off point. Reproduced from Ahmed et al.92
© 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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baseline (change= 0.008, 95% CI –0.002 to 0.018). However, there was a large and statistically significant
negative impact after the CBP, with a change of –0.176 (95% CI –0.203 to –0.149). The health-related quality
of life (HRQoL) implications of the various diagnostic strategies are explored further in the economic evaluation
(see Chapters 4–8).
Safety
This section summarises the safety information for the CBP, which involved TPM-biopsy followed by
TRUS-guided biopsy under the same anaesthesia. The CBP was carried out for the purposes of the study
only; it is important to note that the CBP would not be required in routine clinical practice under any
protocols developed as a result of PROMIS.
Risk of sepsis
There were nine cases of sepsis after the CBP during the study. There was one case of sepsis prior to the
CBP. This equates to a post-CBP risk of sepsis of 9 out of 601 (1.5%, 95% CI 0.7% to 2.8%).
Risk of serious adverse events and side effects
A SAE is defined as any event that leads to death, a life-threatening situation, inpatient hospitalisation,
persistent or significant disability, a congenital anomaly/birth defect or another important medical
condition.97 There were 44 reports of SAEs during the study. This equates to a risk of 44 out of 740
(5.9%, 95% CI 4.4% to 7.9%). Twenty-eight of the events (64%) involved the urogenital system, with
the most common events being urinary retention and urinary tract infections or urosepsis. As reported in
Risk of sepsis, there were 10 cases of sepsis. There were no deaths up to the time limit for reporting SAEs
(30 days after the last study visit). All SAEs, including sepsis cases, were independently reviewed by the
independent Data Monitoring Committee to ensure that the rate of sepsis was no higher than that
reported for TRUS-guided biopsy on its own. No safety concerns were raised during these reviews.
Most men (88%) experienced at least one side effect. Table 17 summarises the numbers of any side
effects documented at the patients’ last study visit.
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TABLE 17 Numbers of side effects after each test for the 576 patients who underwent all tests
Side effect (n with missing data) n (%)
mpMRI
Pain/discomfort (15) 11 (2)
Allergic reaction to contrast medium (16) 1 (< 1)
Other 3 (< 1)
CBP
Pain/discomfort (13) 362 (64)
Dysuria (17) 256 (46)
Haematuria (11) 380 (67)
Haematospermia (51) 291 (55)
Erectile dysfunction (requiring medication, injection therapy or devices) (48) 76 (14)
Urinary tract infection (only if confirmed by a laboratory test) (11) 32 (6)
Systemic urosepsis (9) 8 (1)
Acute urinary retention (12) 58 (10)
Symptoms associated with general/spinal anaesthesia (43) 19 (4)
Other 65 (11)
Total patients with any side effect (8) 501 (88)
Note
Reproduced from Ahmed et al.92 © 2015 The Authors. Published by Elsevier Inc. This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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Chapter 4 Economic evaluation approach
Overview
The economic evaluation conducted for PROMIS is presented in four chapters. Chapter 4 states the aims
and objectives of the economic evaluation and describes the approach used. Chapter 5 describes the
evaluation of the short-term outcomes associated with using the different diagnostic tests to detect CS
cancer. Chapter 6 describes the evaluation of the long-term outcomes associated with treatment compared
with monitoring of men with prostate cancer. Chapter 7 combines the results of Chapters 5 and 6 and
presents conclusions on the cost-effectiveness of the diagnostic strategies.
Introduction
Prostate cancer is the most common cancer in men, with approximately 47,000 new cases diagnosed in
the UK in 2013. It is the second most common cause of death for men in the UK, with approximately
11,000 deaths per year.1 As discussed in Chapter 1, prostate cancer is divided into risk groups based on a
combination of PSA level, Gleason score (i.e. cancer grade) and stage (see Table 1). Low-risk cancer is
considered to be CNS because it is unlikely to have a clinical impact during the man’s remaining lifetime.
The term ‘clinically insignificant’ is also commonly used. Intermediate-risk cancer and high-risk cancer have
a greater risk of progression and are considered to be CS.
Currently in the UK, all men considered to be at risk of having prostate cancer are invited to undergo a
biopsy, usually of the TRUS-guided type, to identify and classify the cancer. The biopsy procedure has
adverse health consequences, albeit mostly temporary, and misses a considerable proportion of CS cancers.
There are two possible ways of improving the current practice of TRUS-guided biopsy for all men
considered to be at risk: (1) choose another test that is better at detecting CS cancer (better sensitivity) or
(2) incorporate additional tests prior to biopsy that might inform the decision to proceed to biopsy (triage
test) and/or might improve the sensitivity of biopsy. The mpMRI is in the latter category, because it may
enable the selection of patients who should have a biopsy and also provide information to enable targeted
biopsies of suspicious areas within the prostate. The mpMRI can be used in combination with TRUS-guided
biopsy or other biopsy types to better detect CS cancer and avoid unnecessary biopsies.
The different ways of combining mpMRI and biopsy form a range of diagnostic strategies for prostate
cancer. These diagnostic strategies have different costs and health outcomes, in both the short term and
the long term. The short-term costs and health outcomes depend on the prices of the tests and their direct
health effects and detection rates in men with and without CS cancer. The long-term costs and health
outcomes relate to the downstream consequences of treatment decisions, which in turn depend on the
detection rates of each test. The short- and long-term costs and health outcomes together determine the
most cost-effective way in which to use mpMRI and biopsy (i.e. the cost-effective diagnostic strategy).
To inform decisions on how best to use the tests in combination, decision modelling is required to
combine the data generated in PROMIS with external information. The clinical data generated in PROMIS
provide information on how accurate mpMRI and biopsy are at detecting CS and CNS prostate cancer.
However, the data do not provide information on the effect of using mpMRI and biopsy in combination
(e.g. the proportion of CS cancers detected when using mpMRI to direct the TRUS-guided biopsy to
suspicious lesions). External information is also required to predict the long-term costs and health
outcomes of the alternative strategies, based on the proportions who are correctly diagnosed with CS
prostate cancer, that is, the quality-adjusted survival and lifetime costs of men according to their cancer
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status and diagnostic classification. Decision modelling structures the available evidence using a
mathematical model, combining the different pieces of information to produce an estimate of the costs
and health outcomes of the different diagnostic strategies. Health outcomes are typically expressed as
quality-adjusted life-years (QALYs), a measure that weights life expectancy with its HRQoL.
An evaluation of the effectiveness of the alternative strategies can rely on the health outcomes associated
with each, the most effective strategy being the one conferring the most health to the potential population
of users. To ascertain cost-effectiveness, however, the consequences of the additional costs that some of
the strategies impose on the NHS also need to be considered. This requires information on the health
opportunity cost of diverting resources to more costly interventions. The health opportunity cost is the health
benefit forgone by other patients if their interventions are no longer funded in order to release resources for
other more costly diagnostic strategies. The cost-effective diagnostic strategy is the strategy that achieves the
greatest health gain net of the health opportunity cost.
Previous research98 has estimated that £13,000 in additional costs displaces 1 QALY. This is the health
opportunity cost for the NHS of offering a more costly intervention and is often referred to as the
cost-effectiveness threshold. Therefore, the most cost-effective diagnostic strategy is the one that achieves
the most QALYs net of its costs, converted into QALYs forgone using the health opportunity cost of £13,000.
NICE uses a higher value, of between £20,000 and £30,000 per QALY, to make recommendations to the
NHS on the cost-effectiveness of new interventions.99 This means that an additional £20,000–30,000 is
assumed to impose on the NHS a loss of 1 QALY.
Aims and objectives of the economic evaluation
The aim of the economic evaluation was to identify the most cost-effective diagnostic strategy in men with
suspected localised prostate cancer from the perspective of the UK NHS, using information on TRUS-guided
biopsy, mpMRI and TPM-biopsy. The evaluation makes use of information generated in PROMIS, supplemented
by external evidence as appropriate, and compares the various ways that these diagnostic tests can be used to
diagnose prostate cancer.
The specific objectives of the economic evaluation were to:
l define potential diagnostic strategies involving combinations of TRUS-guided biopsy, mpMRI and
TPM-biopsy that could reasonably be used in clinical practice
l estimate the proportions of men correctly identified with prostate cancer, both CNS and CS, and men
with cancer who have been missed, for each diagnostic strategy
l estimate the direct HRQoL and NHS costs associated with each diagnostic strategy
l evaluate the expected quality-adjusted survival and NHS costs of men depending on their diagnostic
classifications, treatment decisions and true disease status
l compare the quality-adjusted survival and NHS costs of all diagnostic strategies incrementally to identify
the most cost-effective strategy for a given cost-effectiveness threshold range
l identify the main drivers of cost-effectiveness and explore how they affect the results
l characterise the uncertainty around the results and identify the key areas of uncertainty, which should
be prioritised for future research.
Framework of analyses
The cost-effectiveness of the different diagnostic strategies involving mpMRI, TRUS-guided biopsy and
TPM-biopsy depends on two aspects. First, it depends on the diagnostic performance, direct impact on
HRQoL (mainly through AEs) and costs (mainly depending on the price and level of use of each diagnostic
technology) of the combination of tests forming each diagnostic strategy in correctly classifying men with
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their true disease status. These form the short-term outcomes of testing. Second, it depends on the
long-term health benefits and costs of managing the disease, which in turn depend on the men’s true
disease status and clinical pathway. These form the long-term outcomes of testing. The short-term and
long-term outcomes of testing, once combined, allow the cost-effectiveness of the diagnostic strategies
to be compared. For this reason, the decision model is divided into two components: (1) to evaluate
short-term outcomes and (2) to evaluate long-term outcomes. The decision models were developed in
Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA), with some auxiliary calculations
on diagnostic accuracy carried out in Stata version 13.0. The results of the short-term and long-term
models are combined to evaluate the cost-effectiveness of the different diagnostic strategies over the
patients’ lifetime.
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Chapter 5 Evaluation of short-term outcomes
Methods
A decision tree (see Figure 13) is used to represent the diagnostic process and to evaluate the probability
that men are classified as having no cancer, CNS cancer and CS cancer, conditional on their true disease
status, for every given diagnostic strategy. The diagnostic strategies consist of clinically feasible
combinations of mpMRI, TRUS-guided biopsy and TPM-biopsy; each are evaluated using the different
cancer definitions and cut-off points.
For each diagnostic strategy, the decision tree evaluates:
l the proportion of men classified as having no cancer, CNS cancer and CS cancer, conditional on their
true disease status
l the proportion of men undergoing each diagnostic test
l the direct costs of diagnosis, which consist of the costs of testing and the cost of managing the
adverse effects of the tests
l the direct health outcomes of diagnosis, in terms of the HRQoL impact of the tests
l diagnostic efficiency, that is, the trade-off between the accuracy of the diagnostic strategies in
detecting CS cancer and their direct costs.
Population
The target population was men with suspected prostate cancer who had been referred to secondary care
for further investigation. Their true disease status was defined according to the cancer risk categories
recommended by NICE13 and used in the randomised controlled study comparing expectant management
with active treatment.6 The groups are:
l men with no cancer
l men with low-risk cancer – a PSA level of ≤ 10 ng/ml and a Gleason score of ≤ 6
l men with intermediate-risk cancer – a PSA level of > 10 ng/ml and ≤ 20 and a Gleason score of 7
l men with high-risk cancer – a Gleason score of ≥ 8.
In order to inform the model inputs, the true disease status of men was ascertained using the results of
TPM-biopsy and complemented by TRUS-guided biopsy if cancer had not been detected on TPM-biopsy
but had been detected on TRUS-guided biopsy.
Diagnostic tests
PROMIS classifies men with cancer as having either CS cancer or CNS cancer. The definitions of CS cancer
are discussed in Chapter 2 and are restated in the following section. These definitions correspond to the
classification by cancer risk recommended by NICE.13 Low-risk cancer is assumed to be equivalent to CNS
cancer. Intermediate-risk and high-risk cancer form the group with CS cancer.
Multiparametric magnetic resonance imaging
Multiparametric magnetic resonance imaging is an imaging technique that can be used to report the
physiological properties of the prostate tissue and its morphology. The type of MRI used in PROMIS is
mpMRI with T2 weighting, DW and DCE. Each technique helps to distinguish between normal tissue and
DOI: 10.3310/hta22390 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 39
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
cancer tissue. Detection rates in mpMRI (with T2 weighting, DW and DCE) vary widely in the literature.
A recent systematic review49 reported that the correct classification of men with CS cancer ranged from
58% to 96% (sensitivity), whereas the correct classification of men without CS cancer ranged from 23%
to 87% (specificity).
In PROMIS, the lesions observed by mpMRI are classified according to suspicion of cancer and, if cancer is
suspected, suspicion of CS cancer. There are two CS cancer definitions for mpMRI (Table 18). The primary
mpMRI outcome is definition 2. Definition 2 defines CS cancers as those with a volume of ≥ 0.2 ml and/or
a Gleason score of ≥ 3 + 4. As a secondary outcome, CS cancers are defined as those with a volume of
≥ 0.5 ml and/or a Gleason score of ≥ 4 + 3 (definition 1). The radiologist uses the information from the
scan to score lesions according to suspicion of cancer and CS cancer for each definition using a five-point
Likert scale. This scale ranges from 1 (very low suspicion) to 5 (very high suspicion). The cut-off point for
considering a lesion suspicious enough to warrant further investigation can vary from 2, in which all men
with a score of ≥ 2 are referred, to 5, in which only men with a score of 5 are referred. In PROMIS, a
cut-off point of 3 was adopted. Note that mpMRI is unable to diagnose cancer with certainty; instead, it
classifies lesions according to the degree of suspicion of cancer and CS cancer.
Transrectal ultrasound-guided biopsy
In TRUS-guided biopsy, a probe is inserted through the anus to obtain 10–12 small samples of tissue from
the prostate, guided by an ultrasound scan. The TRUS-guided biopsy has perfect specificity in that if cancer
is detected it undoubtedly means that cancer is present. However, TRUS-guided biopsies miss 30–45% of
CS cancers.2,3 TRUS-guided biopsy has some adverse health effects, which are generally transient.100 Up to
20% of men would refuse a repeat biopsy, even if it was clinically indicated.101
In PROMIS, two definitions are used to classify men on the basis of their TRUS-guided biopsy results
(Table 19). The primary TRUS-guided biopsy outcome defines CS cancer as cancer that exhibits a dominant
Gleason pattern of ≥ 4 and/or any Gleason pattern of ≥ 5 and/or a cancer core length of ≥ 6 mm. As a
secondary outcome, CS cancer is defined as lesions with any Gleason pattern of ≥ 4 and/or a cancer core
length of ≥ 4 mm.
A TRUS-guided biopsy may be used as a first test for all men or it may be used a second time following an
initial TRUS-guided biopsy or following mpMRI (once or twice if the first biopsy did not detect cancer). The
sensitivity of TRUS-guided biopsy is likely to change depending on whether it is used for a first or a second
biopsy, even if only because the patients undergoing a second biopsy differ from those undergoing a first
biopsy. The sensitivity of TRUS-guided biopsy is also likely to differ if it is undertaken before or after
mpMRI, as mpMRI can be used to guide the second biopsy. For these reasons, this study considers six
types of TRUS-guided biopsy, listed in Table 20.
TABLE 18 Definitions of CS cancer for mpMRI
Outcome mpMRI definition
Primary 2: a lesion volume of ≥ 0.2 ml and/or Gleason score of ≥ 3+ 4
Secondary 1: a lesion volume of ≥ 0.5 ml and/or Gleason score of ≥ 4+ 3
TABLE 19 Definitions of CS cancer for TRUS-guided biopsy
Outcome TRUS-guided biopsy definition
Primary 1: dominant Gleason pattern of ≥ 4 and/or any Gleason pattern of ≥ 5 and/or cancer core length of ≥ 6mm
Secondary 2: any Gleason pattern of ≥ 4 and/or cancer core length of ≥ 4 mm
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Template prostate mapping biopsy
A TPM-biopsy involves taking a large number of tissue samples from the prostate using a grid sampling
system. TPM-biopsy is widely regarded as the gold standard as it correctly identifies nearly all men with
CS cancer, who can then receive treatment.53–58,102 However, it is costly and causes adverse effects. On
balance, TPM-biopsy identifies the greatest proportion of men with CS cancer, but may have a higher cost
and greater HRQoL implications. For this analysis, the reference standard is the combination of TPM-biopsy
and TRUS-guided biopsy.
Diagnostic strategies
Each of the three diagnostic tests (mpMRI, TRUS-guided biopsy and TPM-biopsy) can be used in a different
sequence to diagnose prostate cancer. The sequence of tests is determined by whether or not, and when,
to use mpMRI; the type of biopsy (TRUS-guided or TPM); and whether or not men can be rebiopsied.
Although TPM-biopsy can correctly diagnose all men, it involves the use of more health-care resources
and hence has greater costs and may affect HRQoL. Therefore, although it may not be cost-effective to use
TPM-biopsy in all men, it may be worthwhile using it in men selected according to their mpMRI results,
TRUS-guided biopsy results or a combination of the two.
Four key assumptions are made in the design of the diagnostic strategies under evaluation:
1. The only tests considered are mpMRI, TRUS-guided biopsy and TPM-biopsy. This follows from PROMIS,
which compared mpMRI and TRUS-guided biopsy with TPM-biopsy.
2. There can be up to three tests in one diagnostic strategy. Diagnostic episodes may be repeated over
time but this is not explicitly modelled in this analysis.
3. A diagnostic strategy can include up to two biopsies.
4. If included in the strategy, mpMRI can be used only once.
Tables 21–24 identify the 32 diagnostic strategies compared in this work. Table 21 shows the strategies
starting with mpMRI prior to TRUS-guided biopsy (M1–M7) and Table 23 shows the strategies starting with
TRUS-guided biopsy prior to TRUS-guided biopsy (T1–T9). Strategies M1–M7 and T1–T9 do not include
TPM-biopsy. Tables 22 and 24 show the equivalent strategies but including TPM-biopsy as the last biopsy,
replacing TRUS-guided biopsy. Therefore, strategies N1–N7 start with mpMRI and include TPM-biopsy as
the last biopsy in the test sequence and strategies P1–P7 start with a biopsy and include TPM-biopsy as the
last biopsy in the test sequence. This means that in strategy P1, which includes only one biopsy for all men,
all men receive TPM-biopsy. In strategy P2, all men receive TRUS-guided biopsy and men who were classified
as having no cancer receive TPM-biopsy. Men are classified as having ‘de facto’ no cancer in strategies in
which men with suspected CNS cancer on mpMRI are not retested with TRUS-guided biopsy. In other words,
men with suspected CNS cancer on mpMRI are not referred for active surveillance because they have not
TABLE 20 Types of TRUS-guided biopsy
Code Test
T TRUS-guided biopsy before mpMRI
Q TRUS-guided biopsy after a TRUS-guided biopsy that did not detect cancer
R TRUS-guided biopsy after a TRUS-guided biopsy that detected CNS cancer
W TRUS-guided biopsy after a suspicious mpMRI result
Z TRUS-guided biopsy after a TRUS-guided biopsy that did not detect cancer and a suspicious mpMRI result
S TRUS-guided biopsy after a TRUS-guided biopsy that detected CNS cancer and a suspicious mpMRI result
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TABLE 21 Diagnostic strategies M1–M7: starting with mpMRI, with TRUS-guided biopsy as the last biopsy
Strategy First test Result Second test Result Third test Result Final result
M1 mpMRI NC NC
CNS cancer NC
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
M2 mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
M3 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
M4 mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
M5 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
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TABLE 21 Diagnostic strategies M1–M7: starting with mpMRI, with TRUS-guided biopsy as the last biopsy
(continued )
Strategy First test Result Second test Result Third test Result Final result
M6 mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
M7 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
NC, no cancer.
TABLE 22 Diagnostic strategies N1–N7: starting with mpMRI, with TPM-biopsy as the last biopsy
Strategy First test Result Second test Result Third test Result Final result
N1 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
N2 mpMRI NC NC
CNS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
continued
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TABLE 22 Diagnostic strategies N1–N7: starting with mpMRI, with TPM-biopsy as the last biopsy (continued )
Strategy First test Result Second test Result Third test Result Final result
N3 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
N4 mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
N5 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
N6 mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
N7 mpMRI NC NC
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
NC, no cancer.
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TABLE 23 Diagnostic strategies T1–T9: starting with TRUS-guided biopsy, with TRUS-guided biopsy as the
last biopsy
Strategy First test Result Second test Result Third test Result Final result
T1 TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
T2 TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
T3 TRUS-guided
biopsy
NC NC
CNS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
T4 TRUS-guided
biopsy
NC TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
T5 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer NC
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
T6 TRUS-guided
biopsy
NC NC
CNS cancer mpMRI NC CNS cancer
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
continued
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TABLE 23 Diagnostic strategies T1–T9: starting with TRUS-guided biopsy, with TRUS-guided biopsy as the last
biopsy (continued )
Strategy First test Result Second test Result Third test Result Final result
T7 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer NC
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer mpMRI NC NC
CNS cancer NC
CS cancer TRUS-guided
biopsy
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
T8 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
T9 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TRUS-guided
biopsy
NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer mpMRI NC CNS cancer
CNS cancer CNS cancer
CS cancer TRUS-guided
biopsy (S)
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
NC, no cancer.
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TABLE 24 Diagnostic strategies P1–P9: starting with TRUS-guided biopsy, with TPM-biopsy as the last biopsy
Strategy First test Result Second test Result Third test Result Final result
P1 TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
P2 TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
P3 TRUS-guided
biopsy
NC NC
CNS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
P4 TRUS-guided
biopsy
NC TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
P5 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer NC
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
P6 TRUS-guided
biopsy
NC NC
CNS cancer mpMRI NC CNS cancer
CNS cancer CNS cancer
CS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
P7 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer NC
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
continued
DOI: 10.3310/hta22390 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 39
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
been diagnosed with CNS cancer. Instead, they are discharged to primary care where their PSA level is
monitored annually. In contrast, men in whom TRUS-guided biopsy detected CNS cancer are referred for
active surveillance.
Figure 13 shows how these strategies can be translated into decision trees, using strategies M1 and T1 as
examples. The black circles represent chance nodes, in which the outcome depends on a probability. In
strategy M1, all men receive mpMRI. Men identified as having suspected CS cancer on mpMRI receive
TRUS-guided biopsy. The TRUS-guided biopsy can classify these men as not having cancer if no cancer is
detected or as having CNS or CS cancer, depending on the characteristics of the lesions. In strategy T1,
men receive only one single test, TRUS-guided biopsy. The biopsy can classify men as having no cancer,
CNS cancer or CS cancer.
This study evaluates each of the 32 diagnostic strategies using each of the two diagnostic definitions for
mpMRI, TRUS-guided biopsy and TPM-biopsy (see Tables 18 and 19) and between two and five cut-off
TABLE 24 Diagnostic strategies P1–P9: starting with TRUS-guided biopsy, with TPM-biopsy as the last biopsy
(continued )
Strategy First test Result Second test Result Third test Result Final result
CNS cancer mpMRI NC NC
CNS cancer NC
CS cancer TPM-biopsy CNS cancer CNS cancer
CS cancer CS cancer
CS cancer CS cancer
P8 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer CNS cancer
CS cancer CS cancer
P9 TRUS-guided
biopsy
NC mpMRI NC NC
CNS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CS cancer TPM-biopsy NC NC
CNS cancer CNS cancer
CS cancer CS cancer
CNS cancer mpMRI NC CNS cancer
CS cancer CS cancer
NC, no cancer.
EVALUATION OF SHORT-TERM OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
points on the mpMRI Likert scale for suspicion of cancer. In total, the 32 different diagnostic strategies
form 383 substrategies:
l In strategies M1–M7, all men undergo mpMRI, which will then indicate whether one or two
TRUS-guided biopsies are required. Strategies M1–M7 are tested over two mpMRI definitions,
four cut-off points and two TRUS-guided biopsy definitions, forming 112 possible substrategies.
l In strategies N1–N7, all men undergo mpMRI to inform the need for a TRUS-guided biopsy or
TPM-biopsy. In strategies N1 and N2, all men receive mpMRI and, depending on the result, some men
receive TPM-biopsy. Therefore, in strategies N1 and N2, two mpMRI definitions can be used, each over
four cut-off points. This forms 16 substrategies. In N3–N7, the two mpMRI definitions, four cut-off
points and two TRUS-guided biopsy definitions apply, forming 80 substrategies. Therefore, in total,
there are 96 substrategies.
l In strategies T1–T9, all men undergo a TRUS-guided biopsy, which can be subsequently followed by
mpMRI and potentially a second TRUS-guided biopsy. Strategies T1–T4 include only TRUS-guided
biopsy and, therefore, are tested over two definitions of CS cancer, forming eight possible
combinations. Strategies T5–T9 are tested over two mpMRI definitions, four cut-off points and
two TRUS-guided definitions, forming 80 possible combinations. Therefore strategies T1–T9 form
88 possible substrategies.
l In strategies P1–P9, all men undergo either a TRUS-guided biopsy or a TPM-biopsy and may undergo
mpMRI to inform whether or not they should have a second biopsy (TRUS-guided or TPM). Strategy
P1 consists of a TPM-biopsy for all men, which constitutes the reference test and uses the primary
outcome as the definition for CS cancer against which all other tests are compared. Strategies P2–P4
are tested over the two TRUS-guided biopsy definitions. Strategies P5–P9 are tested over the two
mpMRI definitions, four cut-off points and two TRUS-guided definitions. As a result, there are
87 possible substrategies.
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FIGURE 13 Decision trees. (a) Strategy M1: mpMRI in all men and TRUS-guided biopsy in men with suspected
CS cancer; and (b) strategy T1: all men have TRUS-guided biopsy.
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The diagnostic strategies were labelled according to their test combination first (M1–M7, N1–N7, T1–T9 or
P1–P9) and then according to their TRUS-guided biopsy definition (1 or 2), MP-MRI definition (1 or 2) and
cut-off point (2–5). For example, substrategy M1 125 refers to test combination M1, in which all men were
first assessed using MP-MRI definition 2 and cut-off point 5 and then those with suspected CS cancer were
followed up with TRUS-guided biopsy definition 1.
Strategy P1 (testing all men with TPM-biopsy) represents the value of a perfect immediate test. TPM-biopsy
is taken here as the reference test, which correctly identifies the true disease status of all men. TPM-biopsy
is unlikely to be feasible in clinical practice, given its HRQoL and resource implications and the large
number of men referred to secondary care with suspected prostate cancer. The inclusion of strategy P1
aims to show the difference in benefits between (1) a perfect immediate test that is costly (P1) and (2) less
costly and less accurate strategies composed of sequences of tests, in which TPM-biopsy can be used in a
small proportion of men.
Substrategy M7 123 corresponds to the PROMIS-proposed diagnostic pathway. This involves using mpMRI
in all men followed by TRUS-guided biopsy in men whose mpMRI result indicates suspected CS cancer
according to definition 2 and cut-off point 3. TRUS-guided biopsy is evaluated according to definition 1.
Men in whom TRUS-guided biopsy does not detect CS cancer are rebiopsed and classified according to
definition 1.
Substrategy T7 123 corresponds most closely to the strategy recommended in the 2014 NICE clinical
guidelines.13 It involves TRUS-guided biopsy for all men. Men in whom CS cancer according to definition 1
was not detected receive mpMRI. Men with suspected CS cancer on mpMRI using definition 2 and cut-off
point 3 receive a second TRUS-guided biopsy, evaluated according to definition 1. However, in some
hospitals, mpMRI is not available for the diagnosis of prostate cancer and the usual diagnostic strategy is
T4 1––. In T4 1––, all men receive TRUS-guided biopsy assessed according to definition 1. Men in whom
CS cancer was not detected are rebiopsied.
Model inputs
Diagnostic performance
The diagnostic performance of the tests is based as far as possible on the data collected in the diagnostic
study. This provides the diagnostic performance of mpMRI and TRUS-guided biopsy, each used alone,
compared with the reference standard of TPM-biopsy. The diagnostic performance is likely to be different
if the tests are used in combination. This is for two reasons. First, additional information is known, which
can improve the performance of the test. For example, a TRUS-guided biopsy conducted after mpMRI is
likely to be more accurate given that mpMRI can provide information on where the lesions are located.
Second, the characteristics of the men who have been referred for the second test are likely to be
different. For example, the group of men with cancer in whom an initial TRUS-guided biopsy did not find
cancer are likely to have lesions with different characteristics from those in the group of biopsy-naive men.
Consequently, external data are used to inform the diagnostic performance of repeat biopsy, MRI-targeted
biopsy and MRI-targeted repeat biopsy.
The diagnostic performance of the tests is represented as a series of conditional probabilities. The
probabilities of the tests’ classifications given the true disease status are identified in Table 25. The true
disease status is defined in terms of cancer risk because this is the classification commonly used, including in
the NICE clinical guidelines.13 The true cancer status is the most severe result of TPM-biopsy and TRUS-guided
biopsy. Both TPM-biopsy and TRUS-guided biopsy have perfect specificity in that they can classify men as
having cancer only if cancer is present.
Uncertainty is considered by including the diagnostic performance parameters in the model as probability
distributions. In order to capture the uncertainty and the correlation in diagnostic performance, the
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individual patient data obtained in PROMIS were bootstrapped 1000 times. Bootstrapping was used to
account for the correlation between tests. Diagnostic performance obtained from the literature is
incorporated as a beta distribution for counts or a log-normal distribution for relative probabilities. Details
are presented in Appendix 2.
The analysis of the individual patient data for the purposes of the economic evaluation has some different
features from that conducted for PROMIS. Therefore, the diagnostic inputs used in the decision model are
not exactly the same as those reported in Chapter 3. This is for three reasons. First, the disease categories
used in the economic model, with which the test classifications are compared, are different. The clinical
study uses CS compared with CNS, which includes no cancer. The economic evaluation uses four categories:
(1) no cancer, (2) low-risk cancer (equivalent to CNS cancer), (3) intermediate-risk cancer and (4) high-risk
cancer. Intermediate- and high-risk cancers are CS cancers. Second, in PROMIS, compared with TRUS-guided
biopsy, TPM-biopsy found either no cancer or a lower-grade cancer in nine men. Hence, the results of the
TPM-biopsy in these nine men were changed to match the results of the TRUS-guided biopsy. Third, the
definition of CS cancer in PROMIS takes into consideration the cancer core length, whereas the NICE risk
definitions13 do not. This caused an inconsistency between the risk subgroups assigned to seven men
because of their cancer core length. These seven men were excluded from our analysis.
Table 26 summarises the diagnostic performance evidence for each type of TRUS-guided biopsy and its
source. The model requires information on the diagnostic performance of the six types of TRUS-guided
biopsy (tests ‘T’, ‘Q’, ‘R’, ‘W’, ‘Z’ and ‘S’).
Information on the diagnostic performance of test ‘T’ (first TRUS-guided biopsy without prior mpMRI) is
obtained directly from the individual patient data collected in PROMIS.
The diagnostic performance of test ‘Q’ (TRUS-guided biopsy after a TRUS-guided biopsy that did not detect
cancer) is obtained from Roehl et al.103 Roehl et al.103 report the number of cancers detected in men who
underwent a series of TRUS-guided biopsies. The total number of cancers detected is used to calculate the
prevalence of prostate cancer in the study population of 0.38 (n = 963 men with cancer; N = 2526 men
in the initial population). After the second TRUS-guided biopsy, 143 men were classified as having cancer.
Therefore, the probability of detecting cancer given that cancer exists is 0.45. These cancers consist of CNS
and CS cancers; however, no information is provided on the proportion of CNS cancers compared with CS
cancers or how the probability of detection varies by cancer significance. In the absence of this information,
TABLE 25 Diagnostic performance as conditional probabilities
Disease status
Test classification
NC detected CNS cancer detected CS cancer detected
NC p(NC|NC): probability of
detecting NC given that
NC exists
p(CNS|NC): probability of
detecting CNS cancer given
that NC exists
p(CS|NC): probability of
detecting CS cancer given that
NC exists
Low-risk cancer p(NC|low): probability of
detecting NC given that
low-risk cancer exists
p(CNS|low): probability of
detecting CNS cancer given
that low-risk cancer exists
p(CS|low): probability of
detecting CS cancer given that
low-risk cancer exists
Intermediate-risk
cancer
p(NC|int): probability of
detecting NC given that
intermediate-risk cancer exists
p(CNS|int): probability of
detecting CNS cancer given
that intermediate-risk cancer
exists
p(CS|int): probability of
detecting CS cancer given that
intermediate-risk cancer exists
High-risk cancer p(NC|high): probability of
detecting NC given that
high-risk cancer exists
p(CNS|high): probability of
detecting CNS cancer given
that high-risk cancer exists
p(CS|high): probability of
detecting CS cancer given that
high-risk cancer exists
int, intermediate; NC, no cancer.
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TABLE 26 Diagnostic performance parameters for TRUS-guided biopsies
Test Data source Definition
Probability of having each test result given the true disease status, mean (95% CI)
p(NC|low)a p(CNS|low)b p(NC|int)c p(CNS|int)d p(CS|int)e p(NC|high)f p(CNS|high)
g
p(CS|high)h
Ti PROMIS Primary 0.65
(0.55 to 0.75)
0.35
(0.25 to 0.45)
0.24
(0.20 to 0.29)
0.42
(0.36 to 0.47)
0.34
(0.29 to 0.39)
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
Secondary 0.65
(0.55 to 0.75)
0.35
(0.25 to 0.45)
0.24
(0.20 to 0.29)
0.17
(0.13 to 0.21)
0.59
(0.54 to 0.64)
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
Q
j
Roehl et al.103 Primary 0.55
(0.53 to 0.57)
0.45
(0.43 to 0.47)
0.55
(0.53 to 0.57)
0.25
(0.22 to 0.28)
0.20
(0.17 to 0.23)
0.55
(0.53 to 0.57)
0.00
(0.00 to 0.00)
0.45
(0.43 to 0.47)
Secondary 0.55
(0.53 to 0.57)
0.45
(0.43 to 0.47)
0.55
(0.53 to 0.57)
0.10
(0.07 to 0.13)
0.35
(0.32 to 0.38)
0.55
(0.53 to 0.57)
0.00
(0.00 to 0.00)
0.45
(0.43 to 0.47)
Rk Barzell et al.104 1 0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
0.00
(0.00 to 0.00)
0.75
(0.55 to 0.88)
0.25
(0.12 to 0.45)
0.00
(0.00 to 0.00)
0.75
(0.55 to 0.88)
0.25
(0.12 to 0.45)
2 0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
0.00
(0.00 to 0.00)
0.75
(0.63 to 0.85)
0.25
(0.15 to 0.37)
0.00
(0.00 to 0.00)
0.75
(0.63 to 0.85)
0.25
(0.15 to 0.37)
Wl PROMIS and
Schoots et al.105
Primary 0.80
(0.67 to 0.89)
0.20
(0.11 to 0.33)
0.20
(0.15 to 0.24)
0.37
(0.31 to 0.44)
0.43
(0.36 to 0.52)
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
Secondary 0.79
(0.66 to 0.89)
0.21
(0.11 to 0.34)
0.15
(0.09 to 0.21)
0.11
(0.06 to 0.16)
0.74
(0.65 to 0.84)
0.00
(0.00 to 0.00)
0.00
(0.00 to 0.00)
1.00
(1.00 to 1.00)
Zm Schoots et al.105 Same for both
definitions
0.67
(0.02 to 1.00)
0.33
(0.00 to 0.98)
0.05
(0.02 to 0.09)
0.08
(0.03 to 0.17)
0.87
(0.74 to 0.96)
0.05
(0.02 to 0.09)
0.08
(0.03 to 0.17)
0.87
(0.74 to 0.96)
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Test Data source Definition
Probability of having each test result given the true disease status, mean (95% CI)
p(NC|low)a p(CNS|low)b p(NC|int)c p(CNS|int)d p(CS|int)e p(NC|high)f p(CNS|high)
g
p(CS|high)h
Sn Schoots et al.105
(assumption)
Same for both
definitions
0.67
(0.02 to 1.00)
0.33
(0.00 to 0.98)
0.05
(0.02 to 0.09)
0.08
(0.03 to 0.17)
0.87
(0.74 to 0.96)
0.05
(0.02 to 0.09)
0.08
(0.03 to 0.17)
0.87
(0.74 to 0.96)
int, intermediate; NC, no cancer.
a p(NC|low): probability of detecting NC given that low-risk cancer exists.
b p(CNS|low): probability of detecting CNS cancer given that low-risk cancer exists.
c p(NC|int): probability of detecting NC given that intermediate-risk cancer exists.
d p(CNS|int): probability of detecting CNS cancer given that intermediate-risk cancer exists.
e p(CS|int): probability of detecting CS cancer given that intermediate-risk cancer exists.
f p(NC|high): probability of detecting NC given that high-risk cancer exists.
g p(CNS|high): probability of detecting CNS cancer given that high-risk cancer exists.
h p(CS|high): probability of detecting CS cancer given that high-risk cancer exists.
i T: the first biopsy in all men referred to secondary care.
j Q: the second biopsy in men whose first TRUS-guided biopsy ‘T’ did not detect cancer.
k R: the second biopsy in men whose first TRUS-guided biopsy ‘T’ detected CNS cancer.
l W: the first biopsy following a suspicious mpMRI result for cancer.
m Z: the second biopsy following a first biopsy that did not detect cancer and a suspicious mpMRI result for cancer.
n S: the second biopsy following a first biopsy that detected CNS cancer and a suspicious mpMRI result for cancer.
Notes
p(NC|NC) – the probability of detecting NC given that NC exists – is equal to 1 because TRUS-guided biopsy is a perfectly specific test. It can detect cancer only if cancer exists.
The confidence intervals were calculated by Monte Carlo simulation of the parameters in the model.
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9
it is assumed that the proportion misclassified is the same as for the initial TRUS-guided biopsy (test ‘T’) for
intermediate- and high-risk cancers. In mathematical terms:
p(T = CNSjint)
p(T = CSjint)
¼
p(Q = CNSjint)
p(Q = CSjint)
, (1)
where p(T = CNS|int) is the probability of test ‘T’ classifying an individual as having CNS cancer given that
intermediate-risk cancer exists, p(T = CS|int) is the probability of test ‘T’ classifying an individual as having
CS cancer given that intermediate-risk cancer exists, p(Q = CNS|int) is the probability of test ‘Q’ classifying
an individual as having CNS cancer given that intermediate-risk cancer exists and p(Q = CS|int) is the
probability of test ‘Q’ classifying an individual as having CS cancer given that intermediate-risk cancer exists.
Test ‘R’ (TRUS-guided biopsy in men who were classified as having CNS cancer on the first TRUS-guided
biopsy) can classify men as having CNS or CS cancer, because the first TRUS-guided biopsy has already
detected CNS cancer. The diagnostic performance of test ‘R’ is obtained from Barzell et al.104 Barzell
et al.104 compared repeat TRUS-guided biopsy with TPM-biopsy in men in whom CNS cancer had been
detected. There are five definitions for clinical significance.82,106,107 The UCL definitions82 are the ones that
most closely resemble the definitions used in PROMIS and, therefore, ensure comparability. UCL definition
1 defines CS cancer as localised cancer with a maximum total cancer core length of 10 mm, a maximum
cancer core length of 6 mm and a Gleason score of at least 4 + 3 or 3 + 5. UCL definition 2 defines CS
cancer as a maximum total cancer core length of 6 mm, a maximum cancer core length of 4 mm and a
Gleason score of at least 3 + 4. Within PROMIS, the total cancer core lengths were not used because the
additive value of this factor was marginal in the original description. For definition 1, the probability of test
‘R’ (second TRUS-guided biopsy) detecting CS cancer given that CS cancer is present is 0.24 (10 men
tested positive out of 41 men with cancer), whereas for definition 2 the equivalent value is 0.25 (17 men
tested positive out of 69 men with cancer). The model uses these data for the sensitivity of test ‘R’ in
detecting CS cancer: UCL definition 1 for definition 1 TRUS-guided biopsy and UCL definition 2 for
definition 2 TRUS-guided biopsy.
Test ‘W’ (TRUS-guided biopsy after a suspicious mpMRI result) is likely to be more sensitive than test ‘T’
(TRUS-guided biopsy without a prior mpMRI). The mpMRI provides information on the area most likely to
have cancer lesions, which can subsequently be sampled by the TRUS-guided biopsy. Schoots et al.105
report the relative sensitivity of TRUS-guided biopsy targeted by mpMRI and TRUS-guided biopsy in men
with suspicious mpMRI results (cut-off point of ≥ 3) for any cancer and by clinical significance. They report
a relative sensitivity of MRI-targeted, TRUS-guided biopsy compared with TRUS-guided biopsy of 1.20
(95% CI 1.09 to 1.32) for CS cancer and 0.56 (95% CI 0.37 to 0.85) for ‘insignificant cancer’, assumed to
be equivalent to CNS cancer. This represents the ratio between the probability of detecting CS and CNS
cancer, respectively, in men whose mpMRI result is suspicious of cancer, from using the mpMRI scan to
guide the TRUS-guided biopsy compared with conducting a TRUS-guided biopsy blind. Therefore, this
relative sensitivity is applied to the probability of TRUS-guided biopsy detecting CS and CNS cancer in men
with a mpMRI result that was suspicious of cancer (score of ≥ 3) observed in PROMIS.
The performance of test ‘Z’ (TRUS-guided biopsy after a suspicious mpMRI result and no cancer on prior
TRUS-guided biopsy) is also likely to be different from the sensitivity of test ‘T’ (first TRUS-guided biopsy).
PROMIS does not provide information on this because the men received only one TRUS-guided biopsy.
Schoots et al.105 report the probability of mpMRI-guided TRUS-guided biopsy after a previous negative
biopsy detecting CNS and CS cancer. Because the probability of classifying a CS cancer as CNS or as no
cancer is not reported, it is assumed that the distribution of intermediate- or high-risk cancers detected by
the TRUS-guided biopsy targeted by mpMRI, and after a previous negative biopsy, is the same as in the
initial TRUS-guided biopsy. In mathematical terms:
p(T = NCjint)
p(T = CNSjint)
¼
p(Z = NCjint)
p(Z = CNSjint)
, (2)
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where p(T = NC|int) is the probability of test ‘T’ classifying an individual as having no cancer given that
intermediate-risk cancer exists, p(T = CNS|int) is the probability of test ‘T’ classifying an individual as having
CNS cancer given that intermediate-risk cancer exists, p(Z = NC|int) is the probability of test ‘Z’ classifying
an individual as having no cancer given that intermediate-risk cancer exists and p(Z = CNS|int) is the
probability of test ‘Z’ classifying an individual as having CNS cancer given that intermediate-risk cancer
exists. In the absence of further evidence, the diagnostic performance of test ‘Z’ in men with intermediate-
risk cancer is assumed to be representative of the performance of the test in men with high-risk cancer.
Test ‘S’ (second TRUS-guided biopsy following a first TRUS-guided biopsy that detected CNS cancer and a
mpMRI scan suspicious for cancer), similarly to test ‘R’, can classify men only into CNS or CS cancer
because the previous TRUS-guided biopsy has already detected CNS cancer. No evidence was found on
test ‘S’. Its performance is assumed to be equivalent to that of test ‘Z’, as reported in Schoots et al.,105
because they both represent MRI-guided TRUS-guided second biopsy. The probability of test ‘S’ detecting
CS cancer given that CS cancer exists is the sensitivity of MRI-guided TRUS-guided biopsy post previous
negative TRUS-guided biopsy for CS cancer detection as reported in Schoots et al.105 (95% CI 0.71 to 0.95;
p = 0.87). The probability of test ‘S’ detecting CNS cancer given that CS cancer exists is its complement
(95% CI 0.05 to 0.29; p = 0.13).
The diagnostic performance of mpMRI was also obtained from PROMIS and is summarised in Table 27 for
different definitions and cut-off points. In PROMIS, lesions were classified by degree of suspicion for any
cancer and CS cancer using a five-point Likert scale. The score is converted into test classifications (suspicion
of no cancer, suspicion of CNS cancer and suspicion of CS cancer) according to cut-off points 2–5.
It was assumed that no loss of precision would result from conducting mpMRI after a TRUS-guided biopsy.
Biopsy can cause bleeding and inflammation that can take a few months to subside. It was assumed that
mpMRI would take place after this period to maintain the diagnostic performance observed in PROMIS.
TABLE 27 Diagnostic performance of mpMRI, calculated from the individual patient data collected in PROMIS
Disease status
mpMRI classification, mean (95% CI)
No suspicion of cancer Suspicion of CNS cancer Suspicion of CS cancer
Primary definition (definition 2) cut-off point 2
NC 0.00 (0.00 to 0.00) 0.07 (0.03 to 0.11) 0.93 (0.89 to 0.97)
Low-risk cancer 0.00 (0.00 to 0.00) 0.08 (0.02 to 0.14) 0.92 (0.86 to 0.98)
Intermediate-risk cancer 0.01 (0.00 to 0.02) 0.01 (0.00 to 0.02) 0.98 (0.97 to 1.00)
High-risk cancer 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 1.00 (1.00 to 1.00)
Primary definition (definition 2) cut-off point 3
NC 0.33 (0.26 to 0.40) 0.17 (0.11 to 0.23) 0.50 (0.43 to 0.58)
Low-risk cancer 0.28 (0.19 to 0.38) 0.16 (0.08 to 0.24) 0.56 (0.46 to 0.67)
Intermediate-risk cancer 0.08 (0.05 to 0.11) 0.05 (0.02 to 0.07) 0.87 (0.83 to 0.91)
High-risk cancer 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 1.00 (1.00 to 1.00)
Primary definition (definition 2) cut-off point 4
NC 0.86 (0.80 to 0.91) 0.03 (0.01 to 0.05) 0.11 (0.06 to 0.17)
Low-risk cancer 0.75 (0.66 to 0.84) 0.04 (0.01 to 0.09) 0.21 (0.13 to 0.29)
Intermediate-risk cancer 0.30 (0.25 to 0.35) 0.04 (0.02 to 0.07) 0.65 (0.60 to 0.71)
High-risk cancer 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 1.00 (1.00 to 1.00)
continued
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Health-related quality of life
Health-related quality of life is measured using a preference-based scale on which a value of 0 represents
death and a value of 1 represents full health.
Table 28 shows the HRQoL estimates used for the different tests. The underpinning assumptions and
values were drawn from findings in PROMIS and the wider literature.
The men taking part in PROMIS filled in EQ-5D-3L questionnaires at enrolment, after mpMRI, after the CBP
(TRUS-guided biopsy and TPM-biopsy) and at the end of the study (on average 42 days after the CBP).
The EQ-5D-3L profiles were converted into preference-based index scores using the ‘UK tariff’, which is
based on the preferences of a sample of the UK public.96 The index scores after each test were compared
TABLE 27 Diagnostic performance of mpMRI, calculated from the individual patient data collected in PROMIS
(continued )
Disease status
mpMRI classification, mean (95% CI)
No suspicion of cancer Suspicion of CNS cancer Suspicion of CS cancer
Primary definition (definition 2) cut-off point 5
NC 0.96 (0.93 to 0.99) 0.01 (0.00 to 0.02) 0.03 (0.01 to 0.06)
Low-risk cancer 0.98 (0.94 to 1.00) 0.00 (0.00 to 0.00) 0.02 (0.00 to 0.06)
Intermediate-risk cancer 0.60 (0.54 to 0.65) 0.03 (0.01 to 0.05) 0.38 (0.32 to 0.44)
High-risk cancer 0.23 (0.04 to 0.45) 0.00 (0.00 to 0.00) 0.77 (0.55 to 0.96)
Secondary definition (definition 1) cut-off point 2
NC 0.00 (0.00 to 0.00) 0.23 (0.17 to 0.29) 0.77 (0.71 to 0.83)
Low-risk cancer 0.00 (0.00 to 0.00) 0.20 (0.12 to 0.29) 0.80 (0.71 to 0.88)
Intermediate-risk cancer 0.01 (0.00 to 0.02) 0.06 (0.03 to 0.09) 0.93 (0.90 to 0.96)
High-risk cancer 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 1.00 (1.00 to 1.00)
Secondary definition (definition 1) cut-off point 3
NC 0.33 (0.26 to 0.40) 0.41 (0.33 to 0.49) 0.26 (0.19 to 0.33)
Low-risk cancer 0.28 (0.19 to 0.38) 0.40 (0.30 to 0.50) 0.32 (0.22 to 0.41)
Intermediate-risk cancer 0.08 (0.05 to 0.11) 0.18 (0.13 to 0.22) 0.74 (0.69 to 0.79)
High-risk cancer 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 1.00 (1.00 to 1.00)
Secondary definition (definition 1) cut-off point 4
NC 0.86 (0.80 to 0.91) 0.08 (0.04 to 0.13) 0.06 (0.02 to 0.10)
Low-risk cancer 0.75 (0.66 to 0.84) 0.14 (0.08 to 0.22) 0.11 (0.05 to 0.18)
Intermediate-risk cancer 0.30 (0.25 to 0.35) 0.24 (0.19 to 0.28) 0.46 (0.41 to 0.52)
High-risk cancer 0.00 (0.00 to 0.00) 0.06 (0.00 to 0.18) 0.94 (0.82 to 1.00)
Secondary definition (definition 1) cut-off point 5
NC 0.96 (0.93 to 0.99) 0.02 (0.00 to 0.04) 0.02 (0.00 to 0.05)
Low-risk cancer 0.98 (0.94 to 1.00) 0.01 (0.00 to 0.04) 0.01 (0.00 to 0.04)
Intermediate-risk cancer 0.60 (0.54 to 0.65) 0.17 (0.13 to 0.22) 0.23 (0.18 to 0.28)
High-risk cancer 0.23 (0.04 to 0.45) 0.16 (0.00 to 0.35) 0.61 (0.38 to 0.84)
NC, no cancer.
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with the values at enrolment. The results show no evidence of a change in index score when comparing
post-mpMRI scores with baseline scores (mean difference 0.008, 95% CI –0.002 to 0.018). The data also
show a large and statistically significant mean impact of the CBP of –0.176 (95% CI –0.203 to –0.149).
Because the two procedures were undertaken concomitantly, these data cannot inform the effects of each
individual biopsy. The literature reports that TRUS-guided biopsy (carried out under local anaesthesia) has
only minor and transient adverse effects23 and no discernible effect on HRQoL.108
In contrast, there is some evidence that TPM-biopsy affects urinary, bowel and erectile function,55,109 which
could plausibly have an impact on HRQoL. The available evidence suggests that these effects are also
transient and resolve within 30 days to 6 weeks.21,55,57,109 Given this, the model base case assumes that
mpMRI and TRUS-guided biopsy have no effect on HRQoL. In the model, TPM-biopsy is assumed to
decrease HRQoL by 0.176, as observed in PROMIS, over a time period of 2 weeks. This is incorporated in
the model as a normal distribution (mean –0.176, standard error 0.014).
Resource use and costs
The decision tree considers the direct cost of the diagnostic tests and the costs associated with the
resources used to manage their adverse effects.
Resource use resulting from adverse effects
In PROMIS, data on health-care resource use were collected for each man at their end-of-study visit, but it
was not possible to ascribe the resource use to a specific diagnostic test. Therefore, the resource use
associated with the adverse effects of each test was obtained from the literature. For TRUS-guided biopsy,
resource use is informed by Rosario et al.27 Rosario et al.27 prospectively observed 1147 men in the UK
35 days after TRUS-guided biopsy. During this period, 15 men (1.3%) were admitted to hospital, 92 men
(8.0%) consulted a general practitioner, 14 men (1.2%) consulted the urology department nurse and
13 men (1.1%) consulted another source of medical advice. For TPM-biopsy, resource use is informed by
Pepe and Aragona.26 Pepe and Aragona26 report the prevalence of complications, including hospitalisations
and accident and emergency (A&E) admissions, in men with suspected prostate cancer who underwent
fortransperineal prostate biopsy with 12, 18 or > 24 samples (saturation biopsy), at 15–20 days after the
biopsy. Of the 630 men included, 10 men (1.6%) and 91 men (14.4%) experienced a hospital admission and
an A&E admission, respectively. Consultations with general practitioners or other health-care contacts were
not reported. The mpMRI is assumed to involve no health-care resource use caused by adverse effects. Counts
of resource use are incorporated in the model as beta distributions. These are summarised in Table 29.
Unit costs
The model evaluates the cost of testing, which includes the cost of each of the diagnostic tests that form
the diagnostic strategies and the cost of managing their adverse effects. The costs refer to the 2014–15
price year. For the base case, the unit costs are based on hospital care costs in the Reference Costs
2014–15110 and the Unit Costs of Health and Social Care 2015.111 In the scenarios, the unit costs are based
on the payment-by-results (PbR) tariff for 2014/15112 and the Unit Costs of Health and Social Care 2015.111
TABLE 28 The HRQoL impact of diagnostic tests
Parameter Value, mean (95% CI) Source or rationale
Change post mpMRI Assumed zero The change post mpMRI in PROMIS was negligible
Change post
TRUS-guided biopsy
Assumed zero Essink-Bot et al.108 found no impact of TRUS-guided biopsy on
HRQoL
Change post TPM-biopsy –0.176 (–0.15 to –0.20) Obtained from the PROMIS individual patient data. Duration of
decrement assumed to be 2 weeks based on Merrick et al.55 and
Tsivian et al.109
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All of these sources provide the cost of a procedure or appointment to the NHS taking into account
capital, overheads and staffing costs. These costs are included in the model deterministically because their
variation is a result of the heterogeneity in the patient population rather than parameter uncertainty that
can be resolved with additional research. Table 30 shows the unit costs used in the base case.
Analytical methods
The decision tree compares the diagnostic outcomes, short-term costs and health outcomes (measured as
HRQoL) of the different diagnostic strategies. The results are probabilistic in that they represent the
average over 1000 Monte Carlo simulations sampled from the distributions of the parameter inputs.113
The 95% CIs are calculated as the 97.5 and 2.5 percentiles of the Monte Carlo simulations.
TABLE 30 Unit costs used for the base case
Parameter Value (£) Source
Diagnostic tests
TRUS-guided biopsy 403 ‘LB76Z Transrectal ultrasound guided biopsy of the prostate’
TPM-biopsy 1370 ‘LB77Z Transperineal template biopsy of prostate’
mpMRI, T2 weighting, DW and DCE 182 ‘RD03Z MRI scan of one area with pre- and post-contrast’
Management of AEs from testing
A&E admission 132 Average cost of emergency medicine
Hospital admission 587 Average cost of non-elective admission, short stay
Urology department nurse 94 Unit cost of ‘WF01A: non-admitted face-to-face attendance,
follow-up, urology’
Other costs that are common to both scenarios
General practitioner 44 Curtis111
Other health-care advice 7.90 Curtis111
Note
Costs are drawn from NHS Reference Costs 2014–15110 unless otherwise stated.
TABLE 29 Resource use in the short-term model
Parameter Value, % (n/N) Source
Associated with TRUS-guided biopsy
Hospital admission 1.3 (15/1147) Rosario et al.27
Consultation with general practitioner 8.0 (92/1147)
Consultation with urology department nurse 1.2 (14/1147)
Sought other medical advice 1.1 (13/1147)
Associated with TPM-biopsy
Hospital admission 1.6 (10/630) Pepe and Aragona26
A&E admission 14.4 (91/630)
EVALUATION OF SHORT-TERM OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
Results are presented for the 32 strategies over the two definitions of TRUS-guided biopsy for CS cancer,
the two definitions of mpMRI for CS cancer and the four cut-off points. These form 16 substrategies,
as detailed in Table 31. The substrategies are labelled as follows:
l The first number indicates the definition of CS cancer for TRUS-guided biopsy: the primary definition
is definition 1 and the secondary definition is definition 2. Substrategies 112–5 and 122–5 use
TRUS-guided biopsy definition 1, the primary CS definition.
l The second number indicates the definition of CS cancer for mpMRI: the primary definition is definition
2 and the secondary definition is definition 1. Substrategies 122–5 and 222–5 use definition 2, the
primary CS cancer definition.
l The third number indicates the cut-off point: ≥ 2, ≥ 3, ≥ 4 and 5. For example, type 112 uses the
TRUS-guided biopsy definition 1, the mpMRI definition 2 and the cut-off point of ≥ 2.
l There are substrategies for which one or more of the definitions or cut-off points are not applicable;
for example, in T1, only the definition of TRUS-guided biopsy is applicable (1 or 2) because mpMRI is
not performed. These substrategies have a dash (–) to represent where the definition or cut-off point is
not applicable. Therefore, T1 under the TRUS-guided biopsy definition 1 is represented as T1 1––.
TABLE 31 Substrategies by TRUS-guided biopsy CS definition, mpMRI CS definition and mpMRI cut-off point
Substrategy
CS definition
mpMRI cut-off pointTRUS-guided biopsy mpMRI
112 1: primary 1: secondary 2
113 1: primary 1: secondary 3
114 1: primary 1: secondary 4
115 1: primary 1: secondary 5
122 1: primary 2: primary 2
123a 1: primarya 2: primarya 3a
124 1: primary 2: primary 4
125 1: primary 2: primary 5
212 2: secondary 1: secondary 2
213 2: secondary 1: secondary 3
214 2: secondary 1: secondary 4
215 2: secondary 1: secondary 5
222 2: secondary 2: primary 2
223 2: secondary 2: primary 3
224 2: secondary 2: primary 4
225 2: secondary 2: primary 5
a Strategies using TRUS-guided biopsy definition 1, mpMRI definition 2 and mpMRI cut-off point of ≥ 3 correspond to the
primary clinical outcome.
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Results
The results are presented in terms of the men referred for testing:
l the proportion of men with CS cancer detected; this corresponds to the sensitivity of the diagnostic
strategies in detecting CS cancer
l the number of TRUS-guided biopsies; this can vary from zero to two
l the proportion of men who receive TPM-biopsy
l the HRQoL loss attributable to the adverse effects of testing; this applies only to TPM-biopsy
l diagnostic efficiency as the proportion of CS cancers detected per pound spent in testing.
The diagnostic frontier is evaluated by plotting the costs and outcomes of the alternative diagnostic
substrategies. The line formed by the strategies with the most CS cancers detected per pound spent is the
efficiency frontier and identifies the strategies that represent an efficient use of resources for a certain level
of funding. Strategies above the line will detect the same proportion of CS cancers but at a higher cost.
Detection of clinically significant cancer
Figures 14–17 show the probability of detecting CS cancer (i.e. the strategies’ true-positive rate or
sensitivity) for each diagnostic substrategy. The diagnostic strategies are represented on the horizontal axis
and the probability of detecting CS cancer is represented on the vertical axis. The different substrategies
across the different definitions and mpMRI cut-off points are represented as points. The vertical bars
represent the 95% CI for the probability of detecting CS cancer for each substrategy. The figures are
organised by mpMRI cut-off point, from ≥ 2 to 5, to aid interpretation. Appendix 3 (see Tables 49 and 50)
presents the same data in tabular form.
The probability of detecting CS cancer varies between strategies and within the same strategy, depending
on the CS cancer definitions and cut-off points used. The primary TRUS-guided definition for CS cancer
(definition 1) detects up to 0.29 fewer CS cancers than the secondary definition (definition 2). This reflects
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the stringent primary definition for CS cancers. The implication is that the substrategies using definition
2 always detect more CS cancers than those using definition 1, for a given strategy, mpMRI definition and
mpMRI cut-off point.
The difference in the detection of CS cancer between the two mpMRI definitions for CS cancer is smaller
than that between the TRUS-guided definitions and depends on the mpMRI cut-off point. On average, the
primary CS cancer definition for mpMRI (definition 2: lesions with a volume of ≥ 0.2 ml and/or a Gleason
score of ≥ 3 + 4; substrategies 122–5 and 222–5) detects 0.01–0.18 more CS cancers than the secondary
definition (definition 1: lesions with a volume of ≥ 0.5 ml and/or a Gleason score of ≥ 4 + 3; substrategies
112–5 and 212–5). This is because definition 2 (primary) is less stringent and hence more sensitive in detecting
CS cancers.
Lower mpMRI cut-off points detect a large proportion of CS cancers. For example, substrategies using a
mpMRI cut-off point of ≥ 2 (substrategies 112, 122, 212 and 222; see Figure 14) detect nearly all CS
cancers. In contrast, in substrategies using a high mpMRI cut-off point, such as those using a cut-off point
of 5 (substrategies 115, 125, 215 and 225; see Figure 17), a smaller proportion of cancers is detected.
The most sensitive combination of definitions and mpMRI cut-off point to detect CS cancer includes the
secondary TRUS-guided biopsy definition (definition 2), the primary mpMRI definition (definition 2) and a
PI-RADS cut-off point of ≥ 2 (i.e. substrategy 222). This will be referred to hereafter as the ‘most sensitive
definition’. The least sensitive combination of definitions and mpMRI cut-off point uses the primary
TRUS-guided biopsy definition (definition 1), the secondary mpMRI definition (definition 1) and a mpMRI
cut-off point of 5 (i.e. substrategy 115). This will be referred to hereafter as the ‘least sensitive definition’.
As evident in Figures 14–17, strategies including TPM-biopsy detect the most CS cancers. Strategies P1
(all men are tested with TPM-biopsy) and P4 (all men in whom TRUS-guided biopsy did not detect cancer
or detected CNS cancer are retested with TPM-biopsy) detect all CS cancers.
0.0
0.1
0.2
0.3
0.4
0.5
P
ro
b
a
b
il
it
y
 o
f 
d
e
te
ct
in
g
 C
S
 c
a
n
ce
r 
if
 C
S
 c
a
n
ce
r 
e
x
is
ts
0.6
0.7
0.8
0.9
1.0
M1M2M3M4M5M6M7 N1 N2 N3 N4 N5 N6 N7 T1 T2 T3
Strategies
T4 T5 T6 T7 T8 T9 P1 P2 P3 P4 P5 P6 P7 P8 P9
115
125
215
225
Substrategies
FIGURE 17 Sensitivity of strategies with a mpMRI cut-off point of 5.
EVALUATION OF SHORT-TERM OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Some strategies at specific cut-off points and definitions detect most CS cancers:
l P9 consists of TRUS-guided biopsy in all men, mpMRI in men in whom no CS cancer was detected and
rebiopsy with TPM-biopsy in men whose mpMRI result was suspicious of CS cancer (in men for whom
TRUS-guided biopsy detected CNS cancer) or suspicious of any cancer (in men for whom TRUS-guided
biopsy did not detect cancer). P9 using the most sensitive definition (substrategy P9 222) detects all CS
cancers. The proportion of CS cancers detected decreases to a minimum of 56% when using the least
sensitive definition for mpMRI and TRUS-guided biopsy, definition 1 (substrategy P9 115).
l P7 consists of testing all men with TRUS-guided biopsy; men in whom no cancer or CNS cancer is
detected are retested with mpMRI and men with suspected CS cancer are rebiopsied with TPM-biopsy.
This detects 99% of CS cancers under the most sensitive definition for mpMRI and TRUS-guided biopsy,
definition 2 (substrategy P7 222), and 52% under the least sensitive definition (substrategy P7 115).
l N1 consists of testing all men with mpMRI and conducting TPM-biopsy in all men with suspected CS
cancer. It detects 98% of CS cancers under the most sensitive definition of mpMRI, definition 2
(substrategy N1 222), and 28% under the least sensitive definition (substrategy N1 115).
l N2 consists of testing all men with mpMRI and conducting TPM-biopsy in all men with suspected
cancer. It detects 99% of CS cancers under the most sensitive definition of mpMRI, definition 2
(substrategy N2 222), and 44% under the least sensitive definition (substrategy N2 115).
l T7 and T9 detect 95% of all CS cancers under the most sensitive definitions. In T7 and T9, all men
receive TRUS-guided biopsy. In T7, men in whom CS cancer was not detected undergo mpMRI and
those with suspected CS cancer are rebiopsied. In T9, men in whom CS cancer was not detected
undergo mpMRI. Men whose first biopsy indicated no cancer receive a second biopsy if the mpMRI
result is suspicious for any cancer. Men whose first biopsy indicated CNS cancer receive a second
biopsy if the mpMRI result is suspicious for CS cancer.
l M7 consists of testing all men with mpMRI, conducting TRUS-guided biopsy in men with suspected CS
cancer and rebiopsying those in whom CS cancer was not detected. This strategy detects 95% of CS
cancers under the most sensitive definition (substrategy M7 222). Under the least sensitive definition,
M7 detects 26% of CS cancers (substrategy M7 115).
Given that the accuracy data for each diagnostic strategy are drawn from sampled data, there is some
uncertainty regarding the sensitivity of each substrategy in detecting CS cancer. This is greater in strategies
with smaller test sequences that do not include TPM-biopsy, such as T1 [which detects 38% of CS cancers
(95% CI 33% to 43%)] and M1 [which detects 44% of CS cancers (95% CI 36% to 51%)].
The PROMIS-proposed substrategy, M7 123, detects 82% of CS cancers (95% CI 75% to 87%). M7
consists of testing all men with mpMRI, conducting TRUS-guided biopsy in men with suspected CS cancer
and rebiopsying those in whom CS cancer was not detected. This compares favourably with T4 1––, the
standard care substrategy, which does not include mpMRI and which detects 52% of CS cancers (95% CI
45% to 61%). T4 consists of testing all men with TRUS-guided biopsy and repeating this biopsy in those
men in whom CS cancer was not detected. The model calculates that the substrategy most similar to the
NICE recommendations,13 T7 123, detects 85% of CS cancers (95% CI 78% to 91%). In T7, men in whom
CS cancer was not detected undergo mpMRI and those men with suspected CS cancer are rebiopsied.
Biopsies
Number of transrectal ultrasound-guided biopsies
One of the aims of introducing mpMRI in the diagnostic pathway for prostate cancer is to avoid
unnecessary biopsies. Figure 18 shows the number of TRUS-guided biopsies carried out per man referred
for diagnosis for each substrategy. Note that this number can vary only from zero to two because the
diagnostic strategies were constrained to include up to two biopsies. Strategies P1, N1 and N2 do not
include TRUS-guided biopsy and hence the average number of TRUS-guided biopsies per referred man
is zero.
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The strategies starting with TRUS-guided biopsy involve at least one TRUS-guided biopsy per patient;
however, some involve more. Strategy T4, under TRUS-guided biopsy definition 1, has the highest mean
number of TRUS-guided biopsies per man referred, at 1.79. In this strategy, all men have TRUS-guided
biopsy and all men in whom CS cancer is not detected undergo a second TRUS-guided biopsy. Because,
under CS cancer definition 1, fewer CS cancers are detected, 79% of men receive a second TRUS-guided
biopsy. Other strategies starting with TRUS-guided biopsy with a high number of TRUS-guided biopsies per
referred man are strategies T7 and T9, with a maximum of 1.75 and 1.78, respectively. In strategy T7,
all men receive TRUS-guided biopsy and men in whom CS cancer was not detected receive mpMRI. Men
with suspected CS cancer on mpMRI receive a second TRUS-guided biopsy. Strategy T9 is similar, but
also includes rebiopsy in men in whom the mpMRI result showed suspected CNS cancer after an initial
TRUS-guided biopsy that did not detect cancer. Strategies with TRUS-guided biopsy definition 1 for CS
cancer and low cut-off points for the mpMRI score have a greater proportion of men referred for a second
biopsy. Therefore, the average number of TRUS-guided biopsies per referred man increases.
Strategies starting with mpMRI (M1–M7 and N1–N7) have a generally lower mean number of TRUS-guided
biopsies per referred man. However, in two strategies, > 50% of men receive two TRUS-guided biopsies;
these are strategies M6 and M7, under the TRUS-guided biopsy definition 1 and cut-off point of ≥ 2, in
which the average number of TRUS-guided biopsies is 1.51 and 1.66, respectively. In strategy M6, men
with suspected cancer on mpMRI receive a TRUS-guided biopsy and are rebiopsied if no cancer is detected.
In strategy M7, men with suspected CS cancer on mpMRI receive a TRUS-guided biopsy and are rebiopsied
if CS cancer is not detected.
Number of template prostate mapping biopsies
Figure 19 shows the proportion of men who undergo TPM-biopsy. As expected, given the structure of the
strategies, strategies M1–M7 and T1–T9 do not involve TPM-biopsy. Strategies N1–N7 and P1–P9 include
TPM-biopsy as the last biopsy in the series. Some strategies involve TPM-biopsy in all men referred for
diagnosis: P1, which consists of offering TPM-biopsy to all men with no prior testing, and N2, in which
men are first tested with mpMRI and men with suspected cancer receive TPM-biopsy, under the cut-off
point of ≥ 2. Under this cut-off point, all men referred for diagnosis have suspected cancer and, therefore,
receive TPM-biopsy.
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Cost of testing
Figure 20 shows the costs of testing (see Appendix 3, Tables 51 and 52, for the results in tabular form).
The least costly test (at £244, 95% CI £232 to £257) is strategy M1 (mpMRI for all men and TRUS-guided
biopsy for men in whom there is suspicion of CS cancer) using the least sensitive definition. This strategy
is the least costly because it includes only one biopsy and, using this definition and cut-off point, mpMRI
results in only 15% of men being referred for TRUS-guided biopsy. Using more sensitive definitions,
a greater proportion of men are referred for TRUS-guided biopsy.
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The most costly substrategy is P9 112, at £1654 (95% CI £1604 to £1702) per man referred. This
substrategy consists of TRUS-guided biopsy in all men, mpMRI in men in whom no CS cancer was detected
and rebiopsy with TPM-biopsy in men whose mpMRI result was suspicious of CS cancer (in men in whom
TRUS-guided biopsy detected CNS cancer) or suspicious of any cancer (in men in whom TRUS-guided
biopsy did not detect cancer) using the TRUS-guided biopsy definition 1, the secondary mpMRI definition 2
and the cut-off point of ≥ 2.
The 95% CIs are relatively narrow, at up to 9% greater or lower than the average cost. Uncertainty regarding
the cost of testing arises from uncertainty regarding the probability that each test correctly classifies men, which
determines whether or not men receive a subsequent test, and the risk of AEs for strategies involving biopsy.
The PROMIS-proposed substrategy, M7 123, costs £687 (95% CI £657 to £719). This is less than the cost
of T4 1––, the standard care substrategy without mpMRI, at £742 (95% CI £727 to £757), and the cost of
the NICE-proposed substrategy T7 123, at £780 (95% CI £760 to £801).
Health-related quality of life
Only strategies involving TPM-biopsy are associated with a HRQoL loss, because mpMRI and TRUS-guided
biopsy are assumed not to have HRQoL implications. The HRQoL loss depends on the proportion of men
receiving TPM-biopsy and thus, as expected, strategy P1 (in which all men receive TPM-biopsy) presents the
biggest loss at –0.007 QALYs. The strategy with the next greatest HRQoL loss is N2 (mpMRI for all men
and TPM-biopsy for men in whom there is suspicion of cancer) at the cut-off point of ≥ 2, irrespective of
the mpMRI definition.
Diagnostic efficiency
Figure 21 shows the relationship between the proportion of CS cancers detected and the expected cost of
testing. The strategies forming the line (called a frontier) are efficient because they offer the greatest
detection of CS cancers for different costs of testing. Strategies above the efficiency frontier are inefficient
because they are expected to detect fewer CS cancers for the same cost. Table 32 details the strategies
forming the efficiency frontier. None of these strategies, except P4, has HRQoL implications because they
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TABLE 32 Diagnostic strategies in the efficiency frontier
Strategy
TRUS-guided
biopsy
definition
mpMRI
definition
mpMRI
cut-off
point
Detection of
CS cancer,
mean
(95% CI) (%)
Cost (£) of
testing, mean
(95% CI)
M1: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer
2 1 5 22 (17 to 27) 244
(232 to 257)
M3: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
men with CNS cancer at the first biopsy
receive a second TRUS-guided biopsy
2 1 5 24 (20 to 29) 250
(237 to 264)
2 2 5 35 (30 to 41) 290
(273 to 306)
M4: mpMRI for all men and TRUS-guided
biopsy in men with suspicion of any
cancer; men with suspected CS cancer on
mpMRI and in whom CNS cancer was
detected at the first biopsy receive a
second TRUS-guided biopsy
2 2 5 37 (32 to 43) 296
(280 to 312)
M7: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
rebiopsy with TRUS-guided biopsy for
those in whom CS cancer was not detected
2 2 5 40 (35 to 46) 307
(287 to 328)
M3: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
men with CNS cancer at the first biopsy
receive a second TRUS-guided biopsy
2 2 4 57 (51 to 64) 385
(366 to 404)
M4: mpMRI for all men and TRUS-guided
biopsy in men with suspicion of any
cancer; men with suspected CS cancer on
mpMRI and in whom CNS cancer was
detected at the first biopsy receive a
second TRUS-guided biopsy
2 2 4 60 (54 to 67) 400
(382 to 420)
M7: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
rebiopsy with TRUS-guided biopsy for
those in whom CS cancer was not detected
2 2 4 65 (60 to 71) 430
(404 to 458)
T6: TRUS-guided biopsy for all men; men
classified with CNS cancer receive mpMRI
and men with suspected CS cancer
receive a second TRUS-guided biopsy
2 2 3 74 (69 to 78) 488
(473 to 503)
2 2 2 75 (71 to 79) 500
(484 to 517)
M7: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
rebiopsy with TRUS-guided biopsy for
those in whom CS cancer was not detected
2 2 3 85 (81 to 89) 628
(597 to 660)
T7: TRUS-guided biopsy for all men; men
classified as having NC or CNS cancer
receive mpMRI and men with suspected
CS cancer receive a second TRUS-guided
biopsy
2 2 3 91 (86 to 94) 709
(688 to 730)
M7: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
rebiopsy with TRUS-guided biopsy for
those in whom CS cancer was not detected
2 2 2 95 (92 to 98) 807
(777 to 833)
P4: TRUS-guided biopsy in all men and
TPM-biopsy for men in whom the biopsy
did not detect CS cancer
2 Not
applicable
Not
applicable
100
(100 to 100)
1332
(1278 to 1385)
NC, no cancer.
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do not include TPM-biopsy. Neither the PROMIS-proposed substrategy (M7 123) nor any of the standard
care substrategies (T4 1–– and T7 123) form the diagnostic efficiency frontier.
Summary of findings
l Multiparametric magnetic resonance imaging, TRUS-guided biopsy and TPM-biopsy can be used in
32 different combinations to diagnose prostate cancer. Multiparametric magnetic resonance imaging
can be used as a first test for all men referred to secondary care or following a negative TRUS-guided
biopsy result. Likewise, TRUS-guided biopsy can be used as a first test or as a targeted test following
mpMRI. The different combinations have been evaluated for different diagnostic definitions and cut-off
points, forming 383 diagnostic substrategies. Our analysis was informed by the evidence obtained in
PROMIS, together with published studies on repeated TRUS-guided biopsy and TRUS-guided biopsy in
combination with mpMRI.103–105
l The short-term outcomes relate to the immediate consequences of using the different diagnostic
strategies in men with suspected CS cancer. These are the proportion of CS cancers detected
(sensitivity), the number of TRUS-guided biopsies, the proportion of men receiving TPM-biopsy and the
cost of testing (which includes the cost of managing any adverse effects from testing). The proportion
of CS cancers detected and the cost of testing form the cost-efficiency plane and frontier.
l The strategies considered represent a range of levels of use of TRUS-guided biopsy, from 0 to 1.79
biopsies per man. The strategies considered also represent a range of levels of use of TPM-biopsy,
from strategies in which no men receive TPM-biopsy to those in which all men receive this test.
l The proportion of CS cancers detected depends on the diagnostic definition and mpMRI cut-off point.
The most sensitive strategies use the TRUS-guided biopsy definition 2, mpMRI definition 2 and cut-off
point 2. The least sensitive strategies use the TRUS-guided biopsy definition 1, mpMRI definition 1 and
cut-off point 5.
l P1 and P4 detect all CS cancers. Some strategies under the most sensitive definitions and cut-off
point detect almost all CS cancers: N1, N2, P7 and P9, involving TPM-biopsy; T7 and T9, involving
TRUS-guided biopsy as the first test; and M7, involving mpMRI as the first test.
l The diagnostic strategies cost between £244 and £1654 per man to the UK NHS.
l A limited number of strategies form the cost-efficiency frontier. These strategies detect the greatest
proportion of CS cancer by level of spending (on testing and adverse effects management). Of these,
only four substrategies detect ≥ 80% of CS cancers: M7 (substrategies 223 and 222), T7 (substrategy
223) and P4 (substrategy 2––).
¢ In M7, men whose mpMRI result is suspicious of CS cancer receive TRUS-guided biopsy and men in
whom no CS cancer was detected receive a second biopsy.
¢ In T7, all men receive TRUS-guided biopsy and men in whom TRUS-guided biopsy does not detect
CS cancer undergo mpMRI. Men in whom the mpMRI result is suspicious of CS cancer receive a
second biopsy.
¢ In P4, all men receive TRUS-guided biopsy and men in whom TRUS-guided biopsy does not detect
CS cancer undergo TPM-biopsy.
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Chapter 6 Evaluation of long-term outcomes
The cost-effectiveness of the diagnostic strategies depends not only on their short-term outcomes,described in Chapter 5, but also on the long-term outcomes of the subsequent management decisions.
To consider long-term outcomes, information is required on the lifetime costs, survival and quality-adjusted
survival of men conditional on their true disease status and the treatment decision, with these last two
aspects being defined by the diagnostic classification outlined in Table 33.
The clinical effectiveness and cost-effectiveness of treatments will determine the value of the upstream
diagnostic strategies. For this reason, ideally, alternative ways of delivering primary care management (for
patients identified as having no cancer), alternative active surveillance protocols (for those identified with
CNS cancer) and alternative treatment choices for CS cancer should be evaluated to determine the best
diagnostic strategy/test combination. If it is not possible to do so, then the post-testing health-care choices
modelled need to be the most effective/cost-effective, so that the value of testing is appropriately considered.
Otherwise, the cost-effectiveness evaluation of the diagnostic strategies may be biased. For example,
more-sensitive diagnostic strategies are favoured if the net health of radical treatment for intermediate- and
high-risk (i.e. CS) cancers is overestimated. Conversely, less sensitive diagnostic strategies are favoured if the
net health of primary care follow-up and active surveillance in CS cancers is overestimated.
No study was identified that provided the lifetime costs and quality-adjusted survival of men with low-,
intermediate- and high-risk cancer managed with primary care, active surveillance and radical treatment.
Therefore, the 2014 NICE clinical guideline,13 taken to represent the best available evidence in terms of
management and treatment recommendations for prostate cancer in the UK setting, was reviewed. Clinical
guidelines are informed by reviews of the clinical effectiveness and cost-effectiveness evidence, and
bespoke cost-effectiveness modelling, deliberated by an expert committee. They make recommendations
on how patients should be managed in light of the best available evidence and to make the best use of the
available resources. The aim is to replicate in the long-term model the recommended management options.
Evidence on long-term outcomes
National Institute for Health and Care Excellence recommendations and
supporting evidence
As discussed in Chapter 4, the 2014 NICE clinical guideline13 recommends that men diagnosed with localised
prostate cancer are managed depending on the risk of cancer progression. Men with low-risk cancer should
be offered active surveillance. Men with an intermediate risk should be offered RP or radical radiotherapy
(as radical external-beam radiotherapy or as radiotherapy with hormones) but can also consider active
TABLE 33 Long-term management of men by true disease status and diagnostic classification
Disease status
Diagnostic classification
NC detected CNS cancer detected CS cancer detected
NC Primary care follow-up Not applicablea Not applicablea
Low-risk cancer Primary care follow-up Active surveillance Not applicablea
Intermediate-risk cancer Primary care follow-up Active surveillance Radical treatment
High-risk cancer Primary care follow-up Active surveillance Radical treatment
NC, no cancer.
a Men with NC cannot be classified as having CNS or CS cancer. Similarly, men with CNS (i.e. low-risk) cancer cannot be
classified as having CS cancer.
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surveillance or high-dose rate brachytherapy with external-beam radiotherapy. Men with high-risk cancer
should be offered RP or radical radiotherapy (as radical external-beam radiotherapy or as radiotherapy with
hormones). These recommendations are based on the findings of systematic reviews and cost-effectiveness
analyses conducted for the 201413 and 2008114 NICE clinical guidelines on prostate cancer.
The 2014 NICE clinical guideline13 developed a protocol for the active surveillance of men with low-risk
cancer (see Table 2) based on clinical consensus, informed by a systematic review of the protocols for
active surveillance in 16 cohorts and a survey of cancer networks in England and Wales.114 No health
economic evidence was identified on the most cost-effective way of monitoring men diagnosed with
low-risk cancer.
The recommendation of radical treatment for intermediate- and high-risk prostate cancer is based on the
systematic review and cost-effectiveness analysis conducted for the 2008 NICE clinical guideline.114 The
systematic review identified one RCT comparing RP with watchful waiting, the SPCG-4 trial,115 that was
considered to be applicable to the UK context. At the time of this review, the SPCG-4 trial had reported up
to 10 years of follow-up.115,116
Another systematic review of the economic evidence found five studies but considered only two
studies117,118 to be relevant to the UK context. Hummel et al.117 evaluated the cost-effectiveness of different
management options, including active surveillance, from the NHS perspective. The results were driven by
the AEs from the different treatments because it was assumed that the rate of cancer progression and
death were not affected by the treatments. Calvert et al.118 compared watchful waiting with RP in men
with low- or intermediate-risk cancer (Gleason grades 5–7) from a NHS perspective. Although RP increased
survival rates, it also caused a reduction in HRQoL because of the associated AEs. As a result, RP resulted in
fewer health benefits and higher costs than watchful waiting.
Given the evidence from the 10-year follow-up of the SPCG-4 trial, and based on these data, a new
cost-effectiveness analysis was conducted to compare the costs and health outcomes of RP with those
of alternative management options for men with clinically localised prostate cancer.13 The alternative
management options included brachytherapy, standard external-beam radiotherapy, intensity-modulated
radiation therapy, high-intensity focused ultrasonography, cryotherapy and watchful waiting. Health
outcomes were expressed as QALYs. Costs were expressed in Great British pounds (GBP) from a 2006 price
base from the perspective of the UK NHS. The effect of treatment was based on the 10-year follow-up of
the SPCG-4 trial.119 Because the SPCG-4 trial evaluated RP compared with watchful waiting, the cost-
effectiveness of different therapies was explored in a threshold analysis. The time horizon was 20 years.
Radical prostatectomy was found to be more costly than watchful waiting (£10,619 compared with
£6185, respectively). It was effective in extending survival (10.19 life-years compared with 9.69 life-years,
respectively) and improving quality-adjusted survival (7.52 vs. 6.96 QALYs) if AEs were not considered.
However, if AEs were considered, RP was associated with lower quality-adjusted survival (6.36 QALYs
vs. 6.63 QALYs) and, therefore, it was dominated by watchful waiting. Probabilistic sensitivity analysis was
not conducted. The univariate sensitivity analysis suggested that the results were sensitive to the rate of
AEs, but robust to plausible changes in the cost of RP, the cost of watchful waiting and the survival benefit
from RP. Subgroup analysis by cancer risk was not carried out. The threshold analysis suggested that
modest increases in quality-adjusted survival are required for other treatment options to be cost-effective
compared with watchful waiting. However, these increases in quality-adjusted survival depend not only on
the clinical effectiveness of treatments but also on their AE profiles.
Given the cost-effectiveness evidence, the 2008 NICE clinical guideline114 recommended, and the 2014
NICE clinical guideline13 maintained, that men with intermediate-risk localised prostate cancer should be
offered RP or radical radiotherapy. This recommendation includes men with high-risk localised prostate
cancer when there is a realistic prospect of long-term disease control.
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Clinical effectiveness of radical treatment in the recent literature
The 2014 NICE clinical guideline13 recommends RP or radical radiotherapy for men with intermediate- or
high-risk prostate cancer, who are classified in PROMIS as having CS cancer. However, and as discussed in
the previous section, the 2014 NICE guideline found no clear evidence on the clinical effectiveness and
cost-effectiveness of RP compared with radical radiotherapy.
For the current study, the literature was examined for more recent systematic reviews, namely Xiong
et al.120 and Wallis et al.101 These have also been inconclusive. Xiong et al.120 conducted a systematic review
and network meta-analysis of RCTs comparing RP, external-beam radiotherapy, watchful waiting and
cryotherapy for localised prostate cancer. No treatment reached significance at the 95% credible interval
superior although hypofractionated conformal low-dose radiotherapy was the treatment most likely to be
clinically effective (OR vs. watchful waiting 0.53, 95% credible interval 0.10 to 2.88). Wallis et al.101
conducted a systematic review and meta-analysis of RCTs and cohort and case–control studies comparing
RP and radiotherapy for localised prostate cancer. They found that RP statistically significantly reduces
all-cause death [hazard ratio (HR) 1.63, 95% CI 1.54 to 1.73] and death attributable to prostate cancer
(HR 2.08, 95% CI 1.76 to 2.47). However, this study has been criticised for not appropriately accounting
for the risk of bias in observational studies, because men who receive RP are typically younger and
healthier than men who receive radiotherapy.
Given these issues, the reviews were examined for RCTs comparing RP or radiotherapy with expectant
management strategies such as watchful waiting. These were the studies by Graversen et al.,121 Wilt122
Bill-Axelson et al. (the SPCG-4 study)6,115,119,123 and Widmark.124 The trial by Graversenet al.121 was not
included in this review because it recruited participants 4–5 decades in the past and, therefore, is unlikely
to reflect the current standard of care. The trial by Widmark124 which compared radiotherapy with watchful
waiting, was excluded because it has been published only in abstract format. Therefore, two studies were
included: Wilt,8 who reported on PIVOT, and Bill-Axelson et al.,6,115,119,123 who reported on the SPCG-4 RCT
(Table 34). Both studies compare RP with observation. RP reduces the risk of all-cause death, death
TABLE 34 Summary of studies on clinical effectiveness linking prostatectomy, radiotherapy and observation
Item
Study
Wilt8 Bill-Axelson et al.6,115,119,123
Country USA Sweden, Finland and Iceland
Enrolment period 1994–2002 1989–99
Stage (see Table 1) T1–T2 T1b–T2
Interventions and sample
size per group
Observation, n= 367; prostatectomy, n= 364 Observation, n= 348; prostatectomy, n= 347
Outcomes Overall survival, cancer survival, bone
metastases
Overall survival, cancer mortality, distant
metastasis, local progression
Follow-up (years) 10 18
Subgroups Age, ethnicity, Charlson Comorbidity Index,
performance status, PSA level and cancer risk
Age and cancer risk
Entire study population Non-SS: RP reduces risk of all-cause death
and cancer death; SS: RP reduces risk of
bone metastases
SS: RP reduces risk of all-cause death, cancer
death, distant metastases and local
progression
Intermediate risk Non-SS: RP reduces risk of cancer death and
bone metastases; SS: RP reduces risk of
all-cause death
SS: RP reduces risk of all-cause death, cancer
death, distant metastases and local
progression
High risk Non-SS: RP reduces the risk of all-cause
death and cancer death; SS: RP reduces the
risk of bone metastases
Non-SS: RP reduces risk of all-cause death,
cancer death and distant metastases; SS: RP
reduces risk of local progression
SS, statistically significant.
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attributable to prostate cancer and progression, although the magnitude of the effect may depend on the
cancer risk of progression. In the absence of RCT evidence on radiotherapy compared with watchful
waiting (or other types of deferred treatment such as active monitoring) in men with intermediate- and
high-risk cancer, RP was selected in the base case as the treatment of choice for men with intermediate-
and high-risk prostate cancer.
The clinical effectiveness of radical prostatectomy for clinically significant cancer
Following the 2014 NICE clinical guideline,13 the decision model assumes that men classified as having CS
cancer receive RP. The results from the SPCG-4 trial and PIVOT suggest that the treatment effect depends
on the risk of cancer progression. Therefore, the model should include the treatment effect specific to each
cancer risk subgroup. This treatment effect can be obtained from one of the two RCTs identified or from a
meta-analysis of these studies if they are sufficiently homogeneous to allow pooling.
Both the SPCG-4 trial and PIVOT include subgroup analysis by cancer risk. In the SPCG-4 trial, low risk was
defined as a PSA level of < 10 ng/ml and either a Gleason score of < 7 or a World Health Organization
grade of 1; high risk was defined as a PSA level of ≥ 20 ng/ml or a Gleason score of > 7; and the
intermediate-risk group consisted of men who did not fulfil the low-risk or high-risk criteria.6 The risk
stratification was similar in PIVOT. Low risk was defined as a PSA level of ≤ 10 ng/ml, a Gleason score of
≤ 6 and tumour stage T1–T2a; intermediate risk was defined as a PSA level of > 10 ng/ml and ≤ 20 ng/ml,
a Gleason score of 7 and tumour stage T2b; and high risk was defined as men who were not low risk or
intermediate risk but whose cancer was still clinically localised.8 These two definitions are similar to the risk
stratification in the 2014 NICE clinical guidelines.13
To choose the approach for the base case (meta-analysis or single study), the participant characteristics of
the SPCG-4 trial and PIVOT were compared with the characteristics of participants enrolled in PROMIS. The
inclusion criteria for PROMIS were men aged ≥ 18 years at risk of prostate cancer who had been referred
for biopsy, a serum PSA level of ≤ 15 ng/ml within the previous 3 months, suspected stage of ≤ T2 on
rectal examination and fit to undergo all study procedures. In PROMIS, men with intermediate-risk CS
cancer had a mean age of 64.9 years (SD 7.3 years) and their mean PSA level was 8.0 ng/ml (SD 3.0 ng/ml)
and men with high-risk CS cancer had a mean age of 66.8 years (SD 6.5 years) and their mean PSA level
was 8.3 ng/ml (SD 3.4 ng/ml). Their mean age is similar to that of men in the SPCG-4 trial but, within the
risk subgroups, their mean PSA level is lower. In the SPCG-4 trial, men with intermediate-risk cancer had a
mean PSA level of approximately 11.5 ng/ml (SD not reported) and men with high-risk cancer had a mean
PSA level of approximately 25–29 ng/ml (SD not reported). It is not possible to compare the PROMIS
intermediate- and high-risk subgroup characteristics with those of PIVOT because PIVOT does not report
baseline characteristics by subgroup. When comparing the entire PIVOT population with the SPCG-4 trial
population, the mean age in PIVOT is slightly older, the mean PSA level is lower and the mean clinical
stage is less severe, because approximately half of the men in PIVOT had stage T2 cancer compared with
three-quarters of the men in the SPCG-4 trial. Because the SPCG-4 trial population appears to be at a
higher risk of cancer progression than the PROMIS population, PIVOT was selected as the source of the
treatment effect for RP in men with intermediate- and high-risk CS cancer. Recently, the ProtecT study,9
comparing active surveillance, RP and radiotherapy in men with localised prostate cancer, has reported
results. This study was not considered because it does not report results by cancer risk subgroup. Access to
individual-level data from these studies was not sought.
Methods
Overview
The long-term model aims to predict the lifetime QALYs and costs of men with no cancer (who are
followed in primary care), low-risk cancer (who can be followed in primary care or managed with active
surveillance) and intermediate- and high-risk cancer (who can be followed in primary care, be managed
with active surveillance or receive radical treatment). As discussed earlier, the NICE cancer risk
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classifications13 are broadly equivalent to the PROMIS cancer significance definitions: low risk is equivalent
to CNS cancer and intermediate risk and high risk are equivalent to CS cancer.
Ideally, the long-term model would be informed by a RCT in which men with CNS (low-risk) cancer were
randomised to receive primary care management or active surveillance and men with CS (intermediate-
and high-risk) cancer were randomised to receive primary care management, active surveillance or radical
treatment. However, only two RCTs were identified that provide relevant evidence: the SPCG-4 trial6,115,119,123
and PIVOT.124 As discussed earlier, because men in the SPCG-4 trial appear to have more severe cancer than
men in PROMIS, even within their risk subgroups, PIVOT is used as the source of evidence for the base case.
This assumes that observation in PIVOT is equivalent to the NICE-recommended active surveillance
protocol13 in its consequences for health outcomes.
Note that PIVOT stratified patients into subgroups of risk using an imperfect test (TRUS-guided biopsy) and
thus a proportion of patients with a higher risk of cancer were misclassified and included in lower-risk
groups. Given the absence of alternative evidence, the analysis takes the evidence as it is. In addition, the
long-term outcomes of men with cancer who were misclassified as having no cancer and who are followed
in primary care are assumed to be equivalent to those of men who are managed with observation in PIVOT.
The implications of this assumption are explored in the sensitivity analysis. In addition, the PIVOT observation
protocol8 is assumed to be equivalent to the NICE active surveillance protocol13 in its detection of progression
and referral to subsequent treatment.
To predict the lifetime QALYs and costs of men with cancer, information is required on the length of time
that men spend with both localised and metastatic disease. A decision model can predict the lifetime
QALYs and costs of men with cancer, using information on their probability of developing metastases,
their probability of death without metastases and their probability of death once metastases have
developed. There are a number of challenges raised by the data on PIVOT reported by Wilt et al.8 to
inform the cost and QALYs:
l Some men in PIVOT are alive at the time of reporting. Therefore, the model needs to extrapolate the
survival of these men based on the available information.
l Wilt et al.8 report the cumulative prevalence of metastases at 4, 8 and 12 years, which does not allow
for the direct estimation of the probability of developing metastasis.
l Wilt et al.8 do not report the prevalence of death in men who have progressed to metastases. In other
words, this does not allow for the direct estimation of the probability of death from metastasis.
For these reasons, the modelling of long-term outcomes takes a three-step approach:
1. The life-years from diagnosis for each subgroup and management option are predicted using a
partitioned model based on all-cause mortality reported in PIVOT.
2. A plausible set of transition probabilities between progression-free survival, metastases and death are
selected using the life-years predicted from data on the prevalence of metastasis from PIVOT8 and
the prevalence of death following metastasis from another study [Systemic Therapy in Advancing or
Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)].125
3. The lifetime QALYs and costs are predicted using the plausible set of transition probabilities obtained
from step 2.
In summary, for the prediction of long-term outcomes, the model assumes that the health outcomes of
men in PIVOT are representative of the health outcomes of men with prostate cancer. Hence, men with
CS cancer who are classified as such are assumed to be equivalent to the men with intermediate- and
high-risk cancer who are allocated to RP. Men with CS cancer who are classified as having no cancer or as
having CNS cancer are assumed to be equivalent to the men with intermediate- and high-risk cancer who
are allocated to observation. Men with CNS cancer who are classified as having no cancer or as having
CNS cancer are assumed to be equivalent to men with low-risk cancer who are allocated to observation.
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For the calculation of costs, the modelling of long-term outcomes assumes that men classified as having
CS cancer receive active treatment in the form of RP. Men classified as having CNS cancer receive active
surveillance. Men classified as having no cancer are discharged to primary care.
Modelling approach
Step 1: life-years
Appendix 4 reports the modelling approach in detail. In brief, the survival curves reported in the
supplementary material of Wilt et al.8 for each subgroup allocated to observation were digitised using
WebPlotDigitizer version 3.12 (Ankit Rohatgi, Austin, TX, USA), a free online tool. Alternative parametric
distributions were assessed for goodness of fit with the available data. The Weibull distribution was
selected across the three cancer risk subgroups. In the extrapolation period, the Weibull distribution
predicted lower hazards of death than those of the general population. Therefore, at relevant times, the
hazard of death of the general population was used to predict survival.
Step 2: transition probabilities
Step 1 obtains the life-years for each subgroup and each treatment option. However, the prediction of
quality-adjusted survival (i.e. QALYs) and costs requires information about the health state in which these
life-years are lived, namely whether with progression-free or metastatic disease. This requires information
on the transition probabilities from progression-free disease to metastasis or death and from metastasis to
death. This is obtained with a Markov model with three health states (progression-free disease, metastatic
disease and death), evaluated by calibration (Figure 22). The model is calibrated to the life-years predicted
in step 1, the proportion of patients with metastases in Wilt et al.8 and a plausible range of values for the
probability of dying after metastasis from the standard care arm of the STAMPEDE trial.125
Specifically, the calibration model aimed to find a plausible set of transition probabilities that fit the above
criteria. It randomly draws numbers between 0 and 1 from the transitions from progression-free disease
to metastatic disease and death. For the transition from metastatic disease to death, the model draws a
random number from within the 95% CI of the cumulative incidence of all-cause death from the metastatic
disease subgroup allocated to the standard care arm of the STAMPEDE trial.125 A 10% leeway is given to
allow for differences in the disease severity of patients and their management between the STAMPEDE trial
and PIVOT. STAMPEDE is a RCT set in the UK that compares treatments for men with locally advanced and
metastatic prostate cancer. James et al.125 report the survival outcomes of men with newly diagnosed
metastatic prostate cancer who were allocated to the current standard of care, androgen deprivation
therapy.
The calibration model records the transition probabilities that meet three conditions of plausibility: (1) the
life-years are within the 95% CI predicted in step 1, (2) the cumulative incidence of metastases at 12 years
is within the 95% CI of PIVOT and (3) the transition probability from progression-free disease to death is
smaller than the transition probability from metastatic disease to death. The calibration model is run until
1000 plausible sets of transition probabilities for each subgroup are found.
Step 3: lifetime quality-adjusted life-years and costs
Lifetime QALYs and costs are predicted by the same three-state Markov model and the plausible set of
transition probabilities from step 2. A 3.5% discount rate is used to calculate the present value of future
benefits (QALYs) and costs, in line with current NICE guidance.99
Progression free Metastases Death 
FIGURE 22 Structure of the long-term calibration model.
EVALUATION OF LONG-TERM OUTCOMES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Model inputs
The inputs for HRQoL and costs are reported in Table 35. The model assumes that the active treatment of
choice is RP. Men diagnosed with CNS cancer receive active surveillance, as recommended by NICE.13 HRQoL
in men with no cancer is calculated as a function of the men’s age using the Ara and Brazier127 regression
model. Men with localised cancer are assumed to have the same HRQoL as similarly aged men with no
cancer. In other words, localised cancer is assumed to have no effect on men’s HRQoL. The treatment and
management of localised cancer is also assumed to have no HRQoL implications. This is based on the findings
of Korfage et al.,129 who found no effect of treatment on HRQoL post RP. The decrement from metastatic
disease is calculated from Torvinen et al.126 Torvinen et al.126 assessed HRQoL in different stages of prostate
cancer using the EQ-5D, 15D and European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire-C30 (EORTC-30) in Finland between 2009 and 2010. Men with prostate cancer were
divided into five mutually exclusive groups: (1) local disease in the first 6 months after diagnosis (n = 47),
(2) local disease 0.5–1.5 years after diagnosis or recurrence (n = 158), (3) local disease > 1.5 years after
diagnosis (n = 317), (4) metastatic disease (n = 89) and (5) palliative care (n = 19). The decrement for
metastatic disease is estimated for the model as the difference between the weighted average of the local
disease EQ-5D score and the weighted average of the metastatic disease EQ-5D score.
TABLE 35 Parameter inputs used to predict lifetime QALYs and costs
Parameter Value Source
HRQoL
Decrement from
metastatic disease
–0.137 Torvinen et al.:126 calculated as the difference between the average EQ-5D
score reported for localised cancer and the average EQ-5D score reported
for metastatic cancer. The probabilistic value is sampled from the difference
between the distributions (parameterised as beta distributions)
Age-related decrement Ara and Brazier127
Constant 0.9508566
Coefficient on male 0.0212126
Coefficient on age –0.0002587
Coefficient on age
squared
–0.0000332
Unit costs (all deterministic)
Radical treatment total
(one-off cost)
£4667 2014/15 National Tariff Payment System:112 average of the PbR tariff for
‘LB21Z Bladder neck open procedures – male’ and ‘LB22Z Laparoscopic
bladder neck procedures – male’
RP surgery £4275
Urology follow-up £91 2014/15 National Tariff Payment System:112 PbR tariff for ‘WF01A:
Follow-up attendance single professional’
First surgical
consultation
£210 2014/15 National Tariff Payment System:112 PbR tariff for ‘WD01B:
First attendance single professional’
Follow-up surgical
consultation
£91 2014/15 National Tariff Payment System:112 PbR tariff for ‘WF01A:
Follow-up attendance single professional’
Active surveillance total
(per year)
£138 2014/15 National Tariff Payment System:112 PbR tariff for ‘WF01A:
Follow-up attendance single professional’ and cost of PSA test in primary
care, conducted three times per year
Follow-up surgical
consultation
£91
PSA testing in
primary care
£16 × 3
continued
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Radical treatment is costed as the cost of RP. The cost of RP includes the cost of surgery and follows
the approach taken for the 2014 NICE clinical guideline.13 It includes the procedure cost, taken as the
average PbR tariff for ‘LB21Z Bladder neck open procedures – male’ and ‘LB22Z Laparoscopic bladder
neck procedures – male’ (both combined day case/ordinary elective spell tariff), the urology follow-up
appointment (‘WF01A: Follow-up attendance single-professional’), a first surgical consultation (‘WD01B:
First attendance single-professional’) and a follow-up surgical consultation (‘WF01A: Follow-up attendance
single-professional’). Active surveillance is costed as an annual cost corresponding to a once-yearly
outpatient appointment (‘WF01A: Follow-up attendance single-professional’) and three PSA tests in
primary care.
Every year, men incur an annual cost for the management of AEs. This cost is calculated as the weighted
average of the incidence of AEs multiplied by the unit cost of managing those AEs. The incidence of
AEs is obtained from PIVOT. Wilt122 reports patient-reported urinary, erectile and bowel dysfunction at
2 years. The cost of managing AEs is obtained from the PbR tariff for the management of erectile
dysfunction (PbR tariff for LB43Z) and from the 2014 NICE clinical guideline13 for the management of
urinary incontinence and bowel dysfunction (inflated to 2014–15 prices).
Men with no cancer are modelled to have the life expectancy and HRQoL of the UK general
population127,130 and incur the costs of a once-yearly PSA test in primary care.111
TABLE 35 Parameter inputs used to predict lifetime QALYs and costs (continued )
Parameter Value Source
AEs (per year) £205 Weighted average of the cost of managing AEs by the incidence of each AE
Sexual dysfunction
(per year)
£282 2014/15 National Tariff Payment System:112 PbR tariff for ‘LB43Z: Treatment
of erectile dysfunction’
Urinary incontinence
(per year)
£279 NICE13 and Unit Costs of Health and Social Care 2015:111 management with
containment pads, from NICE clinical guideline 2014, inflated from 2008–9
to 2014–15 prices
Bowel dysfunction
(per year)
£1707 NICE13 and Unit Costs of Health and Social Care 2015:111 mean weighted
cost of sigmoidoscopy, laser therapy, enemas and blood transfusion, from
the 2014 NICE clinical guideline, inflated from 2008–9 to 2014–15 prices
Metastatic cancer
(per year)
£1876 Calculated from Lord et al.128 (605.45 years of life predicted from the end
of progression-free disease to death+ 39.92 years from fourth-line palliative
care treatment to chemotherapy; the lifetime cost of treatment is
£1,072,554 (price year 2010–11), which inflated to 2014–15 prices is
£1,136,124111
Incidence of AEs
Following radical treatment Wilt et al.:8 RP group, incidence over 2 years converted to 1-year probability
Sexual dysfunction 231/285
Urinary incontinence 49/287
Bowel dysfunction 35/286
Under active surveillance Wilt et al.:8 observation group, incidence over 2 years converted to 1-year
probability
Sexual dysfunction 18/284
Urinary incontinence 124/281
Bowel dysfunction 32/282
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Results
Step 1: life-years
Table 36 shows the input parameters and life-years predicted from the PIVOT survival curves reported
in Wilt et al.8 In PIVOT, men were aged, on average, 67 years. Their life expectancy using 2012–14
UK life tables130 is 18.38 years. The model predicts a life expectancy of 16.26 years (95% CI 14.77 to
17.26 years) for men with low-risk (CNS) cancer managed with active surveillance, 13.38 years (95% CI
11.59 to 15.09 years) for men with intermediate-risk (CS) cancer managed with active surveillance,
15.65 years (95% CI 13.95 to 16.93 years) for men with intermediate-risk (CS) cancer managed with
radical treatment, 11.15 years (95% CI 9.16 to 13.47 years) for men with high-risk (CS) cancer managed
with active surveillance and 13.23 years (95% CI 10.91 to 15.42 years) for men with high-risk (CS) cancer
managed with radical treatment.
The life expectancy of men with low-risk cancer is lower than that of men with no cancer, but this is
explained by two factors. First, PIVOT was set in the USA and recruited men between 1994 and 2002,
predominantly in the Veterans Affairs Healthcare system; their life expectancy is likely to be lower than the
current life expectancy in the UK for men of a similar age. Second, and to address the heavy tail predicted
by the Weibull parametric model, the hazard rate applied is the maximum between the hazard rate for
death of men with no cancer (from UK life tables) and that of men with low-risk cancer. Nevertheless, the
differences in life expectancy are as expected: men with low-risk (CNS) cancer have a longer life expectancy;
men with intermediate- and high-risk (CS) cancer have a lower life expectancy, but it is higher if they are
treated with RP.
Step 2: transition probabilities
Table 37 shows the transition probabilities predicted by the calibration model. The transition probabilities
from progression-free disease to metastases vary by subgroup and management option. The model
predicts that men with low-risk (CNS) cancer have a yearly probability of 0.008 of progressing to
metastases; this is similar to the probability in men with intermediate- and high-risk (CS) cancer who have
received radical treatment. The model predicts that men with intermediate- and high-risk (CS) cancer
who received watchful waiting have more than double the probability of progressing to metastases. The
predicted probabilities from progression-free disease, and from metastases, to death are similar across
the subgroups.
Step 3: lifetime quality-adjusted life-years and costs
Table 38 shows the lifetime QALYs and costs, discounted at 3.5% and predicted using the plausible set of
transition probabilities. The model predicts that men with low-risk (CNS) cancer who are managed with
active surveillance have 8.45 QALYs (95% CI 7.99 to 8.94 QALYs) and accrue health-care costs of £3994
(95% CI £3301 to £4894) over their lifetime. Men with intermediate-risk (CS) cancer managed with active
TABLE 36 Input parameters and life-years predicted with the partitioned model using a parametric Weibull curve
Subgroup Management
Mean (95% CI)
Scale Shape Life-years
Low-risk cancer Active surveillancea 0.019 (0.015 to 0.023) 1.278 (1.248 to 1.306) 16.26 (14.77 to 17.26)
Intermediate-risk
cancer
Active surveillancea 0.025 (0.022 to 0.029) 1.358 (1.312 to 1.403) 13.38 (11.59 to 15.09)
Radical treatmentb 0.018 (0.015 to 0.021) 15.65 (13.95 to 16.93)
High-risk cancer Active surveillancea 0.027 (0.021 to 0.034) 1.463 (1.436 to 1.489) 11.15 (9.16 to 13.47)
Radical treatmentb 0.020 (0.015 to 0.025) 13.23 (10.91 to 15.42)
a Active surveillance corresponds to the observation group of PIVOT.
b Radical treatment corresponds to the RP group of PIVOT.
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surveillance have 7.29 QALYs (95% CI 6.65 to 8.03 QALYs) and accrue health-care costs of £4130 (95% CI
£3215 to £5351) over their lifetime. Men with high-risk (CS) cancer who receive radical treatment have
8.23 QALYs (95% CI 7.69 to 8.79 QALYs) and accrue health-care costs of £7041 (95% CI £6353 to £7959)
over their lifetime.
The incremental cost-effectiveness ratio (ICER) for radical treatment compared with active surveillance in
men with intermediate-risk (CS) cancer is £3067 per QALY gained. The probability that radical treatment
is cost-effective is 0.91 assuming that the health opportunity cost (i.e. cost-effectiveness threshold) is
£13,000 per QALY gained; it is 0.93 for a health opportunity cost of £20,000 per QALY gained and 0.94
for a health opportunity cost of £30,000 per QALY gained.
Men with high-risk (CS) cancer managed with active surveillance have 6.38 QALYs (95% CI 5.59 to 7.36
QALYs) and accrue health-care costs of £3764 (95% CI £2804 to £5001) over their lifetime. Men with
high-risk (CS) cancer who receive radical treatment have 7.21 QALYs (95% CI 6.42 to 8.18 QALYs) and
accrue health-care costs of £6796 (95% CI £6112 to £7746) over their lifetime.
The ICER for active treatment compared with active surveillance in men with high-risk (CS) cancer is £3602
per QALY gained. The probability that radical treatment is cost-effective is 0.78 for a health opportunity
cost of £13,000 per QALY gained, 0.81 for a health opportunity cost of £20,000 per QALY gained and
0.82 for a health opportunity cost of £30,000 per QALY gained. The implication is that radical treatment is
highly likely to be cost-effective compared with active surveillance for men with CS cancer.
TABLE 37 Transition probabilities predicted by the calibration model
Subgroup Management
Transition probabilities, mean (95% CI)
Progression-free
disease to metastases
Progression-free
disease to death Metastases to death
Low-risk cancer Active surveillancea 0.008 (0.004 to 0.013) 0.050 (0.043 to 0.058) 0.139 (0.058 to 0.226)
Intermediate-risk
cancer
Active surveillancea 0.018 (0.010 to 0.026) 0.064 (0.049 to 0.078) 0.145 (0.071 to 0.223)
Radical treatmentb 0.007 (0.003 to 0.011) 0.054 (0.045 to 0.063) 0.142 (0.062 to 0.226)
High-risk cancer Active surveillancea 0.022 (0.011 to 0.034) 0.080 (0.058 to 0.101) 0.157 (0.087 to 0.226)
Radical treatmentb 0.008 (0.002 to 0.014) 0.070 (0.053 to 0.085) 0.148 (0.071 to 0.225)
a Active surveillance corresponds to the observation group of PIVOT.
b Radical treatment corresponds to the RP group of PIVOT.
TABLE 38 Lifetime QALYs and costs
Subgroup Management
Mean (95% CI)
Lifetime QALYsa Lifetime costs (£)a
Low-risk cancer Active surveillanceb 8.45 (7.99 to 8.94) 3994 (3301 to 4894)
Intermediate-risk cancer Active surveillanceb 7.29 (6.65 to 8.03) 4130 (3215 to 5351)
Radical treatmentc 8.23 (7.69 to 8.79) 7041 (6353 to 7959)
High-risk cancer Active surveillanceb 6.38 (5.59 to 7.36) 3764 (2804 to 5001)
Radical treatmentc 7.21 (6.42 to 8.18) 6796 (6112 to 7746)
a Future QALYs and costs discounted at 3.5% in line with current guidelines.99
b Active surveillance corresponds to the observation group of PIVOT.
c Radical treatment corresponds to the RP group of PIVOT.
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Summary
l The 2014 NICE clinical guideline13 recommends that men with low-risk cancer, equivalent to CNS
cancer, should receive active surveillance and be offered radical treatment if their cancer progresses. It
recommends that men with intermediate- and high-risk cancer, equivalent to CS cancer, should receive
radical treatment if there are reasonable chances of a cure. These recommendations are based on
limited quantitative evidence on the cost-effectiveness of active surveillance and active treatment for
these patients.
l Two good-quality RCTs were identified on the clinical effectiveness of RP compared with watchful
waiting for the management of prostate cancer by risk subgroup: the SPCG-4 trial6,115,119,123 and
PIVOT.8,122 The patients taking part in PIVOT were found to be more comparable to the patients in
PROMIS; therefore, PIVOT was selected to inform the prediction of long-term outcomes. No evidence
was found on the clinical effectiveness of other treatments by risk subgroup. Consequently, RP was
taken as the treatment of choice in patients referred for radical treatment.
l Men with low-risk cancer managed with active surveillance have a life expectancy of 16.26 years on
average. Men with intermediate-risk cancer who receive active surveillance have a life expectancy of
13.38 years on average; this increases to 15.65 years if they receive radical treatment. Men with
high-risk cancer who receive active surveillance have a life expectancy of 11.15 years on average; this
increases to 13.23 years if they receive radical treatment.
l Radical treatment was found to be cost-effective compared with active surveillance in men with
intermediate-risk and high-risk cancer, with an ICER of £3067 per QALY gained and £3602 per QALY
gained, respectively. The probability that radical treatment is cost-effective ranges between 0.74
and 0.93.
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Chapter 7 Cost-effectiveness of diagnostic
strategies
The most cost-effective strategy is the strategy that offers the greatest net health, evaluated at threevalues of health opportunity cost (£13,000, £20,000 and £30,000 per QALY gained). Net health is
calculated by converting the costs associated with each diagnostic strategy into health forgone using the
aforementioned values of health opportunity cost and subtracting this from the direct health outcomes of
each strategy. The health benefits and costs of the diagnostic strategies are evaluated by combining the
results of the short-term model, described in Chapter 5, with those of the long-term model, described in
Chapter 6.
Following TRUS-guided biopsy, men classified as having no cancer are assumed to be discharged, men
classified as having CNS cancer are assumed to receive active surveillance as advised by the NICE clinical
guideline13 and men classified as having CS cancer are assumed to receive immediate radical treatment.
In the model:
l The costs and health outcomes of men with intermediate- and high-risk cancer who receive radical
treatment are assumed to represent the costs and health outcomes of men with CS cancer who are
correctly classified.
l The costs and health outcomes of men with intermediate- and high-risk cancer who receive active
surveillance are assumed to represent the costs and health outcomes of men with CS cancer who are
incorrectly classified as being of low risk or having no cancer.
l The costs and health outcomes of men with low-risk cancer who receive active surveillance are
assumed to represent the costs and health outcomes of men with CNS cancer.
The costs and health outcomes of each strategy are the weighted average of the costs and health benefits
of each group of men, defined by their true cancer status and diagnostic classification, weighted by the
sensitivity and specificity of the diagnostic strategies for classifying them.
Analytical methods
In order to consider uncertainty, analyses were run probabilistically. The 1000 simulations from the model
predicting short-term outcomes were considered together with the 1000 simulations of the model
predicting long-term outcomes to calculate the distribution of overall QALYs and costs associated with
each diagnostic strategy. Results are presented in terms of their averages and 95% CIs, calculated using the
percentile method. The expected overall costs and QALYs are shown in the cost-effectiveness plane and a
cost-effectiveness frontier is drawn. The cost-effectiveness frontier is formed by the substrategies that offer the
most health outcomes per unit of cost. Substrategies to the left of the frontier are not cost-effective, because
those in the frontier achieve more health benefits for the same cost. The probability that a strategy is
cost-effective is shown in the cost-effectiveness acceptability frontier. The probability that a strategy is
cost-effective was calculated as the proportion of simulations in which this strategy offers the most health
benefits net of its costs, for a given value of health opportunity cost.113 The cost-effectiveness acceptability
frontier indicates the probability that the cost-effective alternative, on average (i.e. the strategy with the
highest average net health value), will be cost-effective.131 Remaining sensitivity analyses were conducted
deterministically unless significant changes were observed that warranted in-depth exploration with
probabilistic sensitivity analysis.
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Sensitivity analysis
Bivariate sensitivity analysis on the unit cost of tests
A sensitivity analysis varied the unit costs of TRUS-guided biopsy and mpMRI by ± 50% from their base-case
values (£182 and £403, respectively) and used four unit costs of TPM-biopsy: (1) base case (£1370), (2) base
case + 25% (£1713), (3) base case – 25% (£1028) and (4) microcosting conducted for PROMIS (£1872). The
results are presented in area graphs showing the cost-effective diagnostic strategy for each combination.
Scenario using payment-by-results tariff unit costs
The unit costs of the tests can depend on the source of information. The NHS reference costs110 are used
in the base case. These reflect the average cost across all health-care providers. The cost charged to
commissioners is, however, indicated in the PbR tariff.112 The unit costs of TRUS-guided biopsy and mpMRI
are similar between the NHS reference costs and PbR tariff, at £403 compared with £339, respectively,
and £182 compared with £188, respectively. In contrast, the unit cost of TPM-biopsy is different between
the two sources; £931 (NHS reference costs)110 compared with £1370 (PbR tariff).112 Because the unit
costs of the tests is anticipated to have an impact on the cost-effectiveness results, the model was run
probabilistically using the PbR tariff for the unit costs.
Threshold sensitivity analysis
Additional threshold sensitivity analysis was carried out, aiming to identify the parameters that can have
an impact on the results and indicate the changes in values that change the cost-effective strategy. This
analysis is run deterministically; this means that the point estimates are used rather than the full distribution
to reduce the running time of the decision model. Table 39 summarises the threshold sensitivity analysis and
its rationale.
Impact of repeated testing over time
In the base case, men with intermediate-risk cancer who are misclassified as having low-risk cancer are
assumed to receive active surveillance. Their long-term outcomes are predicted from the intermediate-risk
subgroup of the observation arm of PIVOT. This assumes that men misclassified will not receive radical
treatment in the future. In practice, however, there is the possibility that men are correctly classified in one
of the monitoring episodes of the active surveillance protocol and receive radical treatment at that point.
The evidence on repeated testing and monitoring is, however, sparse. The population of individuals for
retesting (i.e. those who initially tested negative) will differ from the overall PROMIS population and is
likely to differ by the diagnostic strategy initially implemented. This means that the accuracy of retesting
cannot be drawn from the general literature but needs to be drawn from studies that specifically focus
on retesting. In addition, between the initial test and retesting, the disease may progress in risk category,
the rate of which is unknown. For these reasons, the analysis cannot explicitly consider retesting. However,
exploratory analyses were conducted by considering that a proportion of men misclassified in year 0
(i.e. in the first diagnostic episode), and who have not progressed to metastatic disease in subsequent
years, can be correctly classified through retesting. These patients are assumed to receive radical treatment
at that time point. Given the absence of information, the outcomes after radical treatment are unchanged.
A threshold sensitivity analysis finds the smallest change in parameter values that change the cost-effective
strategy from the base case. The lifetime discounted QALYs and costs for treatment delays are calculated
in the long-term model. In order to do this, the model assumes that treatment is received 1–5 years post
referral from primary care. The model calculates the lifetime discounted QALYs and costs as the weighted
average of the QALYs and costs for delays each year weighted by the proportion of men detected
each year.
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Value of future research
In addition to the uncertainty from the structural assumptions explored above, the cost-effectiveness results
are also uncertain because of uncertainty in the parameter inputs, as represented by their CIs (or other
measures of uncertainty such as standard errors). The cost-effectiveness results are presented in terms
of their expected values, CIs and probability that a strategy is cost-effective. This means that there is a
probability that the strategy expected to be cost-effective is actually not cost-effective. This has consequences
in terms of the net health achieved from choosing this strategy. The difference between the net health
achieved from choosing this strategy and the net health achieved by choosing the strategy that is always
cost-effective represents the health losses attributable to uncertainty. These health losses can also be thought
of as the health gain from solving this uncertainty through future research (i.e. the value of future research).
The value of future research in health terms can be converted into monetary units to indicate the maximum
investment to solve this uncertainty.113
TABLE 39 Threshold sensitivity analysis
Analysis Rationale
SA1: relative sensitivity of MRI-targeted
TRUS-guided biopsy (‘W’) in detecting CS
cancer
The inputs used in the base case are obtained from the systematic review and
meta-analysis by Schoots et al.105 TRUS-guided and mpMRI definitions and
cut-off points used in the studies included in the meta-analysis may not directly
map to those used in PROMIS. Increased sensitivity of ‘W’ biopsy will improve
the cost-effectiveness profile of strategies starting with mpMRI. Increased
sensitivity of ‘Z’ biopsy will improve the cost-effectiveness of strategies
including a second biopsy post negative biopsy and suspicious mpMRI
SA2: relative sensitivity of MRI-targeted
second TRUS-guided biopsy (‘Z’) in
detecting CS cancer
SA3: prevalence of intermediate-risk
cancer vs. low-risk cancer
Men in PROMIS had a higher than expected prevalence of intermediate-risk
(CS) cancer (0.53) and a lower than expected probability of not having cancer
(0.28); men referred for diagnosis may have a lower probability of having
intermediate-risk cancer and a higher probability of not having cancer. This
can affect the cost-effectiveness results because the increased probability of CS
cancer favours more sensitive strategies
SA4: probability of NC
SA5: risk of death from TRUS-guided
biopsy
There is some evidence that TRUS-guided biopsy may increase the risk of
death, mainly because of sepsis, although this is uncertain (see Appendix 5).
The base case assumes that biopsy has no risk of death. Including risk of death
from TRUS-guided biopsy will improve the health outcomes of strategies with
fewer TRUS-guided biopsies
SA6: reduced quality-adjusted survival
from incorrect classification as NC
In the base case, men incorrectly classified as having NC have the same
outcomes as men incorrectly classified as having low-risk cancer. However,
their quality-adjusted survival may be lower because they may not be tested in
the future as frequently as men classified as having low-risk cancer
SA7: reduced clinical effectiveness of
radical treatment
The base case assumes that radical treatment in men with intermediate-risk
(CS) cancer is cost-effective, as indicated by the results of the prediction of
long-term outcomes, which is based on PIVOT. However, radical treatment
may be less effective in improving survival. Therefore, the cost-effectiveness
of radical treatment may have been overestimated. This scenario tests how
reductions in the effect of radical treatment affect the cost-effectiveness of the
diagnostic strategies
SA8: HRQoL impact of TRUS-guided
biopsy
The base case assumes that TRUS-guided biopsy has no HRQoL consequences.
However, this may be incorrect because this is a procedure that requires
anaesthesia and may have complications. This sensitivity analysis tests the
impact of assuming that TRUS-guided biopsy has a fraction of the impact of
TPM-biopsy, from 10% of its impact to its full impact (–0.176), over the same
period of 2 weeks
NC, no cancer; SA, sensitivity analysis; ‘W’ biopsy, TRUS-guided biopsy after a suspicious mpMRI result; ‘Z’ biopsy,
TRUS-guided biopsy after a TRUS-guided biopsy that did not detect cancer and a suspicious mpMRI result.
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Base-case results
Health outcomes
Figure 23 shows the health outcomes achieved by each diagnostic substrategy; 95% CIs are not shown
because they greatly overlap (see Appendix 3, Tables 53 and 54, for full results). The health outcomes vary
between 8.30 and 8.75 QALYs.
The substrategy that achieves the least favourable health outcomes is M1 115, at 8.29 QALYs (95% CI
7.94 to 8.68 QALYs). In M1 115, all men receive mpMRI and men with suspected CS cancer according to
the mpMRI definition 1 and cut-off point 5 receive TRUS-guided biopsy. Men who have CS cancer using the
TRUS-guided biopsy definition 1 receive radical treatment; otherwise, men receive active surveillance. This
is the strategy that detects the fewest CS cancers (sensitivity 0.15, 95% CI 0.12 to 0.19; see Appendix 3,
Tables 49 and 50). Therefore, using this strategy, the majority of men with CS cancer are missed and do not
receive immediate treatment.
The substrategy that achieves the most favourable health outcomes is P4 2––, at 8.74 QALYs (95% CI
8.41 to 9.06 QALYs). All men receive TRUS-guided biopsy at definition 2 of clinical significance, which is
the most sensitive in detecting CS cancers. Men in whom CS cancer was not detected receive TPM-biopsy.
P4 2–– detects all CS cancers and minimises the proportion of men who receive TPM-biopsy and who
experience the associated reduction in HRQoL.
The PROMIS-proposed substrategy (M7 123) achieves 8.65 QALYs (95% CI 8.35 to 8.95 QALYs). The standard
care substrategy without mpMRI (T4 1––) achieves 8.49 QALYs (95% CI 8.19 to 8.80 QALYs). The strategy
deemed to be the most similar to the NICE-recommended strategy13 achieves 8.66 QALYs (95% CI 8.36 to
8.97 QALYs).
Costs
Figure 24 shows the lifetime costs of using each diagnostic substrategy; 95% CIs are not shown to improve
readability (see Appendix 3, Tables 55 and 56, for full results). The costs vary between £3500 and nearly £6300
per man referred for testing. Similar to the results for health outcomes, the substrategies using the lowest
mpMRI cut-off point (≥ 2, represented in black), mpMRI definition 2 and TRUS-guided definition 2 have the
highest costs. These substrategies have the highest costs of testing (see Figure 20 and Appendix 3, Tables 51
and 52) and the highest treatment costs, because more men with CS cancer are referred for treatment.
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FIGURE 23 Base-case results: health benefits of each diagnostic strategy.
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The substrategy with the lowest costs is M1 115, at £3497 (95% CI £3007 to £4115), which is also the
substrategy that achieves the least favourable health outcomes, as discussed in Health outcomes. The
smallest proportion of men are referred for TRUS-guided biopsy using the mpMRI definition 1 and cut-off
point 5. The smallest proportion of men are referred for radical treatment, which is more costly than active
surveillance, using the TRUS-guided biopsy definition 1.
The substrategy with the greatest costs is P9 122, at £6277 (95% CI £5858 to £6808). In P9 122, all men
receive TRUS-guided biopsy and men in whom TRUS-guided biopsy at definition 1 did not detect CS
cancer receive mpMRI. Men in whom mpMRI at definition 2 and cut-off point of ≥ 2 was suspicious of
CS cancer are referred to TPM-biopsy. P9 122 detects almost all CS cancers (0.99, 95% CI 0.98 to 1.00)
(see Appendix 3, Table 49) and these men then receive radical treatment, which is more costly than active
surveillance. P9 122 is also more costly in the short term as a result of the large number of tests involved.
The PROMIS-proposed substrategy (M7 123) costs £5027 (95% CI £4609 to £5512). The standard care
substrategy without mpMRI (T4 1––) costs £4603 (95% CI £4174 to £5044). The strategy deemed to be
the most similar to the NICE-recommended strategy13 costs £5173 (95% CI £4755 to £5664).
Cost-effectiveness results
Figure 25 shows each diagnostic substrategy in terms of its average costs and QALYs and defines the
strategies that achieve the most QALYs per pound spent (i.e. the cost-effectiveness frontier, represented as
a black line). Substrategies above the cost-effectiveness frontier cannot be considered to be cost-effective.
This figure does not include the uncertainty around the results to improve readability. Table 40 presents
the same information, including uncertainty, in a tabular format.
Across the three values of health opportunity cost used (£13,000, £20,000 and £30,000 per QALY
gained), the most cost-effective substrategy is M7 222. P4 2–– is on the margin of cost-effectiveness using
the health opportunity value of £30,000 per QALY; the difference in net health between P4 2–– and M7
222 at this value is only 0.0001 QALYs.
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FIGURE 24 Base-case results: costs of each diagnostic strategy.
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In the restricted comparison between the PROMIS-proposed substrategy of M7 123, the standard care
no-mpMRI strategy of T4 1–– and the substrategy deemed to be the most similar to the NICE-recommended
substrategy13 (T7 123), T7 123 is most cost-effective (ICER £8520 per QALY vs. M7 123). The ICER of M7
123 compared with T4 1–– is £2730 per QALY. In the complete comparison of the 383 strategies, these
three strategies have zero probability of being cost-effective.
Figure 26 shows the cost-effectiveness acceptability frontier. The cost-effectiveness acceptability curve plots
the options that are cost-effective in terms of their probability of cost-effectiveness. The most cost-effective
option is the option that offers the most benefits net of its cost, for a given value of health opportunity
cost. For example, at the health opportunity cost of £20,000 per QALY, the cost-effective option is M7 222.
M7 222 is the option that offers the most benefits on average. In some of the simulations, other strategies
are cost-effective. Therefore, the probability that M7 222 is cost-effective corresponds to the proportion of
simulations in which M7 222 offers the most benefits, net of its costs. The cost-effectiveness acceptability
curve is useful in evaluations with a large number of options, which is the case here.
At health opportunity costs lower than £3800 per QALY, M1 115 is the cost-effective substrategy (the
substrategy that detects the fewest CS cancers but is also the least costly). Between the health opportunity
costs of £3000 and £7500 per QALY, a number of substrategies appear to be cost-effective (M1 215 to
T6 222 in Figure 25), but these are associated with a low probability of being cost-effective. At health
opportunity costs of > £7500 up to £30,084 per QALY, M7 222 is the most cost-effective substrategy; the
probability of this strategy being cost-effective ranges from 0.31 to 0.48 depending on the value of the
health opportunity cost. At the health opportunity cost of ≥ £30,084, P4 2–– is the substrategy that is
most likely to be cost-effective. The probability ranges between 0.44 and 0.63 for values of health
opportunity cost up to £50,000 per QALY.
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TABLE 40 Diagnostic strategies in the cost-effectiveness frontier
Strategy
Definition
mpMRI
cut-off
point
QALYs, mean
(95% CI)
Costs, mean
(95% CI) (£) ICER (£)
Net health at
TRUS-guided
biopsy mpMRI
£13,000
per QALY
£20,000
per QALY
£30,000
per QALY
M1: mpMRI for all men and TRUS-guided biopsy in
men suspicious for CS cancer
1 1 5 8.29
(7.94 to 8.68)
3497
(3007 to 4115)
8.024 8.118 8.176
2 1 5 8.33
(7.99 to 8.69)
3608
(3137 to 4191)
3081 8.051 8.148 8.208
M3: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; men with
CNS cancer on the first biopsy receive a second
TRUS-guided biopsy
2 1 5 8.34
(8.01 to 8.70)
3648
(3180 to 4218)
3630 8.059 8.157 8.218
M4: mpMRI for all men and TRUS-guided biopsy
in men with suspicion of any cancer; men with
suspected CS cancer at mpMRI and in whom CNS
cancer was detected on the first biopsy receive a
second TRUS-guided biopsy
2 2 5 8.41
(8.11 to 8.74)
3909
(3477 to 4415)
3738 8.109 8.214 8.279
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS cancer
was not detected
2 2 5 8.42
(8.13 to 8.74)
3965
(3539 to 4455)
3867 8.119 8.226 8.292
M3: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; men with
CNS cancer on the first biopsy receive a second
TRUS-guided biopsy
2 2 4 8.52
(8.23 to 8.82)
4325
(3915 to 4774)
3921 8.183 8.300 8.372
M4: mpMRI for all men and TRUS-guided biopsy
in men with suspicion of any cancer; men with
suspected CS cancer at mpMRI and in whom CNS
cancer was detected on the first biopsy receive a
second TRUS-guided biopsy
2 2 4 8.53
(8.24 to 8.83)
4390
(3979 to 4833)
4031 8.194 8.312 8.386
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS cancer
was not detected
2 2 4 8.56
(8.27 to 8.86)
4502
(4094 to 4937)
4250 8.212 8.333 8.408
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TABLE 40 Diagnostic strategies in the cost-effectiveness frontier (continued )
Strategy
Definition
mpMRI
cut-off
point
QALYs, mean
(95% CI)
Costs, mean
(95% CI) (£) ICER (£)
Net health at
TRUS-guided
biopsy mpMRI
£13,000
per QALY
£20,000
per QALY
£30,000
per QALY
T6: TRUS-guided biopsy for all men; men classified
as having CNS cancer receive mpMRI; men with
suspected CS cancer receive a second TRUS-guided
biopsy
2 2 3 8.60
(8.31 to 8.90)
4693
(4289 to 5127)
4393 8.241 8.367 8.445
2 2 2 8.61
(8.32 to 8.91)
4732
(4327 to 5166)
4633 8.246 8.373 8.452
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS cancer
was not detected
2 2 3 8.66
(8.37 to 8.97)
5021
(4612 to 5496)
5501 8.276 8.412 8.495
T7: TRUS-guided biopsy for all men; men classified
as having NC or CNS cancer receive mpMRI;
men with suspected CS cancer receive a second
TRUS-guided biopsy
2 2 3 8.69
(8.38 to 9.00)
5194
(4780 to 5682)
5778 8.293 8.433 8.519
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS cancer
was not detected
2 2 2 8.72
(8.40 to 9.04)
5367
(4947 to 5876)
7076 8.304 8.449 8.538
P4: TRUS-guided biopsy in all men and TPM-biopsy
in men in whom CS cancer was not detected
2 Not applicable 8.74
(8.41 to 9.06)
5968
(5550 to 6490)
30,084 8.278 8.439 8.538
NC, no cancer.
C
O
S
T
-E
F
F
E
C
T
IV
E
N
E
S
S
O
F
D
IA
G
N
O
S
T
IC
S
T
R
A
T
E
G
IE
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
8
4
Threshold sensitivity analysis
Table 41 shows the results of the threshold sensitivity analysis. Sensitivity analysis 1 tests changes in the
relative sensitivity of MRI-targeted TRUS-guided biopsy (‘W’ biopsy). In the base case, relative sensitivity is
obtained from Schoots et al.,105 at 1.2 (95% CI 1.09 to 1.32). This translates into a sensitivity of 0.74 (95% CI
0.65 to 0.84) using the TRUS-guided biopsy definition 2. Reductions in the sensitivity of MRI-targeted
TRUS-guided biopsy (biopsy ‘W’) in detecting CS cancer change the cost-effective substrategy from M7 222
to T7 222 at the health opportunity cost of £13,000 per QALY gained, to T9 222 at the health opportunity
cost of £20,000 per QALY gained and to P4 2–– at the health opportunity cost of £30,000 per QALY gained.
The cost-effective substrategy is robust to increases in sensitivity.
Sensitivity analysis 2 tests changes in the sensitivity of MRI-targeted second TRUS-guided biopsy in men in
whom the first TRUS-guided biopsy is negative for cancer. The base case uses a sensitivity of 0.87 (95% CI
0.74 to 0.96), which is obtained from Schoots et al.105 Increases in the sensitivity of MRI-targeted second
TRUS-guided biopsy in men with a prior negative biopsy result (biopsy ‘Z’) change the cost-effective
substrategy to T7 222 at £13,000 per QALY and T9 222 at £20,000 and £30,000 per QALY.
Sensitivity analysis 3 tests changes in the proportion of intermediate-risk (CS) cancer compared with
low-risk (CNS) cancer. A lower proportion of intermediate-risk (CS) cancer favours the cost-effectiveness
of less sensitive, less resource-intensive strategies. The value used in the base case is 0.53, obtained from
the individual patient data collected in PROMIS. The results are robust to changes in the proportion of
intermediate-risk (CS) cancer compared with low-risk (CNS) cancer.
Sensitivity analysis 4 tests changes in the probability of no cancer. As for sensitivity analysis 3, a higher
probability of no cancer (and, therefore, a lower probability of cancer and CS cancer) favours less-sensitive and
less-resource-intensive strategies. The value used in the base case is 0.28, which was obtained from PROMIS.
Changes in the proportion of men with cancer do not affect which substrategy is the most cost-effective.
Sensitivity analysis 5 tests the impact of including the risk of death from TRUS-guided biopsy. Some studies
suggest that the risk of death from biopsy can be up to 0.01 (see Appendix 5 for a review). Including
a risk of death of 0.5–1.5% (i.e. 5000–15,000 men die per 1,000,000 men receiving a biopsy) from
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FIGURE 26 Cost-effectiveness acceptability frontier.
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complications of biopsy changes the cost-effective strategy to P1 at £20,000 and £30,000 per QALY
gained; including a risk of death of 2.0% changes the cost-effective strategy to P1 at £30,000 per QALY.
Sensitivity analysis 6 tests the impact of reduced quality-adjusted survival from incorrect classification as no
cancer. A reduction in health gains of 0.01 QALYs from incorrect classification as no cancer changes the
cost-effective substrategy from M7 222 to P4 2–– at £30,000 per QALY gained. Reductions of ≥ 0.10
QALYs change the cost-effective substrategy from M7 222 to T9 222 at £13,000 per QALY gained and
from M7 222 to P4 2–– at £20,000 and £30,000 per QALY gained.
TABLE 41 Results of the threshold sensitivity analysis
Analysis
Cost-effective substrategy at the health opportunity cost of
£13,000 per
QALY gained
£20,000 per
QALY gained
£30,000 per
QALY gained
Base case M7 222 M7 222 M7 222
SA1: changes in relative sensitivity of MRI-targeted TRUS-guided biopsy (‘W’) in detecting CS cancer; sensitivity of
TRUS-guided biopsy at base case = 1.2
1.00–1.10 T7 222 T9 222 P4 2––
1.15–1.19 M7 222 M7 222 P4 2––
1.20–1.50 M7 222 M7 222 M7 222
SA2: changes in sensitivity of MRI-targeted second TRUS-guided biopsy (‘Z’) in detecting CS cancer; sensitivity of
TRUS-guided biopsy at base case = 0.87
0.92–1.00 T7 222 T9 222 T9 222
SA3: prevalence of intermediate-risk cancer vs. low-risk cancer; base case = 0.53
0.35–0.53 No changes from base case
SA4: probability of NC; base case = 0.28
0.28–0.53 No changes from base case
SA5: risk of death from biopsy that changes cost-effective substrategy; no risk at base case
0.5–1.0% M7 222 P1 P1
1.5% N1 123 P1 P1
2.0% N2 114 N2 123 P1
SA6: reduced quality-adjusted survival from incorrect classification as NC (QALY reduction)
0.01 M7 222 M7 222 P4 2––
0.09 M7 222 P4 2–– P4 2––
≥ 0.10 T9 222 P4 2–– P4 2––
SA7: reduced clinical effectiveness of radical treatment
–10% T7 223 M7 222 M7 222
–15% M1 215 T7 223 M7 222
–20% M1 115 M1 115 T6 222
SA8: HRQoL impact of TRUS-guided biopsy
10% of TPM-biopsy impact M7 222 M7 222 P4 2––
60% of TPM-biopsy impact M7 222 M7 222 P1 –––
Same impact as TPM-biopsy M7 222 M7 222 M7 222
NC, no cancer; SA, sensitivity analysis.
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Sensitivity analysis 7 tests the impact of reducing the clinical effectiveness of radical treatment. The base
case is informed by PIVOT,122 which shows that radical treatment in men with intermediate-risk (CS) cancer
is cost-effective. However, radical treatment may be less effective in improving survival than suggested by
PIVOT.8 Therefore, the cost-effectiveness of radical treatment may have been overestimated. Reducing the
effectiveness of radical treatment will favour diagnostic substrategies that are less costly and detect fewer CS
cancers, which will subsequently be directed for treatment.
The results are sensitive to the clinical effectiveness of radical treatment. Reducing the effectiveness by
10% changes the cost-effective substrategy at the health opportunity cost of £13,000 per QALY from
M7 222 to T7 223. Subsequent reductions change the cost-effective substrategy to M1 215 and then to
M1 115. At the health opportunity cost of £20,000 per QALY, the cost-effective substrategy changes to
T7 223 if the effectiveness of radical treatment is 15% lower; larger reductions change the cost-effective
substrategy to M1 115. At the health opportunity cost of £30,000 per QALY, reductions beyond 20%
change the cost-effective substrategy from M7 222 to T6 222. These results suggest that, if radical
treatment is less effective than suggested by PIVOT, less sensitive and less costly diagnostic strategies
are more likely to be cost-effective. These results also shed light on the impact of alternative treatment
options. Some men receive radiotherapy instead of radical treatment. If radiotherapy is as cost-effective as
radical treatment, the cost-effective diagnostic strategy is the same. If radiotherapy is less beneficial, its
ICER compared with active surveillance is greater. The sensitivity analysis (sensitivity analysis 7) suggests
that reductions in the benefits of radical treatment of < 10% do not change the cost-effective strategy.
Larger reductions change the cost-effective strategy to less costly but also less sensitive strategies such as
T7 223.
Sensitivity analysis 8 tests the impact of a reduction in HRQoL attributable to TRUS-guided biopsy. The
results are robust in that M7 222 remains the cost-effective substrategy at the lower bounds of the health
opportunity cost. At the £30,000 per QALY threshold, the cost-effective substrategy changes to P4 2—
for small HRQoL reductions. As the reduction is more pronounced, the cost-effective strategy changes to
P1—.
Bivariate sensitivity analysis on the cost of diagnostic tests
Figure 27–38 show the results of the bivariate sensitivity analysis on the unit costs of TRUS-guided biopsy
and mpMRI, by the cost of TPM-biopsy. The unit costs are varied by ± 50%; the unit cost of TRUS-guided
biopsy is represented on the vertical axis, whereas the unit cost of mpMRI is represented on the horizontal
axis. Each figure refers to a unit cost of TPM-biopsy (base case at £1370, +25% at £1713, –25% at
£1028 and the cost estimated for PROMIS at £1872) and a health opportunity cost (£13,000, £20,000
and £30,000 per QALY). The square delineated in black represents the base-case unit cost of TRUS-guided
biopsy and mpMRI. The figures show the cost-effective substrategy for a combination of unit costs,
distinguished by colours.
Figure 27 shows the cost-effective substrategy using the base-case cost for TPM-biopsy at the health
opportunity cost of £13,000. M7 222 is the cost-effective substrategy unless the cost of mpMRI is
increased. The cost-effective substrategy is T9 222 if the unit cost of mpMRI is increased and the unit cost of
TRUS-guided biopsy is reduced. If both the unit cost of mpMRI and the unit cost of TRUS-guided biopsy are
increased, the cost-effective substrategy is T7 222. At the higher opportunity cost of £20,000 per QALY (see
Figure 28), the cost-effective substrategy is robust as M7 222, unless very high unit costs of mpMRI are coupled
with very low unit costs of TRUS-guided biopsy. At £30,000 per QALY (see Figure 29), the cost-effective
substrategy is also M7 222, unless the costs of mpMRI and TRUS-guided biopsy increase. Figures 30–32 and
Figures 36–38, using higher unit costs for TPM-biopsy, show a similar pattern. Figures 33–35 show the results
for a lower cost of TPM-biopsy (£1028). The cost-effective strategy is more sensitive to changes in the unit costs
of TRUS-guided biopsy and mpMRI using this unit cost. At the health opportunity cost of £13,000 per QALY,
M7 222 is cost-effective. However, this can change to T9 222, T7 222 or P1 depending on the unit costs of
mpMRI and TRUS-guided biopsy. At the health opportunity cost of £20,000 per QALY, M7 222 is cost-effective
only at lower costs of mpMRI. The cost-effective substrategy for a wider range of unit costs is P4 2–– or P1.
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FIGURE 28 Bivariate sensitivity analysis: TPM-biopsy cost = £1370, health opportunity cost = £20,000 per QALY.
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FIGURE 27 Bivariate sensitivity analysis: TPM-biopsy cost = £1370, health opportunity cost = £13,000 per QALY.
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FIGURE 29 Bivariate sensitivity analysis: TPM-biopsy cost= £1370, health opportunity cost = £30,000 per QALY.
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FIGURE 30 Bivariate sensitivity analysis: TPM-biopsy cost= £1713, health opportunity cost = £13,000 per QALY.
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FIGURE 31 Bivariate sensitivity analysis: TPM-biopsy cost = £1713, health opportunity cost = £20,000 per QALY.
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FIGURE 32 Bivariate sensitivity analysis: TPM-biopsy cost = £1713, health opportunity cost = £30,000 per QALY.
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FIGURE 34 Bivariate sensitivity analysis: TPM-biopsy cost= £1028, health opportunity cost = £20,000 per QALY.
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FIGURE 33 Bivariate sensitivity analysis: TPM-biopsy cost= £1028, health opportunity cost = £13,000 per QALY.
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FIGURE 35 Bivariate sensitivity analysis: TPM-biopsy cost = £1028, health opportunity cost = £30,000 per QALY.
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FIGURE 36 Bivariate sensitivity analysis: TPM-biopsy cost = £1872, health opportunity cost = £13,000 per QALY.
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There is some variation in the unit costs of the tests. These figures can be used to indicate the cost-effective
substrategy for a given combination of unit costs. For example, the average unit cost of TRUS-guided biopsy
using the code LB76Z is £403. However, 20,502 men received it as a day case procedure, at a cost of £533,
whereas 17,846 men received it as an outpatient procedure, at a cost of £223. At the TPM-biopsy cost of
£1397, similar to the base-case average NHS reference cost,110 M7 222 is cost-effective unless the cost of
mpMRI increases to > £197 per scan.
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FIGURE 38 Bivariate sensitivity analysis: TPM-biopsy cost= £1872, health opportunity cost = £30,000 per QALY.
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FIGURE 37 Bivariate sensitivity analysis: TPM-biopsy cost= £1872, health opportunity cost = £20,000 per QALY.
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The results suggest that the unit costs of the tests, particularly TPM-biopsy, are a driver of the cost-effectiveness
results. Higher TPM-biopsy costs favour the cost-effectiveness of highly sensitive strategies, such as M7 222,
which do not include TPM-biopsy. Very high mpMRI costs favour strategies that start with TRUS-guided
biopsy rather than mpMRI. However, at lower TPM-biopsy costs, and depending on the health opportunity
cost adopted, the cost-effective strategy may involve TPM-biopsy for a large number of men, such as in
P1 and P4 2––.
Scenario: using the payment-by-results tariff for the unit costs of the tests
Figure 39 shows the cost-effectiveness plane for the scenario using the PbR tariff for the unit costs of the
tests. The substrategies in the cost-effectiveness frontier are similar to those in in the cost-effectiveness
frontier in the base case. Four strategies forming the frontier start with mpMRI (M1, M3, M4 and M7) and
five strategies start with biopsy (T1, T6, T7, P4 and P1). The cost-effective strategy depends on the value
of the health opportunity cost. At £13,000 per QALY gained, the cost-effective substrategy is M7 222.
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FIGURE 39 Cost-effectiveness plane for the scenario using the PbR tariff.
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On average, M7 222 achieves the highest net health, at 8.307 QALYs. At £20,000 and £30,000 per QALY
gained, the cost-effective substrategy is P4 2––. However, the difference between P4 2–– and P1, the next
best substrategy, is small, at 0.001 QALYs.
Figure 40 shows the cost-effectiveness acceptability frontier. As with the base-case results, the substrategy
most likely to be cost-effective at values of health opportunity cost of < £3000 per QALY gained is M1 115.
There is a region of uncertainty around £3000–6000 per QALY gained, where a number of substrategies
appear in the frontier. M7 222 is most likely to be cost-effective up to a value of health opportunity cost of
£17,500 per QALY. P4 2–– is the substrategy most likely to be cost-effective at values of > £17,500 per
QALY gained.
The threshold sensitivity analyses described earlier were also conducted using the PbR tariff for the unit
costs (see Appendix 6). In general, the results are similar to those of the base case. In addition to M7 222
and P4 2––, the substrategies that emerge as potentially cost-effective are typically T7 222, T9 222 and P1.
Scenario: the impact of repeated testing over time
Table 42 shows the results of the sensitivity analysis of repeat testing. In the base case, M7 222 is the
cost-effective substrategy. It correctly classifies 95.0% of men with intermediate-risk cancer; 2.0% of these
men are misclassified as having low-risk cancer and 3.0% are misclassified as having no cancer. This analysis
shows that only when ≥ 45.0% of the men misclassified, that is, 2.5% of the men with intermediate-risk
cancer who are incorrectly classified, are correctly classified at subsequent testing rounds does the cost-effective
strategy change. The cost-effective substrategy M7 222 changes to T7 222 at the health opportunity cost of
£13,000 per QALY and to T9 222 at the health opportunity costs of £20,000 and £30,000 per QALY. This
means that, if men with intermediate-risk cancer who are incorrectly classified can be correctly classified and
treated in the future, less-sensitive and less-costly diagnostic strategies are favoured.
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FIGURE 40 Cost-effectiveness acceptability frontier for the scenario using the PbR tariff.
DOI: 10.3310/hta22390 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 39
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
95
Value of future research
Table 43 shows the value of future research in solving the uncertainty regarding which substrategy is
cost-effective. The cost-effective substrategy is M7 222. The net health achieved is the average of the net
health achieved in each of the 1000 simulations, which represent possible realisations of the parameter
values given the current evidence. This is between 8.304 and 8.538 QALYs per man referred for testing.
Hypothetically, under perfect information, between 8.320 and 8.551 QALYs per man referred could be
achieved. This is the average of the maximum net health in each of the possible realisations of the
parameter values. The difference between the maximum of the net health achievable and the net health
achieved on average by the cost-effective strategy corresponds to the health losses because of parameter
uncertainty.113 These health losses correspond to the upper bound of the value of future research to
resolve this uncertainty. Depending on the unit costs used and the value of the health opportunity cost,
the health loss because of parameter uncertainty is between 0.012 and 0.015 QALYs per man referred
for testing.
According to NHS Reference Costs 2014–15,110 there are approximately 39,000 TRUS-guided prostate
biopsies performed each year in the NHS. If each of these biopsies corresponds to a new patient referred
for testing, the health losses attributable to additional research are between 468 and 585 QALYs. Over
5 years, this amounts to 2187–2734 QALYs lost. This means that, if this uncertainty was resolved, there
would be 2187–2734 QALYs gained. The investment warranted by this uncertainty can be calculated by
converting the health gains from perfect information into monetary units using the health opportunity
cost. The maximum investment warranted by this uncertainty is between £7.6M and £10.1M over a 1-year
time horizon and between £35.5M and £47.4M over a 5-year time horizon.
TABLE 43 Value of future research
Results
Health opportunity cost of
£13,000 per
QALY gained
£20,000 per
QALY gained
£30,000 per
QALY gained
Cost-effective substrategy M7 222 M7 222 M7 222
Net health of cost-effective substrategy 8.304 8.449 8.538
Maximum net health achievable 8.320 8.461 8.551
Health loss because of parameter uncertainty per man referred
for testing
0.015 0.012 0.013
Health loss because of parameter uncertainty per 39,000 men
referred per year
585 468 507
Health loss because of parameter uncertainty over 5 years 2734 2187 2369
Value of additional research per year (£) 7,605,000 9,360,000 10,140,000
Value of additional research over 5 years (£) 35,538,767 43,740,021 47,385,023
TABLE 42 Results of the threshold sensitivity analysis on the impact of retesting
Proportion of men
reclassified in the
future (%)
Cost-effective substrategy at the health opportunity cost of
£13,000 per QALY gained £20,000 per QALY gained £30,000 per QALY gained
0–40 M7 222 M7 222 M7 222
45 M7 222 T9 222 T9 222
50–100 T7 222 T9 222 T9 222
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Chapter 8 Discussion of the diagnostic study
PROMIS is the first study to present blinded data on the diagnostic accuracy of both mpMRI and TRUS-guided biopsy compared with an accurate reference test in biopsy-naive men with suspected prostate
cancer. It is also the largest registered trial to date in this at-risk population. PROMIS represents level 1b
evidence for the assessment of diagnostic accuracy. The study design allowed highly reliable and precise
accuracy estimates for both TRUS-guided biopsy and mpMRI to be obtained across a number of centres,
and the conduct and reporting of each test was standardised and performed blind to the other test results.
Generalisability and cancer prevalence
Despite the number of withdrawals following consent, there were no significant differences between those
who withdrew after registration and those who completed all of the tests. We would expect this to be the
case as the mpMRI findings were blinded to patients and physicians. Withdrawal after consent of the men
with large prostates may have led to a reduction in the number of men with no cancer or CNS cancers,
because larger prostates tend to lead to an elevated PSA level as a result of benign prostatic hyperplasia.
Although a significant number of men were screened in order to recruit our cohort, the screening log data
indicated that there were no differences in age or PSA level between patients who were screened as
eligible for the study but who did not enter the study and those who did enter the study.
The prevalence of any cancer or CS cancer was much higher than we anticipated. This was a function of
the combined biopsy strategy – a diagnostic approach that has rarely been tried before. The effect was the
identification of a large, and almost certainly representative, sample of men with prostate cancer from the
cohort referred for biopsy. This figure might have also been influenced by our withdrawal of men with
large prostates (> 100 ml), which could not be biopsied using the reference test.
Nonetheless, our data are not outliers with respect to the literature. Previous TPM-biopsy studies have
found a higher prevalence of CS prostate cancer than studies using TRUS-guided biopsy.82,132 No single
sampling system identifies all disease. The combination of TRUS-guided biopsy and TPM-biopsy probably
represents the best detection strategy that is available.
The degree to which the prevalence of CS prostate cancer is contingent on the sampling method used
does raise questions about where the threshold of clinical significance should be placed. This highlights
the uncertainty around what constitutes clinical significance in prostate cancer.133 PROMIS was conducted
within a health-care system that does not have a formal prostate cancer screening programme in place.
In jurisdictions where screening has been in place for some time, it is likely that the prevalence of CS
cancer among men undergoing biopsy will be lower than in the UK, where a formal population-based PSA
screening programme is not recommended.
Diagnostic accuracy: findings and implications
On TPM-biopsy, 408 men (71%) who were tested had cancer (CNS and CS cancer), of which 230 cases
(40%) were CS according to the primary definition. The primary definition of clinical significance used in
our study was a Gleason score of ≥ 4 + 3 of any length and/or a maximum cancer core length of ≥ 6 mm of
any grade in any location on TPM-biopsy. Using our primary reporting schema for mpMRI (as described in
Chapter 3), with a score of ≥ 3 considered a suspicious scan, mpMRI was more sensitive than TRUS-guided
biopsy (93%, 95% CI 88% to 96% vs. 48%, 95% CI 42% to 55%; p < 0.0001) and less specific (41%,
95% CI 36% to 46% vs. 96%, 95% CI 94% to 98%; p < 0.0001). Furthermore, using these primary
definitions and thresholds, the NPV of mpMRI was 89% and the PPV was 51%.
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The relatively low specificity and PPV seen with mpMRI mean that 73% of patients would test positive
on mpMRI and would still require a biopsy. Because of the low specificity of mpMRI, 50% of this 73%
(or 36% of men in absolute terms) would undergo an unnecessary biopsy after mpMRI triage. In the
current diagnostic pathway, 100% of men have biopsies and about 60% (346/576) of these biopsies
might be considered unnecessary as they were carried out in men without CS cancer.
Our results show that, of the 27% of men who would not receive a biopsy on the basis of their mpMRI
result, 10% (17 men in our sample) would have CS cancer missed.
Using mpMRI to triage men might allow 158 out of 576 (27%) men to avoid a primary biopsy, resulting in
28 out of 576 (5%) fewer CNS cancers being diagnosed. If subsequent TRUS-guided biopsy needles were
directed by mpMRI findings, an estimate of up to 102 out of 576 more cases (18%) of CS cancer might be
detected compared with the standard pathway of TRUS-guided biopsy for all.
PROMIS was unable to test the strategy of targeting biopsies to suspicious areas because of the blinded
nature of the study design. In the above paragraph, we assumed that deployment of the needles should
be guided by the mpMRI findings and might be equivalent to the high accuracy of a TPM-biopsy strategy.
The PRECISION trial has recently tested this assumption by randomising men to either systematic
TRUS-guided biopsy or a MRI-targeted approach. It found that fewer men were biopsied, fewer cancers of
a Gleason score of 6 were found and greater numbers of men with cancer of a Gleason score of ≥ 7 were
detected by using mpMRI prior to biopsy.134
Intraobserver and interobserver variability in the reporting of multiparametric magnetic
resonance imaging
PROMIS was intentionally designed to be conducted at multiple sites. When the analysis was stratified
between the central training site (UCLH) and non-UCLH sites, the results were almost identical between
the two groups, which was reassuring.
Agreement between radiologists has implications in terms of quality assurance if mpMRI were to be rolled
out nationally. Note that the interobserver agreement results in PROMIS indicate that there was moderate
agreement in mpMRI scores between two independent radiologists. Our results show that variation on the
Likert scale was usually by 1 point. Nonetheless, this is an important consideration and highlights the need
for a robust training programme for radiologists.
Furthermore, there was no difference in diagnostic accuracy between the UCLH site and the non-UCLH
sites. For both groups, the percentage of CS cases missed is about 3% and the percentage of men who
may be able to avoid a biopsy is about 27%.
Context within the literature
Our results support the findings of recent systematic reviews assessing the diagnostic accuracy of mpMRI.49,135
The reviews found sensitivities of 58–96%, NPVs of 63–98% and specificities of 23–87%. The broad
ranges are attributable to the studies being conducted at single centres, each of which used different target
conditions on different reference standards and different thresholds for designating a positive scan. Other
limitations common to most of the studies were retrospective analysis, non-blinding of imaging findings
(making them vulnerable to incorporation and reporting biases) and comparison of mpMRI with reference
tests that were inaccurate (i.e. TRUS-guided biopsy) or inappropriate (i.e. radical treatment).
One other prospective study compared mpMRI with TPM-biopsy.136,137 This study reported a sensitivity of
96%, specificity of 36%, NPV of 92% and PPV of 52% for the detection of CS cancer, which was defined
as a Gleason score of 7–10 with > 5% at Gleason grade 4, ≥ 20% positive cores or ≥ 7 mm cancer.
This was a single-centre, non-blinded study that permitted scanners with two magnetic field strengths
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(1.5 T or 3.0 T), used fewer sampling cores in the TPM-biopsy protocol and did not include TRUS-guided
biopsy, which is the current standard test.138
Service provision and health-care system issues
We have shown that high-quality mpMRI can be delivered in a multicentre setting in the UK NHS.
However, we have not considered the impact that this could have on health-care settings from a capacity
perspective in terms of access to high-quality mpMRI and have not formally evaluated aspects of radiology
training to ensure high-quality reporting nor the need or otherwise of high-quality MRI-targeted biopsies.
In health-care systems where rates of prior PSA testing are higher, the proportion of men with CS prostate
cancer according to our definition is likely to be lower. If mpMRI were used as a triage test in these settings,
the proportion of men who could potentially avoid a primary biopsy might be larger. Furthermore, the recent
ProtecT trial9 demonstrates no cancer-specific survival benefit over active monitoring when men are treated
with RP or radical radiotherapy, although there was a beneficial effect in reducing time to metastases.139
With the majority of patients having low-risk disease in ProtecT, weight is added to the need for strategies,
such as mpMRI, that reduce the diagnosis of CNS cancer and are better able to identify higher-risk disease.
We acknowledge that, in the longer term, the number and type of patients being referred to secondary care
may change depending on the future validation of potential screening strategies.140
We note that, although a positive MRI result is associated with a very high OR of harbouring CS prostate
cancer and, as a result, has dominated prediction models that incorporate MRI and blood or urine
biomarkers,141 there is still much work to do in this area to explore the incremental value of using an
inexpensive and easily applied biomarker as a triage test prior to MRI or as a companion test, particularly
in relation to an ‘indeterminate’ MRI scan. Many of the MRI studies being planned will incorporate urine
and blood-based biomarkers as well as existing validated risk calculators.140
Limitations of the diagnostic study
PROMIS had some limitations. First, TPM-biopsy is limited by the size of the template grid equipment and
interference with needle insertion from the bony pubic arch. This meant that some men with very large
prostates (> 100 ml) had to be excluded from the study, which may result in a slight decrease in the
proportion of true negatives in the study population. However, although it is too invasive for routine use
in the clinic, TPM-biopsy offered the precision required for a highly accurate reference test by virtue of its
uniform 5-mm sampling density over the entire prostate.142
Second, we acknowledge that PROMIS represents a selected group, although it is encouraging that men
who were subsequently withdrawn from the study did not differ from those who completed it in terms
of the baseline data we collected. We also acknowledge that these men may differ in terms of other
characteristics that we did not measure.
Third, some systematic error may have been introduced into the standard test by the sequence in which
TPM-biopsy and TRUS-guided biopsy were performed, and we were unable to control for this. Carrying
out TPM-biopsy before TRUS-guided biopsy may have contributed to the poor accuracy of the standard
test because of swelling, distortion and tissue disruption. The sequencing was based on patient safety
considerations and on the need to preserve the integrity of the reference test. Infection is a major risk
associated with TRUS-guided biopsy because of breaching of the rectal mucosa. Participants might have
been exposed to excess risk if bacteria had been introduced into the prostate prior to multiple needle
deployments of an inherently sterile TPM-biopsy.
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Fourth, because of the need for blinding, the targeting of suspicious lesions identified in MRI was not
possible, and we cannot accurately assess the clinical utility of a MRI-targeted biopsy approach. Fifth,
although we included some measurements of interobserver variability, these were between two expert
readers. Further work is required to measure the interobserver variability of expert and non-expert
reporters. Last, we acknowledge that likelihood ratios and area under the receiver operating characteristic
curves were not part of the prespecified analysis plan. These metrics provide an overall measure of test
performance and clarify the relative strengths and weaknesses of each test, particularly as likelihood ratios
are independent of disease prevalence.
The mpMRI scans were performed using a magnetic field strength of 1.5 T. This was chosen because it is
widely available and because we assumed that any benefit shown was likely to be at least maintained at
higher magnetic field strengths, where it is possible to achieve greater signal-to-noise ratios.
Finally, we acknowledge the benefits of communicating risk using the 1–5 ordinal scale conferred by the
Gleason grade group.143 Our end points cannot, unfortunately, be reclassified using Gleason grade group
as they incorporated histopathology for our primary end point (Gleason grade 4 + 3 or Gleason grade
group 3) and secondary end point (Gleason grade 3 + 4 or Gleason grade group 2), and the cancer core
length thresholds, which are not part of the Gleason grade group definitions. One of the principal
outcomes of PROMIS is that a normal MRI result was not associated with any Gleason grade group of ≥ 3.
Recommendations for further research
PROMIS is a unique data set that will continue to be an important resource for further research. Future
work is likely to include the following.
l modelling of prognostic factors for CS cancer and development and validation of a risk score calculator
for the presence of CS cancer
l radiological issues:
¢ optimisation of sequencing (T2, DW, DCE)
¢ reporting methodology
¢ training and quality assurance for scanners and radiologists
l pathology issues:
¢ characterisation of disease
¢ correlation between TPM-biopsy and MRI lesion location
l biomarker/translational research analyses using the subset of blood and urine samples that have
been collected.
Conclusions
Transrectal ultrasound-guided biopsy performs poorly as a diagnostic test for CS prostate cancer.
Multiparametric magnetic resonance imaging identifies a large proportion of men with suspected CS
cancer who will then have TRUS-guided biopsy for diagnosis, in which the biopsy strategy should be
guided by the mpMRI findings. Using mpMRI as a triage test avoids biopsy in up to 27% of men with
non-CS cancer or no cancer who were referred for testing. However, mpMRI as a triage test missed
17 men with CS cancer (3% of the whole PROMIS cohort) as a result of a biopsy not being performed.
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Chapter 9 Discussion of the economic evaluation
Main findings
Multiparametric magnetic resonance imaging, TRUS-guided biopsy and TPM-biopsy can be used in a
range of combinations and with different definitions and cut-off points to detect CS cancer in men
referred to secondary care for further investigation. The combinations, definitions and cut-off points form
383 diagnostic strategies, which detect 15–100% of CS cancers, depending on the way that the tests
re used in combination, their definitions for CS cancer and the cut-off point used. Strategies using the
TRUS-guided biopsy definition 2, mpMRI definition 2 and cut-off point 2 detect the largest proportion of
CS cancers compared with the same strategies using other definitions and cut-off points. The HRQoL
consequences of testing are small and relate only to TPM-biopsy. The diagnostic strategies cost between
£244 and £1653 for the UK NHS.
The quality-adjusted life expectancy and health-care costs of men diagnosed with prostate cancer at an
average age of 67 years depend on the severity of their cancer and on their treatment. Men with low-risk
cancer who are managed with active surveillance have an average life expectancy of 16.26 years. Men
with intermediate-risk cancer who receive active surveillance have an average life expectancy of 13.38 years;
this increases to 15.65 years if they are treated with radical treatment. Men with high-risk cancer who
receive active surveillance have an average life expectancy of 11.15 years; this increases to 13.23 years if
they are treated with radical treatment. These estimates translate to discounted lifetime health benefits and
costs, which informed the outcomes of men undergoing each diagnostic strategy. In order to assess the
cost-effective strategy, the results of the short-term model on the costs and outcomes of testing were
combined with the results of the long-term model on the costs and outcomes of radical treatment and
observation.
In the base case, using NHS reference costs,110 the cost-effective strategy at the health opportunity costs
of £13,000, £20,000 and £30,000 per QALY gained involves testing all men with mpMRI at definition 2,
cut-off point 2 for CS cancer, using MRI-targeted TRUS-guided biopsy at definition 2 to detect CS cancer
and rebiopsying those men in whom CS cancer was not detected (substrategy M7 222). M7 222 achieves
8.72 discounted QALYs (95% CI 8.40 to 9.04 discounted QALYs) and costs £5367 (95% CI £4947 to
£5876). M7 222 detects 95% of CS cancers (95% CI 92% to 98%).
A main driver of cost-effectiveness is the unit cost of each test, particularly TPM-biopsy. At a higher
TPM-biopsy unit cost (e.g. £1872 per test), the cost-effective substrategy is M7 222 unless the unit cost of
mpMRI is almost doubled and the unit cost of TRUS-guided biopsy is maintained or reduced. At a lower
TPM-biopsy unit cost (e.g. £931), M7 222 is cost-effective if the unit cost of mpMRI is reduced, unless the
£13,000 per QALY health opportunity cost is used. A reduced unit cost of TPM-biopsy favours the
substrategies that include TPM-biopsy and that detect more CS cancers, such as P4 2––.
Under base-case assumptions, the results are generally robust to uncertain assumptions. Apart from M7
222 and P4 2––, the substrategies that emerge as potentially cost-effective in the sensitivity analysis are
generally T7 222, T9 222 and P1. With T7 222 and T9 222, all men receive TRUS-guided biopsy as the first
test and men classified as having no cancer or CNS cancer receive mpMRI. In T7, men with suspected CS
cancer receive a second TRUS-guided biopsy (MRI guided). In T9, men with suspected CS cancer, as well
as men with suspected CNS cancer on mpMRI but a prior no cancer result on the first biopsy, receive a
second TRUS-guided biopsy (MRI guided). These strategies appear to be potentially cost-effective according
to the TRUS-guided biopsy definition 2, mpMRI definition 2 and cut-off point of 2. In P1–––, all men
receive TPM-biopsy and no further tests.
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The value-of-information analysis indicates the magnitude of health losses because of uncertainty in the
parameter estimates. It suggests that up to 0.015 QALYs per man referred for testing could be gained if
better information was available. Given the large number of men referred for testing each year in the UK,
this relatively small health loss translates into a large loss at the population level. Future research that
resolves this uncertainty is worth up to £9.3M. More research is required to be conducted on which
specific parameters most contribute to the health losses attributable to uncertainty, in order to better
target investments in future research.
Comparison with other studies
The cost-effectiveness of mpMRI in combination with TRUS-guided biopsy has been subject to increasing
research. A recent systematic review on the cost-effectiveness of mpMRI for the diagnosis of prostate
cancer144 found five studies, although only three compared mpMRI as a first screening test in combination
with TRUS-guided biopsy in an incremental analysis.13,145,146 In addition, another study has been published
more recently.147 These studies compared up to two ways of using mpMRI, either as a first screening
test to determine which men should receive MRI-targeted TRUS-guided biopsy13,146,147 or as MRI-targeted
TRUS-guided biopsy for all men13 or for men with a previous negative biopsy result.145 None of the studies
had access to individual patient data; therefore, all inputs were obtained from the literature or expert
opinion. As in the current evaluation, mpMRI was found to be cost-effective as a first test before
TRUS-guided biopsy.
Two of these studies were conducted in a UK setting.13,145 Mowatt et al.145 compared targeted TRUS-guided
biopsy with systematic extended core TRUS-guided biopsy. The population was men who had suspected
prostate cancer with a prior negative or inconclusive biopsy and with an indication for repeat biopsy. This
study found T2-weighted MRI-targeted TRUS-guided biopsy to be cost-effective, although the health gains
and additional costs compared with the least costly strategy (systematic extended-core TRUS-guided biopsy)
were very small.
The economic evaluation conducted for the 2014 NICE clinical guideline13 compared a strategy of mpMRI
followed by MRI-targeted TRUS-guided biopsy in men with a MRI scan suspicious of cancer with TRUS-guided
biopsy. The population was newly referred men with symptoms of prostate cancer. The mpMRI+ TRUS-guided
biopsy strategy achieved lower health benefits, but was also less costly, than the TRUS-guided biopsy alone.
Although the ICER for MP-MRI+TRUS-guided biopsy compared with TRUS-guided biopsy alone was
approximately £16,000 per QALY, which is generally considered to be cost-effective, the cost savings were
found to be insufficient to justify the lower health benefits.
Strengths
To our knowledge, this is the first study to examine the cost-effectiveness of all of the possible ways of
using mpMRI, TRUS-guided biopsy and TPM-biopsy to diagnose prostate cancer and distinguish between
CNS and CS cancer. Having access to the individual patient data from the PROMIS clinical study facilitated
the comparison of not only the different combinations of tests, but also different definitions and diagnostic
cut-off points to define the disease. This makes this study the most comprehensive cost-effectiveness
analysis of alternative diagnostic strategies for prostate cancer to date.
This evaluation was informed primarily by the diagnostic information collected in PROMIS. PROMIS is the
first multicentre study to evaluate the diagnostic performance of TRUS-guided biopsy and mpMRI in a
blinded fashion compared with a reference test of TPM-biopsy. Therefore, it forms the best available
evidence on TRUS-guided biopsy and mpMRI. Additional information on the diagnostic performance of
repeat tests and tests performed in combination was sought from the literature, and recent systematic
reviews were used whenever possible.23,105
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This study explicitly distinguishes between the short-term outcomes of the diagnostic strategies and the
long-term outcomes from the subsequent management decisions informed by diagnosis. Furthermore, it
overcomes the limitations in the available evidence on long-term outcomes with a novel calibration method
to obtain the quality-adjusted survival and lifetime costs. Extensive sensitivity analysis explores the sensitivity
of the results to parameter uncertainty and to assumptions regarding the management of men in clinical
practice. Probabilistic sensitivity analysis indicates the impact that parameter uncertainty had on the results.
Value-of-information analysis shows the magnitude of health losses attributable to parameter uncertainty
and the potential for investment in future research.
Limitations
This study has some limitations, mostly related to the fact that evidence on the long-term outcomes of
men with prostate cancer and on the diagnostic performance of tests in repeated testing episodes is itself
limited. Data on the long-term outcomes of men with prostate cancer, by risk subgroup and management,
were obtained from a recently published RCT, PIVOT.8 Given that only summary data were available, we
developed a method to predict quality-adjusted survival and costs from information on overall survival,
cumulative incidence of metastases and mortality following metastases. It assumes that the probabilities of
disease progression and death are constant over time, which is unrealistic. However, this is unlikely to have
a major impact on the results because the aim is to obtain long-term outcomes on average for radical
treatment or active surveillance, rather than selecting between treatments.
Importantly, the long-term outcomes of men with prostate cancer who are incorrectly classified as having no
cancer were assumed to be equivalent to those of men allocated to active surveillance. These men would not
be recruited for studies on prostate cancer; therefore, the consequences of misdiagnosis are, by definition,
unknown. The cost-effectiveness of less-sensitive diagnostic strategies is favoured if the long-term outcomes
of men who are incorrectly classified as having no cancer were overestimated. The implication is that the
base case may be biased towards M7 222 and against P4 2–– and P1–––, which detect all cancers. For this
reason, the sensitivity analysis establishes the minimum reduction in health outcomes that misclassified men
would need to experience to change the cost-effective strategy. A reduction as small as 0.01 QALYs,
equivalent to 3.7 days in full health, changes the cost-effective strategy at the health opportunity cost of
£30,000 per QALY. Reductions of ≥ 0.1 QALYs, equivalent to 37 days in full health, change the strategies
at £13,000 and £20,000 per QALY. As a benchmark, 1–2% increases in the hazard of all-cause death
(HR 1.01–1.02) reduce life expectancy by 0.07–0.13 years in men with intermediate-risk cancer. The implication
is that small changes in survival may have a large impact on the results. Therefore, the follow-up of men with
suspected prostate cancer but in whom cancer was not detected requires further investigation and may have
an impact on the most cost-effective diagnostic strategy.
It was not possible to account for the impact of repeated tests over time on the outcomes and costs of men
who are managed with active surveillance. As discussed earlier, these men are likely to be different in their
cancer characteristics from the men first referred for diagnosis. Furthermore, the cancer may progress in
size and differentiation at an unknown rate. To some extent, the impact of repeated testing is included in
the long-term outcomes, having been based on the active surveillance group of PIVOT,8 which included
repeated testing and the possibility of treatment over time. However, if the sensitivity of the watchful
waiting protocol in PIVOT is lower than that of the active surveillance protocol recommended by NICE,13
the long-term outcomes of men misclassified as having low-risk cancer may have been underestimated.
This was the rationale of the threshold sensitivity analysis to find the smallest proportion of reclassified men
that would change the cost-effective strategy. However, it is difficult to relate this minimum proportion to
the sensitivity of the active surveillance protocol recommended by NICE. Consequently, more research is
required on the sensitivity of repeated testing and its implications upstream to the cost-effectiveness of
diagnostic strategies.
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Remaining areas of uncertainty and areas for further research
The cost-effective diagnostic strategy depends on the cost-effectiveness of active treatment; however,
the long-term outcomes of men with prostate cancer remain uncertain and the evidence base, perhaps,
remains insufficient. The 2014 NICE clinical guideline13 recommends that men with low-risk cancer should
be offered active surveillance, whereas men with intermediate- and high-risk cancer should be offered
radical treatment. These recommendations are mostly based on expert consensus rather than formal
quantitative evaluations to identify for whom treatment should be recommended, how to monitor men
with lower-risk cancer and which treatments should be prioritised. The lack of evidence on management
decisions has upstream implications for the cost-effectiveness of diagnostic strategies because their costs
and benefits are partly determined by the costs and benefits of active surveillance and treatment. If
treatment is more beneficial than suggested by the evidence from PIVOT,8 the benefits of more-sensitive
strategies have been underestimated. Conversely, if treatment is less beneficial, the benefits of less-sensitive
strategies have been underestimated. This is explored in the threshold sensitivity analysis, which showed
that the less-sensitive and less-costly diagnostic strategies become cost-effective for a 15–20% reduction in
the clinical effectiveness of radical treatment.
The ProtecT study9, which compared RP, radiotherapy and active monitoring in men with prostate cancer,
may help resolve this uncertainty. At the time of conducting this analysis, the 10-year follow-up results are
available, but only for the entire trial population. Active treatment showed no effect on mortality, although
few deaths occurred, but a significant reduction in cancer progression (HR 0.39, 95% CI 0.27 to 0.54).
This is similar to the results of PIVOT8 (relative risk for bone metastasis 0.44, 95% CI 0.25 to 0.76).
However, this refers to the entire trial population, almost 80% of whom had low-risk cancer and,
therefore, would not be offered active treatment according to NICE’s recommendations.13 Evidence is
required on the effect of active treatment specifically in men with intermediate- and high-risk (CS) cancer,
for whom the NICE guidelines13 recommend treatment.
Moreover, the predicted long-term outcomes are affected by the misclassification of men by TRUS-guided
biopsy in PIVOT.8 In PIVOT, patients were diagnosed, enrolled and classified by risk on the basis of a biopsy
result and not on the basis of their true disease status. The biopsy is an imperfect test in that it produces a
considerable proportion of false-negative results, with evidence from PROMIS suggesting that only 34% of
intermediate-risk patients are identified as having CS cancer. The implications are twofold. First, the men
enrolled in PIVOT may not be representative of the men with cancer in the general population. This is only
an issue if the patients who were missed by the biopsy have a different prognosis from the prognoses of
the patients enrolled in PIVOT. Second, the PIVOT risk groups may have been misclassified and this may
introduce bias in the prediction of long-term outcomes and the relative clinical effectiveness of radical
treatment, and, therefore, may introduce bias to the benefits of correctly detecting CS cancer. Quality-
adjusted survival may have been underestimated in the high-risk subgroup if the sensitivity of TRUS-guided
biopsy is higher for higher cancer severity; hence, the high-risk subgroup may consist of men with the
most severe cancer, who have worse prognoses. Because only 18 out of 576 men in PROMIS had high-risk
cancer, any bias arising is unlikely to affect the results.
Quality-adjusted survival may also have been underestimated in the intermediate- and low-risk subgroups
in PIVOT if these were contaminated by more severe patients. This may be an issue particularly for
long-term outcomes post radical treatment if its effects are more pronounced in the intermediate-risk
subgroup. If the quality-adjusted survival of men treated with radical treatment was more underestimated
than that of men managed with observation, the benefits of more-sensitive strategies in detecting CS
cancer may have been underestimated. This issue can be resolved only with better-quality evidence on the
outcomes of men with prostate cancer, based on a perfect test such as TPM-biopsy for their diagnosis
and classification.
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There is some uncertainty regarding the costs of the tests, particularly TPM-biopsy, which affects the
results. The NHS reference cost for TPM-biopsy is approximately 25% higher than the PbR tariff, which
makes strategies with TPM-biopsy less likely to be cost-effective.
In principle, the unit costs of resource use should reflect the cost to the budget holder under whose
perspective the analysis is conducted (i.e. the UK NHS).148 This would suggest that appropriate unit costs
should reflect what the NHS actually pays external individuals or organisations – in this case, what hospitals
pay staff and the suppliers of equipment, services and consumables. Hence, unit costs would be based on
the mean reference costs reported by relevant hospital trusts. However, the UK NHS is devolved into a
range of organisations: NHS England, clinical commissioning groups, hospital trusts, etc. When a patient is
managed in secondary care, the hospital is generally reimbursed by the relevant clinical commissioning
group that has referred them, according to the PbR tariff. The PbR tariff is informed by NHS reference
costs, adjusted for inflation and changes in efficiency. If the specific perspective of the analysis is that of
clinical commissioning groups, for example, the PbR tariff may be the more relevant basis for estimating
unit costs. The impact of changes in the unit costs is provided in the multivariate sensitivity analysis (see
Chapter 7, Threshold sensitivity analysis).
The value-of-information analysis explored the expected costs to population health associated with
parameter uncertainty and the maximum expected benefit associated with investment in further research.
It shows that, although the expected health loss attributable to parameter uncertainty is small at the
per-patient level, it sums to a considerable amount at the population level over 5 years, given the large
number of men referred for investigation. In order to inform which research to commission in the future,
the value-of-information analysis should be developed further. This could take a number of avenues. The
expected value of perfect parameter information can indicate which parameters are driving the uncertainty
and have greater consequences, and hence should be prioritised for investment. The expected value of
sample information can be explored in order to help inform the most cost-effective study design and
sample size to obtain information on a specific parameter. There is also an important question regarding
the structural uncertainties in the model. Specifically, the model assumes that men receiving expectant
management have the outcomes of men in the observation arm of PIVOT. However, in practice, these
men may receive active treatment over time. This was explored in the scenario analysis. However, future
research could extend the model to account for this assumption as a parameter and explore its impact in
the value-of-information analysis. There is little guidance on how to develop this work in practice and
future methodological research may address this gap.
The results suggest that the most cost-effective strategy is using mpMRI as the first test, rather than
TRUS-guided biopsy. It may be difficult to implement this change, because it implies a shift in resources
from histopathology to imaging departments. Although financial resources are more straightforward to
transfer, there may be issues around capacity, namely related to skilled staff and capital investment in
equipment. Consequently, more consideration and research may be required on how best to implement
this policy and manage change.
This study suggests that mpMRI is cost-effective as the first test for the diagnosis of prostate cancer when
followed by MRI-targeted TRUS-guided biopsy in men in whom mpMRI suggests suspicion for CS cancer
and a second biopsy if no CS cancer is found. The cost-effective strategy uses the most sensitive definitions
and cut-off point for CS cancer: definition 2 for TRUS-guided biopsy (any Gleason pattern of ≥ 4 and/or
cancer core length of ≥ 4 mm) and definition 2 for mpMRI (lesion volume of ≥ 0.2 ml and/or a Gleason
score of ≥ 3 + 4) at the cut-off point of ≥ 2 on the Likert scale for suspicion of CS cancer.
This study makes it clear that the value of the diagnostic test depends on the value of the treatment
options that follow. Here, the most cost-effective strategy is one that detects almost all men with CS
cancer because active treatment was found to be highly cost-effective in this population. The findings are
sensitive to the costs of the tests, hence the motivation for the bivariate sensitivity analysis indicating the
most cost-effective strategy for a wide range of unit costs of each test. This can inform decisions in
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contexts facing different sets of prices. The findings are also sensitive to the sensitivity of MRI-targeted
TRUS-guided biopsy compared with TRUS-guided biopsy alone, which was tested in the threshold sensitivity
analysis. As with any research, the findings are grounded on the evidence used. The cost-effectiveness of
diagnostic tests depends on the cost-effectiveness of subsequent treatment decisions. If radical treatment is
less beneficial than PIVOT suggests, the scope for investment in diagnosis is smaller, and less-sensitive and
less-costly strategies are favoured. This study makes clear how the value of treatment can have upstream
implications for the value of the diagnostic tests.
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Chapter 10 Conclusions
The results from PROMIS suggest that a diagnostic strategy that incorporates mpMRI as an initial test inunscreened men referred for prostate biopsy may be useful in three ways. First, it is likely to reduce the
proportion of men having unnecessary biopsies. Second, fewer men with clinically important prostate
cancer will be missed. Third, the incorporation of mpMRI may enhance the cost-effectiveness of the
prostate cancer diagnostic and therapeutic pathway.
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Appendix 1 Supplementary clinical results
Centres
Participants were recruited from the following NHS hospitals in England: UCLH (lead centre), Basingstoke
and North Hampshire Hospital, Imperial College/Charing Cross Hospital, Musgrove Park Hospital,
Maidstone Hospital, Southmead Hospital, Whittington Hospital, Wrexham Maelor Hospital, Royal
Hallamshire Hospital, Frimley Park Hospital and Southampton General Hospital.
Screening
Screening log data were of adequate quality in 6 of the 11 centres. These centres provided 608 of the
740 registrations. In summary, 608 out of 1618 men (38%) who were screened at these centres were
registered into the study. However, about half of the 1010 non-registered men were ineligible according
to the entry criteria (n = 450) and in 68 men there was a valid clinical reason for non-entry. For 378 men
(37%), the reason for not registering was patient or clinician refusal; in addition, 11 men (1%) experienced
delays but would have been eligible. According to the baseline characteristics we were able to collect on
these non-registered men, there were no strong differences in age or PSA level between the 389 men who
were either delayed or refused entry and those who consented to be registered into PROMIS.
Results of diagnostic tests (supplementary)
TABLE 44 Summary of grades of cancer according to TPM-biopsy pathology results
Gleason gradesa
Any cancer
(N= 408)
CS according to definition
1a (N= 230) 2a (N= 331) 3a (N= 308)
Cancer core length
(mm), mean (SD)
6.3 (3.8) 9.1 (2.7) 7.4 (3.4) 7.5 (3.4)
3+ 3, n 100 10b 23b 0
3+ 4, n 252 164b 252 252
3+ 5, n 1 1 1 1
4+ 3, n 44 44 44 44
4+ 5, n 7 7 7 7
5+ 4, n 4 4 4 4
a Definitions 1, 2 and 3 are provided in Chapter 2, Definitions of clinically significant prostate cancer.
b Men classified as CS on the basis of core length despite having low Gleason grades.
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Case illustrations
Figure 41 illustrates a case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a
man harbouring CS cancer. Axial mpMRI scans are shown in a man with a PSA level of 12.4 ng/ml and
normal DRE. The mpMRI shows a 39-ml prostate volume and a right-sided lesion (Likert score of 5/5) on
(clockwise from top left) T2-weighted, diffusion-weighted high b-value and ADC map and dynamic
contrast enhanced images (all other areas had a Likert score of 1–2/5). TRUS-guided biopsy detected no
cancer and TPM-biopsy found a Gleason score of 4 + 3 and a cancer core length of 4 mm in a total of
8 out of 70 scores taken (primary definition of CS prostate cancer) that was concordant with the mpMRI.
On the TPM-biopsy diagram, each white or coloured box represents an area biopsied with one core.
TRUS-guided biopsy showed no cancer.
Figure 42 illustrates a case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a
man harbouring no cancer. It shows a series of images demonstrating mpMRI in a man with a PSA level of
8.9 ng/ml and a normal DRE, showing a 45-ml prostate volume and no suspicious area lesion on mpMRI
(T2-weighted image only shown). This was reported as a Likert score of 2. TPM-biopsy and TRUS-guided
biopsy detected no cancer.
TABLE 45 Summary of grades of cancer according to TRUS-guided biopsy pathology results
Gleason gradesa Any cancer (N= 286)
CS according to definition
1a (N= 124) 2a (N= 203) 3a (N= 151)
Cancer core length (mm), mean (SD) 5.2 (4.1) 8.4 (4.3) 6.6 (4.1) 6.7 (4.4)
3+ 3, n 135 26b 52b 0
3+ 4, n 103 50b 103 103
3+ 5, n 1 1 1 1
4+ 3, n 34 34 34 34
4+ 4, n 6 6 6 6
4+ 5, n 4 4 4 4
5+ 3, n 1 1 1 1
5+ 4, n 2 2 2 2
a Definitions 1, 2 and 3 provided in Chapter 2, Definitions of clinically significant prostate cancer.
b Men classified as CS on the basis of core length despite having low Gleason grades.
TABLE 46 Agreement between mpMRI and TRUS-guided biopsy for the detection of CS cancer
mpMRI
TRUS-guided biopsy, n
Total+ CS cancer – NC or CNS cancer
+ CS cancer 115 303 418
– NC or CNS cancer 9 149 158
Total 124 452 576
NC, no cancer.
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(a)
(b)
FIGURE 41 A case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a man harbouring
CS cancer. (a) mpMRI; (b) TPM-biopsy; and (c) TRUS-guided biopsy. ASAP, atypical small acinar proliferation; G3, Gleason 3;
HGPIN, high-grade prostate intraepithelial neoplasia; Inflamm, inflammation; ISUP, International Society of Urological
Pathology; Lymphovas, Lymphovascular. (continued)
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(c)
FIGURE 41 A case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a man harbouring
CS cancer. (a) mpMRI; (b) TPM-biopsy; and (c) TRUS-guided biopsy. ASAP, atypical small acinar proliferation; G3, Gleason 3;
HGPIN, high-grade prostate intraepithelial neoplasia; Inflamm, inflammation; ISUP, International Society of Urological
Pathology; Lymphovas, Lymphovascular.
(a)
FIGURE 42 A case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a man harbouring no
cancer. (a) mpMRI; (b) TPM-biopsy; and (c) TRUS-guided biopsy. ASAP, atypical small acinar proliferation; G3, Gleason 3;
HGPIN, high-grade prostate intraepithelial neoplasia; Inflamm, inflammation; ISUP, International Society of Urological
Pathology; Lymphovas, Lymphovascular. (continued )
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Clinical implications of introducing multiparametric magnetic
resonance imaging
Two scenarios were explored. In the best-case scenario (Figure 43), the results of mpMRI would be used to
direct TRUS-guided biopsy. In the worst-case scenario (Figure 44), TRUS-guided biopsy after mpMRI would
be conducted without direction from mpMRI.
Best-case scenario
l Biopsies, n = 418 (73% of total).
l Significant cancer detected, n = 213 (37% of total; 93% of 230 with TPM sig disease).
l Significant cancer missed, n = 17 (3% of total; 7% of 230 with TPM sig disease).
l Overdiagnosis if insignificant cancers offered active surveillance, n = 0.
l Overdiagnosis if insignificant cancers are treated, n= 121 (21% of total; 35% of 346 without TPM sig disease).
(b)
(c)
FIGURE 42 A case showing correlation of TRUS-guided biopsy and mpMRI with TPM-biopsy for a man harbouring no
cancer. (a) mpMRI; (b) TPM-biopsy; and (c) TRUS-guided biopsy. ASAP, atypical small acinar proliferation; G3, Gleason 3;
HGPIN, high-grade prostate intraepithelial neoplasia; Inflamm, inflammation; ISUP, International Society of Urological
Pathology; Lymphovas, Lymphovascular.
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MRI test
(n = 576)
Insignificant cancer
(n = 55)
No cancer
(n = 103)
Significant cancer
(n = 418)
No further tests, just active
surveillance or discharge
(n = 158; 17 cases of
TPM significant cancer
missed)
TRUS-guided biopsy
(non-directed)
(n = 418)
Insignificant cancer
(n = 129)
No cancer
(n = 174)
Significant cancer
(n = 115)
Cases of TPM
significant cancer
detected
(n = 77)
Cases of TPM
significant cancer
missed
(n = 31)
Cases of TPM
significant cancer
detected
(n = 105)
FIGURE 44 Flow chart showing worst-case scenario (TRUS-guided biopsy not directed by mpMRI).
MRI test
(n = 576)
Insignificant cancer
(n = 55)
No cancer
(n = 103)
Significant cancer
(n = 418)
No further tests, just active
surveillance or discharge
(n = 158; 17 cases of
TPM significant cancer
missed)
MRI-guided TRUS-guided
biopsy (assumed to be 
same as TPM-biopsy)
(n = 418)
Insignificant cancer
(n = 121)
No cancer
(n = 84)
Significant cancer
(n = 213)
Active
surveillance or
treatment?
Active
surveillance
Treatment
FIGURE 43 Flow chart showing best-case scenario (TRUS-guided biopsy directed by mpMRI).
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Worst-case scenario
l Biopsies, n = 418 (73% of total).
l Significant cancer detected, n = 77 + 105 = 182 (32% of total; 79% of 230 with TPM sig disease).
l Significant cancer missed, n = 17 + 31 = 48 (8% of total; 21% of 230 with TPM sig disease).
l Overdiagnosis, n = 244 – 182 = 62 (11% of total; 18% of 346 without TPM sig disease).
Agreement between sites for multiparametric magnetic resonance
imaging measurements
In order to determine whether or not the lead radiology site (UCLH, responsible for training all other sites)
demonstrated different diagnostic accuracy from the non-UCLH sites, the results were compared for the
primary outcome analysis between mpMRI definition 2, cut-off point 3 and TPM-biopsy definition 1 variables
for the detection of CS cancer. The results were almost identical (Tables 47 and 48 and Figures 45 and 46).
For both groups, the proportion of CS cases that were missed was about 3% and the proportion of men
who may be able to avoid a biopsy was about 27%.
TABLE 47 Diagnostic results for mpMRI (definition 2, cut-off point 3) relative to TPM-biopsy (definition 1) for the
UCLH site alone
mpMRI
TPM-biopsy, n
+ CS – CNS Total
+ CS 85 75 160
– CNS 6 56 62
Total 91 131 222
Notes
Sensitivity = 93% (95% CI 86% to 98%); PPV= 53% (95% CI 45% to 61%).
Specificity = 43% (95% CI 34% to 52%); NPV = 90% (95% CI 80% to 96%).
TABLE 48 Diagnostic results for mpMRI (definition 2, cut-off point 3) relative to TPM-biopsy (definition 1) for
non-UCLH sites
mpMRI
TPM-biopsy, n
+ CS – CNS Total
+ CS 128 130 258
– CNS 11 85 96
Total 139 215 354
Notes
Sensitivity = 92% (95% CI 86% to 96%); PPV= 50% (95% CI 43% to 56%).
Specificity = 40% (95% CI 33% to 46%); NPV = 89% (95% CI 80% to 94%).
DOI: 10.3310/hta22390 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 39
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
Index test (MRI)
(n = 354)
Non-significant cancer
(n = 96)
Cancer present
(n = 128)
Cancer present
(n = 11)
No cancer present
(n = 85)
No cancer present
(n = 130)
Significant cancer
(n = 258)
FIGURE 46 Results for detection of CS cancer for mpMRI (definition 2, cut-off point 3) relative to TPM-biopsy
(definition 1) for non-UCLH sites.
Index test (MRI)
(n = 222)
Non-significant cancer
(n = 62)
Cancer present
(n = 85)
Cancer present
(n = 6)
No cancer present
(n = 56)
No cancer present
(n = 75)
Significant cancer
(n = 160)
FIGURE 45 Results for detection of CS cancer for mpMRI (definition 2, cut-off point 3) relative to TPM-biopsy
(definition 1) for the UCLH site alone.
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Appendix 2 Analysis of individual patient data
on the diagnostic performance of multiparametric
magnetic resonance imaging and transrectal
ultrasound-guided biopsy
This analysis was carried out for the purposes of the economic evaluation. Figure 47 depicts the analysisof the individual patient data collected in PROMIS to obtain simulations of the diagnostic performance
of mpMRI and TRUS-guided biopsy.
1. Correct TPM-biopsy results
2. Classify men according to the PIVOT
categories: low risk, intermediate risk
and high risk of cancer
3. Classify men as no cancer, CNS cancer 
and CS cancer according to mpMRI and 
TRUS-guided biopsy results for different 
definitions and cut-off points
4. Exclude from analysis those men 
classified in PROMIS as CS cancer on the 
basis of cancer core length, if, according 
to the PIVOT categories, these men have 
low risk of cancer (n = 7 men)
5. Bootstrap sample (n = 569 men) over
1000 times and calculate proportion 
of men by disease category and test
classification
TPM-biopsy is assumed to be a perfect test;
however, this was not the case in the PROMIS study. 
Men in whom TRUS-guided biopsy detected cancer, 
but TPM-biopsy did not, have their TPM-biopsy results
changed as per TRUS-guided biopsy (n = 9 men)
These are the categories that will be used for the
prediction of the long-term outcomes:
• no cancer, n = 159 men
• low-risk cancer, n = 98 men
• intermediate-risk cancer, n = 301 men
• high-risk cancer, n = 18 men
FIGURE 47 Analysis of individual patient data.
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Appendix 3 Full results of the economic analyses
Tables 49–56 show the full results of the economic analyses.
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TABLE 49 Sensitivity by strategy: TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Sensitivity by substrategy, average (95% CI)
112 113 114 115 122 123 124 125
M1 0.44 (0.36 to 0.51) 0.36 (0.30 to 0.42) 0.24 (0.20 to 0.29) 0.15 (0.12 to 0.19) 0.46 (0.38 to 0.53) 0.41 (0.35 to 0.48) 0.32 (0.27 to 0.38) 0.21 (0.17 to 0.25)
M2 0.46 (0.39 to 0.54) 0.43 (0.36 to 0.50) 0.34 (0.29 to 0.40) 0.22 (0.18 to 0.27) 0.46 (0.39 to 0.54) 0.43 (0.36 to 0.50) 0.34 (0.29 to 0.40) 0.22 (0.18 to 0.27)
M3 0.72 (0.66 to 0.78) 0.58 (0.52 to 0.64) 0.39 (0.34 to 0.44) 0.22 (0.18 to 0.27) 0.76 (0.70 to 0.81) 0.68 (0.62 to 0.73) 0.52 (0.47 to 0.58) 0.33 (0.28 to 0.38)
M4 0.75 (0.68 to 0.80) 0.66 (0.59 to 0.71) 0.48 (0.43 to 0.54) 0.29 (0.25 to 0.34) 0.76 (0.70 to 0.82) 0.70 (0.64 to 0.75) 0.54 (0.48 to 0.60) 0.34 (0.29 to 0.39)
M5 0.59 (0.52 to 0.65) 0.48 (0.42 to 0.54) 0.32 (0.27 to 0.37) 0.19 (0.15 to 0.23) 0.61 (0.55 to 0.68) 0.55 (0.49 to 0.61) 0.43 (0.37 to 0.48) 0.27 (0.23 to 0.31)
M6 0.62 (0.55 to 0.68) 0.58 (0.52 to 0.64) 0.45 (0.40 to 0.51) 0.29 (0.24 to 0.33) 0.62 (0.55 to 0.68) 0.58 (0.52 to 0.64) 0.45 (0.40 to 0.51) 0.29 (0.24 to 0.33)
M7 0.87 (0.81 to 0.93) 0.70 (0.64 to 0.76) 0.46 (0.40 to 0.52) 0.26 (0.21 to 0.31) 0.92 (0.85 to 0.97) 0.82 (0.75 to 0.87) 0.63 (0.57 to 0.69) 0.39 (0.33 to 0.44)
N1 0.94 (0.91 to 0.96) 0.75 (0.70 to 0.80) 0.49 (0.44 to 0.55) 0.28 (0.23 to 0.33) 0.98 (0.97 to 1.00) 0.88 (0.84 to 0.91) 0.67 (0.62 to 0.73) 0.41 (0.36 to 0.47)
N2 0.99 (0.98 to 1.00) 0.92 (0.89 to 0.95) 0.71 (0.66 to 0.77) 0.44 (0.38 to 0.49) 0.99 (0.98 to 1.00) 0.92 (0.89 to 0.95) 0.71 (0.66 to 0.77) 0.44 (0.38 to 0.49)
N3 0.77 (0.72 to 0.81) 0.62 (0.56 to 0.67) 0.41 (0.36 to 0.46) 0.23 (0.19 to 0.28) 0.80 (0.76 to 0.85) 0.72 (0.67 to 0.76) 0.55 (0.50 to 0.61) 0.34 (0.29 to 0.39)
N4 0.79 (0.74 to 0.83) 0.69 (0.64 to 0.74) 0.50 (0.45 to 0.56) 0.30 (0.26 to 0.35) 0.81 (0.76 to 0.85) 0.74 (0.69 to 0.78) 0.57 (0.52 to 0.63) 0.35 (0.30 to 0.41)
N5 0.61 (0.55 to 0.67) 0.49 (0.44 to 0.55) 0.33 (0.29 to 0.38) 0.19 (0.16 to 0.23) 0.64 (0.57 to 0.70) 0.57 (0.51 to 0.63) 0.44 (0.39 to 0.50) 0.28 (0.24 to 0.32)
N6 0.64 (0.58 to 0.70) 0.60 (0.54 to 0.66) 0.47 (0.42 to 0.53) 0.29 (0.25 to 0.34) 0.64 (0.58 to 0.70) 0.60 (0.54 to 0.66) 0.47 (0.42 to 0.53) 0.29 (0.25 to 0.34)
N7 0.94 (0.91 to 0.96) 0.75 (0.70 to 0.80) 0.49 (0.44 to 0.55) 0.28 (0.23 to 0.33) 0.98 (0.97 to 1.00) 0.88 (0.84 to 0.91) 0.67 (0.62 to 0.73) 0.41 (0.36 to 0.47)
T1 0.38 (0.33 to 0.43) a a a a a a a
T2 0.42 (0.37 to 0.48) a a a a a a a
T3 0.48 (0.41 to 0.56) a a a a a a a
T4 0.52 (0.45 to 0.61) a a a a a a a
T5 0.56 (0.51 to 0.62) 0.52 (0.47 to 0.58) 0.47 (0.42 to 0.52) 0.42 (0.38 to 0.48) 0.57 (0.52 to 0.63) 0.55 (0.50 to 0.61) 0.51 (0.46 to 0.56) 0.45 (0.40 to 0.50)
T6 0.70 (0.64 to 0.75) 0.63 (0.58 to 0.69) 0.54 (0.49 to 0.59) 0.46 (0.41 to 0.51) 0.72 (0.66 to 0.77) 0.68 (0.62 to 0.73) 0.60 (0.55 to 0.66) 0.51 (0.46 to 0.56)
T7 0.89 (0.81 to 0.94) 0.78 (0.71 to 0.84) 0.63 (0.57 to 0.68) 0.51 (0.45 to 0.56) 0.91 (0.84 to 0.97) 0.85 (0.78 to 0.91) 0.73 (0.67 to 0.79) 0.58 (0.53 to 0.64)
T8 0.57 (0.52 to 0.63) 0.56 (0.51 to 0.62) 0.52 (0.46 to 0.57) 0.46 (0.41 to 0.51) 0.57 (0.52 to 0.63) 0.56 (0.51 to 0.62) 0.52 (0.46 to 0.57) 0.46 (0.41 to 0.51)
T9 0.90 (0.82 to 0.95) 0.81 (0.75 to 0.87) 0.68 (0.62 to 0.73) 0.54 (0.49 to 0.60) 0.91 (0.84 to 0.97) 0.86 (0.79 to 0.91) 0.74 (0.68 to 0.80) 0.59 (0.53 to 0.64)
A
P
P
E
N
D
IX
3
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
3
6
Strategy
Sensitivity by substrategy, average (95% CI)
112 113 114 115 122 123 124 125
P1 1.00 (1.00 to 1.00) a a a a a a a
P2 0.60 (0.55 to 0.66) a a a a a a a
P3 0.77 (0.73 to 0.81) a a a a a a a
P4 1.00 (1.00 to 1.00) a a a a a a a
P5 0.59 (0.54 to 0.64) 0.54 (0.49 to 0.60) 0.48 (0.43 to 0.53) 0.43 (0.38 to 0.48) 0.60 (0.55 to 0.65) 0.57 (0.53 to 0.63) 0.53 (0.48 to 0.58) 0.46 (0.42 to 0.51)
P6 0.75 (0.70 to 0.79) 0.67 (0.62 to 0.72) 0.56 (0.51 to 0.61) 0.47 (0.42 to 0.52) 0.77 (0.72 to 0.81) 0.72 (0.68 to 0.77) 0.64 (0.59 to 0.68) 0.53 (0.48 to 0.58)
P7 0.96 (0.94 to 0.98) 0.84 (0.80 to 0.87) 0.67 (0.62 to 0.71) 0.52 (0.47 to 0.58) 0.99 (0.98 to 1.00) 0.92 (0.90 to 0.94) 0.79 (0.74 to 0.82) 0.61 (0.56 to 0.66)
P8 0.60 (0.55 to 0.66) 0.59 (0.54 to 0.64) 0.54 (0.49 to 0.59) 0.47 (0.42 to 0.52) 0.60 (0.55 to 0.66) 0.59 (0.54 to 0.64) 0.54 (0.49 to 0.59) 0.47 (0.42 to 0.52)
P9 0.97 (0.96 to 0.98) 0.88 (0.85 to 0.90) 0.72 (0.67 to 0.76) 0.56 (0.51 to 0.61) 0.99 (0.98 to 1.00) 0.93 (0.91 to 0.95) 0.80 (0.75 to 0.83) 0.62 (0.57 to 0.67)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 50 Sensitivity by strategy: TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Sensitivity by substrategy, average (95% CI)
212 213 214 215 222 223 224 225
M1 0.71 (0.62 to 0.81) 0.57 (0.50 to 0.66) 0.38 (0.32 to 0.45) 0.22 (0.17 to 0.27) 0.74 (0.66 to 0.84) 0.66 (0.58 to 0.76) 0.51 (0.44 to 0.59) 0.32 (0.27 to 0.38)
M2 0.75 (0.66 to 0.85) 0.70 (0.61 to 0.79) 0.54 (0.47 to 0.63) 0.34 (0.28 to 0.40) 0.75 (0.66 to 0.85) 0.70 (0.61 to 0.79) 0.54 (0.47 to 0.63) 0.34 (0.28 to 0.40)
M3 0.79 (0.73 to 0.86) 0.64 (0.58 to 0.71) 0.42 (0.37 to 0.48) 0.24 (0.20 to 0.29) 0.83 (0.77 to 0.89) 0.74 (0.68 to 0.81) 0.57 (0.51 to 0.64) 0.35 (0.30 to 0.41)
M4 0.84 (0.77 to 0.90) 0.76 (0.70 to 0.83) 0.59 (0.52 to 0.66) 0.36 (0.31 to 0.42) 0.84 (0.78 to 0.90) 0.78 (0.71 to 0.84) 0.60 (0.54 to 0.67) 0.37 (0.32 to 0.43)
M5 0.82 (0.77 to 0.88) 0.66 (0.60 to 0.73) 0.44 (0.38 to 0.49) 0.25 (0.20 to 0.29) 0.86 (0.81 to 0.92) 0.77 (0.72 to 0.83) 0.59 (0.53 to 0.65) 0.37 (0.32 to 0.42)
M6 0.87 (0.82 to 0.93) 0.81 (0.76 to 0.86) 0.63 (0.57 to 0.69) 0.39 (0.33 to 0.45) 0.87 (0.82 to 0.93) 0.81 (0.76 to 0.86) 0.63 (0.57 to 0.69) 0.39 (0.33 to 0.45)
M7 0.91 (0.87 to 0.95) 0.73 (0.68 to 0.78) 0.48 (0.43 to 0.54) 0.27 (0.22 to 0.32) 0.95 (0.92 to 0.98) 0.85 (0.81 to 0.89) 0.65 (0.60 to 0.71) 0.40 (0.35 to 0.46)
N1 a a a a a a a a
N2 a a a a a a a a
N3 0.81 (0.75 to 0.87) 0.65 (0.59 to 0.71) 0.43 (0.37 to 0.49) 0.24 (0.20 to 0.29) 0.85 (0.79 to 0.90) 0.76 (0.70 to 0.81) 0.58 (0.52 to 0.64) 0.36 (0.31 to 0.42)
N4 0.85 (0.79 to 0.91) 0.77 (0.71 to 0.84) 0.59 (0.52 to 0.66) 0.36 (0.31 to 0.42) 0.85 (0.80 to 0.91) 0.79 (0.73 to 0.85) 0.61 (0.55 to 0.68) 0.38 (0.32 to 0.44)
N5 0.84 (0.79 to 0.89) 0.68 (0.62 to 0.74) 0.44 (0.39 to 0.50) 0.25 (0.20 to 0.30) 0.88 (0.84 to 0.93) 0.79 (0.74 to 0.84) 0.61 (0.55 to 0.66) 0.37 (0.32 to 0.43)
N6 0.89 (0.84 to 0.94) 0.83 (0.78 to 0.87) 0.64 (0.58 to 0.70) 0.39 (0.34 to 0.45) 0.89 (0.84 to 0.94) 0.83 (0.78 to 0.87) 0.64 (0.58 to 0.70) 0.39 (0.34 to 0.45)
N7 0.94 (0.91 to 0.96) 0.75 (0.70 to 0.80) 0.49 (0.44 to 0.55) 0.28 (0.23 to 0.33) 0.98 (0.97 to 1.00) 0.88 (0.84 to 0.91) 0.67 (0.62 to 0.73) 0.41 (0.36 to 0.47)
T1 0.61 (0.56 to 0.66) b b b b b b b
T2 0.69 (0.64 to 0.74) b b b b b b b
T3 0.65 (0.60 to 0.70) b b b b b b b
T4 0.73 (0.69 to 0.78) b b b b b b b
T5 0.80 (0.75 to 0.84) 0.76 (0.71 to 0.81) 0.71 (0.66 to 0.75) 0.66 (0.61 to 0.71) 0.81 (0.76 to 0.85) 0.79 (0.74 to 0.83) 0.74 (0.70 to 0.79) 0.69 (0.64 to 0.74)
T6 0.74 (0.70 to 0.79) 0.72 (0.67 to 0.76) 0.68 (0.63 to 0.72) 0.65 (0.60 to 0.69) 0.75 (0.71 to 0.79) 0.74 (0.69 to 0.78) 0.71 (0.66 to 0.75) 0.67 (0.62 to 0.71)
T7 0.93 (0.88 to 0.96) 0.86 (0.82 to 0.90) 0.77 (0.72 to 0.81) 0.69 (0.65 to 0.74) 0.95 (0.90 to 0.98) 0.91 (0.86 to 0.94) 0.83 (0.79 to 0.87) 0.74 (0.69 to 0.78)
T8 0.81 (0.76 to 0.86) 0.79 (0.75 to 0.84) 0.75 (0.70 to 0.80) 0.69 (0.64 to 0.74) 0.81 (0.76 to 0.86) 0.79 (0.75 to 0.84) 0.75 (0.70 to 0.80) 0.69 (0.64 to 0.74)
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Strategy
Sensitivity by substrategy, average (95% CI)
212 213 214 215 222 223 224 225
T9 0.94 (0.89 to 0.97) 0.90 (0.85 to 0.93) 0.82 (0.77 to 0.86) 0.73 (0.68 to 0.77) 0.95 (0.90 to 0.98) 0.92 (0.87 to 0.95) 0.84 (0.80 to 0.88) 0.75 (0.70 to 0.79)
P1 a b b b b b b b
P2 0.84 (0.80 to 0.88) b b b b b b b
P3 0.77 (0.73 to 0.81) b b b b b b b
P4 1.00 (1.00 to 1.00) b b b b b b b
P5 0.83 (0.78 to 0.87) 0.78 (0.74 to 0.82) 0.72 (0.67 to 0.76) 0.67 (0.62 to 0.71) 0.84 (0.79 to 0.88) 0.81 (0.77 to 0.85) 0.76 (0.72 to 0.80) 0.70 (0.65 to 0.75)
P6 0.76 (0.72 to 0.80) 0.73 (0.69 to 0.77) 0.69 (0.64 to 0.73) 0.65 (0.60 to 0.70) 0.77 (0.73 to 0.81) 0.75 (0.71 to 0.79) 0.72 (0.68 to 0.76) 0.67 (0.63 to 0.72)
P7 0.97 (0.96 to 0.99) 0.90 (0.87 to 0.92) 0.79 (0.75 to 0.83) 0.70 (0.65 to 0.75) 0.99 (0.99 to 1.00) 0.95 (0.93 to 0.97) 0.87 (0.83 to 0.90) 0.76 (0.72 to 0.80)
P8 0.84 (0.80 to 0.88) 0.82 (0.78 to 0.86) 0.77 (0.73 to 0.81) 0.71 (0.66 to 0.75) 0.84 (0.80 to 0.88) 0.82 (0.78 to 0.86) 0.77 (0.73 to 0.81) 0.71 (0.66 to 0.75)
P9 0.99 (0.98 to 0.99) 0.94 (0.92 to 0.96) 0.85 (0.81 to 0.88) 0.74 (0.70 to 0.78) 1.00 (0.99 to 1.00) 0.96 (0.95 to 0.97) 0.88 (0.85 to 0.90) 0.77 (0.72 to 0.81)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 51 Costs of testing by strategy: TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Cost of testing by substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
M1 544 (531 to 556) 409 (392 to 427) 310 (294 to 325) 244 (232 to 257) 581 (573 to 588) 482 (467 to 499) 366 (349 to 383) 280 (265 to 295)
M2 596 (592 to 600) 522 (509 to 536) 381 (364 to 399) 287 (272 to 301) 596 (592 to 600) 522 (509 to 536) 381 (364 to 399) 287 (272 to 301)
M3 631 (611 to 654) 474 (451 to 499) 349 (327 to 371) 264 (248 to 280) 674 (656 to 693) 562 (539 to 587) 423 (398 to 447) 311 (291 to 332)
M4 684 (667 to 701) 587 (568 to 607) 421 (399 to 442) 306 (287 to 324) 689 (672 to 707) 602 (581 to 624) 438 (415 to 461) 318 (298 to 338)
M5 716 (692 to 739) 488 (464 to 514) 342 (322 to 363) 257 (242 to 273) 780 (759 to 800) 608 (583 to 635) 418 (397 to 442) 301 (284 to 320)
M6 807 (790 to 826) 678 (653 to 702) 441 (418 to 465) 310 (292 to 328) 807 (790 to 826) 678 (653 to 702) 441 (418 to 465) 310 (292 to 328)
M7 804 (776 to 831) 553 (524 to 583) 382 (354 to 408) 277 (258 to 296) 873 (850 to 896) 687 (657 to 719) 475 (447 to 504) 333 (310 to 357)
N1 1399 (1357 to 1438) 946 (890 to 1004) 613 (561 to 664) 392 (349 to 435) 1524 (1500 to 1547) 1193 (1142 to 1245) 801 (745 to 857) 512 (464 to 560)
N2 1575 (1565 to 1585) 1328 (1284 to 1371) 853 (797 to 912) 534 (485 to 581) 1575 (1565 to 1585) 1328 (1284 to 1371) 853 (797 to 912) 534 (485 to 581)
N3 839 (784 to 897) 628 (581 to 677) 443 (404 to 483) 309 (284 to 339) 895 (836 to 953) 749 (696 to 805) 557 (508 to 605) 386 (350 to 422)
N4 891 (838 to 946) 741 (698 to 788) 514 (476 to 554) 352 (323 to 380) 911 (853 to 967) 789 (737 to 844) 572 (525 to 621) 392 (356 to 428)
N5 1124 (1065 to 1186) 676 (625 to 728) 419 (386 to 457) 288 (266 to 313) 1252 (1192 to 1311) 906 (848 to 967) 542 (500 to 588) 351 (324 to 381)
N6 1308 (1249 to 1366) 1046 (987 to 1107) 582 (536 to 629) 364 (336 to 393) 1308 (1249 to 1366) 1046 (987 to 1107) 582 (536 to 629) 364 (336 to 393)
N7 1420 (1348 to 1487) 894 (831 to 961) 552 (497 to 609) 353 (318 to 392) 1566 (1495 to 1629) 1173 (1098 to 1245) 733 (672 to 795) 457 (413 to 505)
T1 415 (412 to 420) a a a a a a a
T2 627 (610 to 644) a a a a a a a
T3 531 (516 to 547) a a a a a a a
T4 742 (727 to 757) a a a a a a a
T5 681 (658 to 705) 591 (573 to 608) 544 (531 to 556) 523 (513 to 533) 707 (683 to 730) 636 (616 to 657) 564 (550 to 578) 532 (522 to 543)
T6 571 (550 to 592) 541 (524 to 558) 511 (497 to 525) 488 (477 to 500) 578 (557 to 599) 559 (541 to 579) 531 (515 to 547) 501 (488 to 515)
T7 837 (816 to 858) 717 (700 to 736) 639 (625 to 655) 595 (585 to 607) 870 (849 to 890) 780 (760 to 801) 680 (663 to 697) 618 (606 to 633)
T8 719 (695 to 743) 665 (642 to 687) 571 (557 to 586) 534 (523 to 545) 719 (695 to 743) 665 (642 to 687) 571 (557 to 586) 534 (523 to 545)
T9 875 (855 to 894) 791 (772 to 810) 667 (652 to 683) 607 (596 to 619) 882 (861 to 901) 809 (790 to 829) 687 (671 to 705) 620 (608 to 635)
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Strategy
Cost of testing by substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
P1 1398 (1392 to 1405) a a a a a a a
P2 1127 (1070 to 1179) a a a a a a a
P3 805 (754 to 854) a a a a a a a
P4 1517 (1472 to 1561) a a a a a a a
P5 1091 (1031 to 1150) 787 (741 to 833) 628 (601 to 655) 558 (542 to 577) 1179 (1117 to 1240) 940 (890 to 995) 698 (664 to 733) 590 (569 to 614)
P6 819 (767 to 871) 720 (677 to 762) 618 (585 to 653) 539 (518 to 563) 844 (789 to 899) 781 (732 to 829) 686 (647 to 727) 585 (556 to 614)
P7 1496 (1440 to 1550) 1092 (1044 to 1143) 831 (789 to 872) 682 (655 to 713) 1608 (1554 to 1658) 1305 (1248 to 1363) 968 (922 to 1017) 760 (726 to 797)
P8 1219 (1154 to 1278) 1037 (980 to 1093) 722 (686 to 759) 597 (575 to 622) 1219 (1154 to 1278) 1037 (980 to 1093) 722 (686 to 759) 597 (575 to 622)
P9 1638 (1589 to 1686) 1373 (1319 to 1424) 936 (893 to 982) 722 (694 to 754) 1654 (1604 to 1702) 1414 (1361 to 1466) 996 (949 to 1045) 767 (733 to 803)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 52 Costs of testing by strategy: TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Cost of testing by substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
M1 544 (531 to 556) 409 (392 to 427) 310 (294 to 325) 244 (232 to 257) 581 (573 to 588) 482 (467 to 499) 366 (349 to 383) 280 (265 to 295)
M2 596 (592 to 600) 522 (509 to 536) 381 (364 to 399) 287 (272 to 301) 596 (592 to 600) 522 (509 to 536) 381 (364 to 399) 287 (272 to 301)
M3 577 (560 to 595) 431 (412 to 451) 323 (305 to 341) 250 (237 to 264) 617 (603 to 633) 511 (492 to 532) 385 (366 to 404) 290 (273 to 306)
M4 630 (618 to 643) 545 (528 to 561) 394 (377 to 413) 292 (276 to 308) 632 (620 to 646) 551 (534 to 570) 400 (382 to 420) 296 (280 to 312)
M5 707 (682 to 731) 481 (456 to 507) 338 (317 to 358) 255 (240 to 271) 770 (746 to 791) 599 (572 to 625) 412 (390 to 435) 298 (279 to 316)
M6 797 (777 to 818) 669 (642 to 694) 434 (411 to 458) 306 (287 to 323) 797 (777 to 818) 669 (642 to 694) 434 (411 to 458) 306 (287 to 323)
M7 740 (710 to 769) 503 (475 to 532) 350 (328 to 374) 261 (244 to 278) 807 (777 to 833) 628 (597 to 660) 430 (404 to 458) 307 (287 to 328)
N1 a a a a a a a a
N2 a a a a a a a a
N3 657 (620 to 703) 484 (450 to 522) 353 (328 to 380) 264 (246 to 283) 704 (663 to 750) 580 (543 to 625) 429 (399 to 463) 312 (289 to 336)
N4 709 (672 to 753) 598 (565 to 633) 424 (400 to 452) 306 (286 to 326) 719 (678 to 766) 620 (583 to 663) 445 (414 to 478) 319 (296 to 342)
N5 1092 (1023 to 1157) 651 (597 to 706) 403 (369 to 442) 280 (258 to 306) 1218 (1147 to 1284) 876 (812 to 941) 520 (474 to 568) 339 (310 to 370)
N6 1275 (1210 to 1339) 1015 (950 to 1080) 558 (509 to 608) 350 (320 to 383) 1275 (1210 to 1339) 1015 (950 to 1080) 558 (509 to 608) 350 (320 to 383)
N7 1206 (1118 to 1286) 726 (653 to 796) 446 (398 to 500) 300 (272 to 333) 1341 (1251 to 1423) 973 (891 to 1051) 583 (522 to 645) 371 (333 to 411)
T1 415 (412 to 420) b b b b b b b
T2 627 (610 to 644) b b b b b b b
T3 476 (463 to 489) b b b b b b b
T4 687 (671 to 705) b b b b b b b
T5 681 (658 to 705) 591 (573 to 608) 544 (531 to 556) 523 (513 to 533) 707 (683 to 730) 636 (616 to 657) 564 (550 to 578) 532 (522 to 543)
T6 496 (480 to 511) 477 (464 to 490) 462 (452 to 472) 451 (443 to 459) 500 (484 to 517) 488 (473 to 503) 471 (460 to 484) 457 (448 to 466)
T7 762 (738 to 785) 653 (635 to 671) 590 (577 to 604) 559 (549 to 569) 792 (769 to 816) 709 (688 to 730) 620 (605 to 637) 574 (562 to 586)
T8 719 (695 to 743) 665 (642 to 687) 571 (557 to 586) 534 (523 to 545) 719 (695 to 743) 665 (642 to 687) 571 (557 to 586) 534 (523 to 545)
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Strategy
Cost of testing by substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
T9 799 (776 to 822) 727 (705 to 747) 618 (603 to 634) 570 (559 to 582) 804 (781 to 828) 737 (715 to 759) 627 (611 to 644) 576 (564 to 588)
P1 a,b b b b b b b b
P2 1127 (1070 to 1179) b b b b b b b
P3 620 (580 to 660) b b b b b b b
P4 1332 (1278 to 1385) b b b b b b b
P5 1091 (1031 to 1150) 787 (741 to 833) 628 (601 to 655) 558 (542 to 577) 1179 (1117 to 1240) 940 (890 to 995) 698 (664 to 733) 590 (569 to 614)
P6 623 (582 to 663) 560 (530 to 591) 509 (489 to 531) 472 (459 to 486) 639 (595 to 683) 596 (560 to 633) 541 (515 to 569) 491 (474 to 509)
P7 1299 (1238 to 1358) 932 (884 to 979) 721 (689 to 757) 615 (595 to 637) 1402 (1341 to 1462) 1120 (1066 to 1181) 823 (782 to 867) 666 (639 to 695)
P8 1219 (1154 to 1278) 1037 (980 to 1093) 722 (686 to 759) 597 (575 to 622) 1219 (1154 to 1278) 1037 (980 to 1093) 722 (686 to 759) 597 (575 to 622)
P9 1442 (1383 to 1500) 1213 (1157 to 1269) 826 (786 to 869) 655 (631 to 682) 1448 (1387 to 1507) 1229 (1171 to 1288) 851 (808 to 896) 673 (645 to 702)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 53 Base case: overall QALYs by strategy – TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Overall QALYs by substrategy, average (95% CI)
112 113 114 115 122 123 124 125
M1 8.44 (8.14 to 8.76) 8.40 (8.09 to 8.73) 8.34 (8.01 to 8.70) 8.29 (7.94 to 8.68) 8.45 (8.15 to 8.78) 8.43 (8.13 to 8.75) 8.38 (8.07 to 8.72) 8.32 (7.99 to 8.69)
M2 8.46 (8.16 to 8.78) 8.44 (8.14 to 8.76) 8.39 (8.08 to 8.73) 8.33 (7.99 to 8.69) 8.46 (8.16 to 8.78) 8.44 (8.14 to 8.76) 8.39 (8.08 to 8.73) 8.33 (7.99 to 8.69)
M3 8.60 (8.30 to 8.90) 8.52 (8.23 to 8.82) 8.42 (8.12 to 8.74) 8.33 (8.00 to 8.69) 8.61 (8.32 to 8.91) 8.57 (8.28 to 8.87) 8.49 (8.20 to 8.80) 8.38 (8.07 to 8.72)
M4 8.61 (8.32 to 8.91) 8.56 (8.27 to 8.86) 8.47 (8.18 to 8.78) 8.37 (8.06 to 8.71) 8.62 (8.32 to 8.92) 8.58 (8.29 to 8.88) 8.50 (8.21 to 8.81) 8.39 (8.09 to 8.73)
M5 8.52 (8.24 to 8.82) 8.46 (8.17 to 8.77) 8.38 (8.06 to 8.72) 8.31 (7.97 to 8.68) 8.54 (8.26 to 8.83) 8.50 (8.22 to 8.81) 8.44 (8.14 to 8.75) 8.36 (8.03 to 8.71)
M6 8.54 (8.26 to 8.84) 8.52 (8.23 to 8.82) 8.45 (8.16 to 8.77) 8.36 (8.05 to 8.71) 8.54 (8.26 to 8.84) 8.52 (8.23 to 8.82) 8.45 (8.16 to 8.77) 8.36 (8.05 to 8.71)
M7 8.68 (8.38 to 8.99) 8.58 (8.30 to 8.89) 8.46 (8.17 to 8.77) 8.35 (8.03 to 8.70) 8.70 (8.39 to 9.02) 8.65 (8.35 to 8.95) 8.55 (8.26 to 8.84) 8.42 (8.12 to 8.74)
N1 8.70 (8.39 to 9.02) 8.61 (8.31 to 8.90) 8.47 (8.18 to 8.78) 8.36 (8.04 to 8.70) 8.73 (8.40 to 9.05) 8.67 (8.37 to 8.98) 8.57 (8.28 to 8.86) 8.43 (8.13 to 8.75)
N2 8.73 (8.40 to 9.06) 8.69 (8.38 to 9.01) 8.59 (8.30 to 8.89) 8.44 (8.14 to 8.76) 8.73 (8.40 to 9.06) 8.69 (8.38 to 9.01) 8.59 (8.30 to 8.89) 8.44 (8.14 to 8.76)
N3 8.62 (8.32 to 8.91) 8.54 (8.25 to 8.84) 8.43 (8.13 to 8.75) 8.34 (8.00 to 8.70) 8.64 (8.34 to 8.94) 8.59 (8.30 to 8.88) 8.50 (8.22 to 8.81) 8.39 (8.09 to 8.73)
N4 8.63 (8.34 to 8.93) 8.58 (8.28 to 8.87) 8.48 (8.19 to 8.79) 8.37 (8.06 to 8.71) 8.64 (8.34 to 8.94) 8.60 (8.31 to 8.89) 8.51 (8.22 to 8.82) 8.40 (8.09 to 8.73)
N5 8.53 (8.25 to 8.83) 8.47 (8.18 to 8.78) 8.39 (8.07 to 8.72) 8.32 (7.97 to 8.69) 8.55 (8.26 to 8.84) 8.51 (8.23 to 8.81) 8.45 (8.15 to 8.76) 8.36 (8.04 to 8.71)
N6 8.55 (8.27 to 8.84) 8.53 (8.24 to 8.82) 8.46 (8.17 to 8.77) 8.37 (8.05 to 8.71) 8.55 (8.27 to 8.84) 8.53 (8.24 to 8.82) 8.46 (8.17 to 8.77) 8.37 (8.05 to 8.71)
N7 8.70 (8.39 to 9.02) 8.61 (8.31 to 8.90) 8.47 (8.19 to 8.78) 8.36 (8.04 to 8.70) 8.73 (8.40 to 9.06) 8.67 (8.37 to 8.98) 8.57 (8.28 to 8.86) 8.43 (8.13 to 8.75)
T1 8.41 (8.11 to 8.74) a a a a a a a
T2 8.44 (8.14 to 8.75) a a a a a a a
T3 8.47 (8.16 to 8.78) a a a a a a a
T4 8.49 (8.19 to 8.80) a a a a a a a
T5 8.51 (8.22 to 8.81) 8.49 (8.20 to 8.80) 8.46 (8.17 to 8.78) 8.44 (8.14 to 8.75) 8.52 (8.23 to 8.82) 8.50 (8.22 to 8.81) 8.48 (8.19 to 8.79) 8.45 (8.15 to 8.77)
T6 8.58 (8.29 to 8.88) 8.55 (8.26 to 8.84) 8.50 (8.21 to 8.81) 8.46 (8.16 to 8.77) 8.59 (8.30 to 8.89) 8.57 (8.28 to 8.87) 8.53 (8.25 to 8.83) 8.48 (8.19 to 8.80)
T7 8.68 (8.38 to 9.00) 8.62 (8.33 to 8.93) 8.55 (8.26 to 8.84) 8.48 (8.19 to 8.79) 8.69 (8.38 to 9.02) 8.66 (8.36 to 8.97) 8.60 (8.31 to 8.91) 8.52 (8.24 to 8.82)
T8 8.52 (8.23 to 8.82) 8.51 (8.22 to 8.81) 8.49 (8.19 to 8.80) 8.45 (8.16 to 8.77) 8.52 (8.23 to 8.82) 8.51 (8.22 to 8.81) 8.49 (8.19 to 8.80) 8.45 (8.16 to 8.77)
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Strategy
Overall QALYs by substrategy, average (95% CI)
112 113 114 115 122 123 124 125
T9 8.69 (8.38 to 9.01) 8.64 (8.35 to 8.95) 8.57 (8.29 to 8.87) 8.50 (8.21 to 8.81) 8.70 (8.39 to 9.02) 8.67 (8.37 to 8.98) 8.61 (8.31 to 8.91) 8.52 (8.24 to 8.82)
P1 8.73 (8.40 to 9.06) a a a a a a a
P2 8.53 (8.25 to 8.83) a a a a a a a
P3 8.62 (8.33 to 8.92) a a a a a a a
P4 8.74 (8.41 to 9.06) a a a a a a a
P5 8.52 (8.24 to 8.82) 8.50 (8.21 to 8.80) 8.47 (8.17 to 8.78) 8.44 (8.14 to 8.75) 8.53 (8.25 to 8.83) 8.51 (8.23 to 8.81) 8.49 (8.20 to 8.80) 8.46 (8.16 to 8.77)
P6 8.61 (8.31 to 8.90) 8.57 (8.27 to 8.86) 8.51 (8.23 to 8.81) 8.46 (8.16 to 8.77) 8.62 (8.33 to 8.91) 8.59 (8.30 to 8.89) 8.55 (8.26 to 8.84) 8.49 (8.21 to 8.80)
P7 8.72 (8.40 to 9.04) 8.65 (8.36 to 8.95) 8.56 (8.29 to 8.86) 8.49 (8.20 to 8.80) 8.73 (8.40 to 9.06) 8.70 (8.38 to 9.00) 8.63 (8.33 to 8.93) 8.54 (8.25 to 8.83)
P8 8.53 (8.25 to 8.83) 8.52 (8.24 to 8.82) 8.50 (8.21 to 8.80) 8.46 (8.17 to 8.77) 8.53 (8.25 to 8.83) 8.52 (8.24 to 8.82) 8.50 (8.21 to 8.80) 8.46 (8.17 to 8.77)
P9 8.72 (8.40 to 9.05) 8.67 (8.38 to 8.98) 8.59 (8.30 to 8.89) 8.51 (8.22 to 8.81) 8.73 (8.40 to 9.06) 8.70 (8.39 to 9.01) 8.63 (8.34 to 8.94) 8.54 (8.26 to 8.83)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 54 Base case: overall QALYs by strategy – TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Overall QALYs by substrategy, average (95% CI)
212 213 214 215 222 223 224 225
M1 8.59 (8.29 to 8.89) 8.52 (8.22 to 8.82) 8.41 (8.11 to 8.74) 8.33 (7.99 to 8.69) 8.61 (8.31 to 8.90) 8.56 (8.27 to 8.86) 8.48 (8.19 to 8.79) 8.38 (8.06 to 8.72)
M2 8.61 (8.31 to 8.91) 8.58 (8.29 to 8.88) 8.50 (8.21 to 8.80) 8.39 (8.08 to 8.73) 8.61 (8.31 to 8.91) 8.58 (8.29 to 8.88) 8.50 (8.21 to 8.80) 8.39 (8.08 to 8.73)
M3 8.63 (8.33 to 8.93) 8.55 (8.26 to 8.85) 8.44 (8.14 to 8.76) 8.34 (8.01 to 8.70) 8.65 (8.35 to 8.95) 8.61 (8.31 to 8.90) 8.52 (8.23 to 8.82) 8.40 (8.09 to 8.73)
M4 8.65 (8.35 to 8.96) 8.62 (8.32 to 8.92) 8.52 (8.24 to 8.82) 8.40 (8.10 to 8.73) 8.66 (8.35 to 8.96) 8.62 (8.33 to 8.92) 8.53 (8.24 to 8.83) 8.41 (8.11 to 8.74)
M5 8.65 (8.35 to 8.95) 8.56 (8.27 to 8.86) 8.44 (8.15 to 8.76) 8.34 (8.01 to 8.70) 8.67 (8.37 to 8.98) 8.62 (8.33 to 8.92) 8.53 (8.24 to 8.82) 8.41 (8.11 to 8.73)
M6 8.67 (8.38 to 8.98) 8.64 (8.35 to 8.94) 8.55 (8.26 to 8.84) 8.42 (8.12 to 8.74) 8.67 (8.38 to 8.98) 8.64 (8.35 to 8.94) 8.55 (8.26 to 8.84) 8.42 (8.12 to 8.74)
M7 8.69 (8.38 to 9.01) 8.60 (8.31 to 8.90) 8.47 (8.18 to 8.77) 8.35 (8.03 to 8.70) 8.72 (8.40 to 9.04) 8.66 (8.37 to 8.97) 8.56 (8.27 to 8.86) 8.42 (8.13 to 8.74)
N1 a a a a a a a a
N2 a a a a a a a a
N3 8.64 (8.34 to 8.93) 8.56 (8.26 to 8.85) 8.44 (8.14 to 8.76) 8.34 (8.01 to 8.70) 8.66 (8.36 to 8.96) 8.61 (8.32 to 8.91) 8.52 (8.23 to 8.82) 8.40 (8.10 to 8.73)
N4 8.66 (8.36 to 8.96) 8.62 (8.32 to 8.92) 8.53 (8.24 to 8.82) 8.40 (8.10 to 8.73) 8.66 (8.36 to 8.96) 8.63 (8.33 to 8.93) 8.54 (8.25 to 8.83) 8.41 (8.11 to 8.74)
N5 8.65 (8.35 to 8.95) 8.57 (8.28 to 8.87) 8.45 (8.15 to 8.76) 8.35 (8.02 to 8.70) 8.68 (8.38 to 8.98) 8.63 (8.34 to 8.93) 8.53 (8.25 to 8.83) 8.41 (8.11 to 8.74)
N6 8.68 (8.38 to 8.99) 8.65 (8.35 to 8.95) 8.55 (8.26 to 8.85) 8.42 (8.12 to 8.74) 8.68 (8.38 to 8.99) 8.65 (8.35 to 8.95) 8.55 (8.26 to 8.85) 8.42 (8.12 to 8.74)
N7 8.71 (8.39 to 9.02) 8.61 (8.31 to 8.91) 8.47 (8.19 to 8.78) 8.36 (8.04 to 8.70) 8.73 (8.40 to 9.06) 8.67 (8.38 to 8.98) 8.57 (8.28 to 8.86) 8.43 (8.13 to 8.75)
T1 8.54 (8.25 to 8.83) b b b b b b b
T2 8.58 (8.29 to 8.88) b b b b b b b
T3 8.56 (8.27 to 8.85) b b b b b b b
T4 8.60 (8.31 to 8.90) b b b b b b b
T5 8.64 (8.34 to 8.94) 8.61 (8.33 to 8.91) 8.59 (8.30 to 8.88) 8.56 (8.27 to 8.86) 8.64 (8.35 to 8.94) 8.63 (8.34 to 8.93) 8.61 (8.32 to 8.91) 8.58 (8.29 to 8.88)
T6 8.61 (8.31 to 8.90) 8.59 (8.30 to 8.89) 8.57 (8.28 to 8.87) 8.55 (8.27 to 8.85) 8.61 (8.32 to 8.91) 8.60 (8.31 to 8.90) 8.59 (8.30 to 8.88) 8.57 (8.27 to 8.86)
T7 8.70 (8.39 to 9.02) 8.67 (8.37 to 8.97) 8.62 (8.33 to 8.92) 8.58 (8.29 to 8.88) 8.71 (8.40 to 9.03) 8.69 (8.38 to 9.00) 8.65 (8.36 to 8.96) 8.60 (8.31 to 8.91)
T8 8.64 (8.35 to 8.95) 8.63 (8.34 to 8.94) 8.61 (8.32 to 8.91) 8.58 (8.29 to 8.88) 8.64 (8.35 to 8.95) 8.63 (8.34 to 8.94) 8.61 (8.32 to 8.91) 8.58 (8.29 to 8.88)
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Strategy
Overall QALYs by substrategy, average (95% CI)
212 213 214 215 222 223 224 225
T9 8.71 (8.39 to 9.03) 8.69 (8.38 to 9.00) 8.64 (8.35 to 8.95) 8.60 (8.30 to 8.90) 8.71 (8.40 to 9.04) 8.70 (8.39 to 9.01) 8.66 (8.36 to 8.96) 8.61 (8.31 to 8.91)
P1 a,b b b b b b b b
P2 8.65 (8.36 to 8.96) b b b b b b b
P3 8.62 (8.33 to 8.92) b b b b b b b
P4 8.74 (8.41 to 9.06) b b b b b b b
P5 8.65 (8.35 to 8.95) 8.62 (8.34 to 8.92) 8.59 (8.30 to 8.89) 8.57 (8.28 to 8.86) 8.65 (8.36 to 8.96) 8.64 (8.35 to 8.94) 8.61 (8.33 to 8.91) 8.58 (8.29 to 8.88)
P6 8.62 (8.32 to 8.91) 8.60 (8.31 to 8.90) 8.58 (8.29 to 8.87) 8.56 (8.27 to 8.85) 8.62 (8.33 to 8.91) 8.61 (8.32 to 8.90) 8.59 (8.30 to 8.89) 8.57 (8.28 to 8.86)
P7 8.72 (8.40 to 9.05) 8.69 (8.38 to 8.99) 8.63 (8.34 to 8.93) 8.58 (8.30 to 8.88) 8.73 (8.41 to 9.06) 8.71 (8.40 to 9.02) 8.67 (8.37 to 8.98) 8.61 (8.32 to 8.91)
P8 8.65 (8.36 to 8.96) 8.64 (8.35 to 8.95) 8.62 (8.33 to 8.92) 8.59 (8.29 to 8.89) 8.65 (8.36 to 8.96) 8.64 (8.35 to 8.95) 8.62 (8.33 to 8.92) 8.59 (8.29 to 8.89)
P9 8.73 (8.40 to 9.05) 8.71 (8.39 to 9.02) 8.66 (8.36 to 8.96) 8.60 (8.31 to 8.90) 8.73 (8.41 to 9.06) 8.72 (8.40 to 9.03) 8.67 (8.38 to 8.98) 8.62 (8.33 to 8.91)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 55 Costs by strategy: TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Costs by substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
M1 4260 (3828 to 4755) 3995 (3538 to 4502) 3714 (3235 to 4291) 3497 (3007 to 4115) 4329 (3900 to 4814) 4156 (3718 to 4659) 3897 (3444 to 4439) 3627 (3156 to 4217)
M2 4351 (3926 to 4834) 4227 (3787 to 4724) 3941 (3484 to 4466) 3651 (3184 to 4239) 4351 (3926 to 4834) 4227 (3787 to 4724) 3941 (3484 to 4466) 3651 (3184 to 4239)
M3 4817 (4401 to 5258) 4430 (4015 to 4863) 3985 (3541 to 4491) 3633 (3158 to 4211) 4917 (4507 to 5359) 4672 (4261 to 5104) 4282 (3862 to 4744) 3848 (3409 to 4368)
M4 4908 (4499 to 5351) 4662 (4250 to 5088) 4212 (3786 to 4702) 3788 (3340 to 4328) 4938 (4530 to 5384) 4743 (4332 to 5171) 4326 (3909 to 4779) 3872 (3431 to 4383)
M5 4678 (4263 to 5118) 4268 (3836 to 4743) 3867 (3407 to 4403) 3571 (3090 to 4172) 4787 (4372 to 5227) 4511 (4091 to 4953) 4121 (3681 to 4619) 3747 (3286 to 4299)
M6 4824 (4411 to 5267) 4624 (4204 to 5060) 4184 (3755 to 4667) 3780 (3330 to 4332) 4824 (4411 to 5267) 4624 (4204 to 5060) 4184 (3755 to 4667) 3780 (3330 to 4332)
M7 5235 (4809 to 5728) 4703 (4292 to 5146) 4139 (3704 to 4633) 3707 (3239 to 4269) 5374 (4949 to 5879) 5027 (4609 to 5512) 4507 (4083 to 4941) 3968 (3534 to 4454)
N1 5935 (5514 to 6457) 5178 (4761 to 5640) 4421 (3976 to 4920) 3849 (3376 to 4412) 6135 (5696 to 6659) 5630 (5208 to 6129) 4906 (4479 to 5357) 4189 (3756 to 4689)
N2 6201 (5764 to 6740) 5837 (5403 to 6349) 5024 (4608 to 5489) 4252 (3813 to 4749) 6201 (5764 to 6740) 5837 (5403 to 6349) 5024 (4608 to 5489) 4252 (3813 to 4749)
N3 5093 (4684 to 5542) 4638 (4227 to 5071) 4112 (3668 to 4629) 3696 (3220 to 4264) 5210 (4785 to 5670) 4923 (4522 to 5357) 4464 (4043 to 4925) 3949 (3510 to 4475)
N4 5184 (4772 to 5639) 4870 (4462 to 5293) 4340 (3919 to 4820) 3850 (3403 to 4389) 5231 (4811 to 5694) 4995 (4591 to 5434) 4508 (4088 to 4956) 3973 (3532 to 4490)
N5 5122 (4720 to 5565) 4484 (4052 to 4949) 3962 (3502 to 4488) 3611 (3128 to 4208) 5297 (4895 to 5736) 4842 (4422 to 5277) 4270 (3826 to 4759) 3812 (3346 to 4361)
N6 5363 (4960 to 5807) 5027 (4618 to 5469) 4352 (3921 to 4842) 3850 (3405 to 4393) 5363 (4960 to 5807) 5027 (4618 to 5469) 4352 (3921 to 4842) 3850 (3405 to 4393)
N7 5955 (5536 to 6477) 5126 (4711 to 5583) 4360 (3915 to 4850) 3809 (3342 to 4360) 6177 (5755 to 6692) 5609 (5192 to 6108) 4837 (4410 to 5281) 4134 (3703 to 4630)
T1 4038 (3602 to 4537) a a a a a a a
T2 4324 (3900 to 4798) a a a a a a a
T3 4317 (3884 to 4772) a a a a a a a
T4 4603 (4174 to 5044) a a a a a a a
T5 4604 (4192 to 5036) 4451 (4040 to 4901) 4315 (3898 to 4783) 4221 (3801 to 4702) 4646 (4235 to 5077) 4539 (4122 to 4977) 4397 (3983 to 4851) 4276 (3864 to 4750)
T6 4721 (4303 to 5150) 4580 (4180 to 5007) 4394 (3995 to 4838) 4242 (3833 to 4711) 4755 (4331 to 5190) 4673 (4266 to 5099) 4523 (4127 to 4954) 4336 (3934 to 4795)
T7 5286 (4856 to 5778) 4992 (4574 to 5454) 4671 (4268 to 5108) 4424 (4027 to 4883) 5363 (4939 to 5868) 5173 (4755 to 5664) 4882 (4480 to 5327) 4574 (4176 to 5006)
T8 4661 (4254 to 5089) 4582 (4169 to 5011) 4418 (4006 to 4869) 4287 (3874 to 4754) 4661 (4254 to 5089) 4582 (4169 to 5011) 4418 (4006 to 4869) 4287 (3874 to 4754)
T9 5343 (4916 to 5844) 5124 (4709 to 5594) 4774 (4365 to 5211) 4490 (4096 to 4933) 5378 (4952 to 5879) 5217 (4799 to 5707) 4903 (4497 to 5351) 4585 (4187 to 5014)
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Strategy
Costs by substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
P1 6035 (5596 to 6572) a a a a a a a
P2 5118 (4715 to 5547) a a a a a a a
P3 5073 (4668 to 5531) a a a a a a a
P4 6153 (5728 to 6688) a a a a a a a
P5 5058 (4650 to 5489) 4681 (4257 to 5117) 4421 (4006 to 4896) 4267 (3846 to 4748) 5164 (4761 to 5598) 4883 (4472 to 5308) 4561 (4148 to 5017) 4352 (3936 to 4822)
P6 5046 (4643 to 5491) 4819 (4418 to 5246) 4539 (4133 to 4985) 4313 (3902 to 4786) 5102 (4693 to 5545) 4965 (4567 to 5395) 4731 (4329 to 5163) 4451 (4056 to 4904)
P7 6065 (5647 to 6581) 5462 (5049 to 5930) 4921 (4515 to 5358) 4541 (4139 to 4988) 6227 (5804 to 6751) 5810 (5398 to 6325) 5254 (4854 to 5713) 4764 (4364 to 5185)
P8 5207 (4807 to 5636) 4997 (4585 to 5428) 4601 (4185 to 5046) 4368 (3951 to 4835) 5207 (4807 to 5636) 4997 (4585 to 5428) 4601 (4185 to 5046) 4368 (3951 to 4835)
P9 6230 (5814 to 6749) 5809 (5404 to 6299) 5113 (4719 to 5570) 4643 (4245 to 5084) 6277 (5858 to 6808) 5936 (5528 to 6448) 5297 (4902 to 5763) 4780 (4380 to 5205)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 56 Costs by strategy: TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Costs by substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
M1 4706 (4282 to 5165) 4347 (3918 to 4807) 3934 (3482 to 4458) 3608 (3137 to 4191) 4798 (4370 to 5265) 4571 (4144 to 5042) 4209 (3776 to 4690) 3807 (3367 to 4337)
M2 4825 (4395 to 5300) 4665 (4249 to 5119) 4274 (3836 to 4744) 3844 (3400 to 4370) 4825 (4395 to 5300) 4665 (4249 to 5119) 4274 (3836 to 4744) 3844 (3400 to 4370)
M3 4878 (4469 to 5324) 4478 (4071 to 4914) 4015 (3572 to 4519) 3648 (3180 to 4218) 4981 (4562 to 5451) 4729 (4321 to 5173) 4325 (3915 to 4774) 3872 (3438 to 4380)
M4 4997 (4582 to 5460) 4796 (4382 to 5248) 4355 (3939 to 4804) 3884 (3448 to 4395) 5008 (4590 to 5473) 4823 (4404 to 5275) 4390 (3979 to 4833) 3909 (3477 to 4415)
M5 5056 (4649 to 5515) 4566 (4148 to 5003) 4054 (3622 to 4554) 3665 (3202 to 4238) 5185 (4769 to 5658) 4863 (4449 to 5319) 4386 (3966 to 4834) 3900 (3465 to 4403)
M6 5226 (4811 to 5698) 4995 (4589 to 5451) 4466 (4051 to 4906) 3943 (3511 to 4439) 5226 (4811 to 5698) 4995 (4589 to 5451) 4466 (4051 to 4906) 3943 (3511 to 4439)
M7 5228 (4823 to 5732) 4698 (4291 to 5139) 4135 (3713 to 4623) 3705 (3242 to 4261) 5367 (4947 to 5876) 5021 (4612 to 5496) 4502 (4094 to 4937) 3965 (3539 to 4455)
N1 a a a a a a a a
N2 a a a a a a a a
N3 4978 (4568 to 5438) 4547 (4142 to 4983) 4055 (3615 to 4554) 3667 (3196 to 4232) 5089 (4664 to 5565) 4817 (4409 to 5266) 4384 (3975 to 4829) 3903 (3466 to 4410)
N4 5097 (4681 to 5572) 4865 (4454 to 5317) 4395 (3981 to 4840) 3903 (3463 to 4411) 5115 (4697 to 5596) 4910 (4487 to 5365) 4449 (4036 to 4886) 3939 (3508 to 4442)
N5 5469 (5062 to 5944) 4757 (4339 to 5202) 4133 (3697 to 4637) 3697 (3238 to 4267) 5661 (5251 to 6132) 5165 (4745 to 5626) 4513 (4104 to 4960) 3952 (3514 to 4457)
N6 5732 (5326 to 6204) 5368 (4960 to 5826) 4611 (4197 to 5055) 3999 (3567 to 4497) 5732 (5326 to 6204) 5368 (4960 to 5826) 4611 (4197 to 5055) 3999 (3567 to 4497)
N7 5742 (5326 to 6247) 4958 (4552 to 5408) 4255 (3821 to 4730) 3756 (3291 to 4304) 5952 (5522 to 6464) 5410 (5002 to 5889) 4688 (4276 to 5114) 4047 (3615 to 4534)
T1 4423 (4016 to 4852) b b b b b b b
T2 4762 (4351 to 5196) b b b b b b b
T3 4548 (4142 to 4967) b b b b b b b
T4 4888 (4485 to 5306) b b b b b b b
T5 4989 (4585 to 5435) 4835 (4428 to 5275) 4699 (4289 to 5132) 4605 (4197 to 5045) 5030 (4625 to 5479) 4923 (4519 to 5370) 4782 (4374 to 5220) 4661 (4259 to 5097)
T6 4716 (4310 to 5149) 4652 (4249 to 5081) 4574 (4180 to 5003) 4511 (4117 to 4939) 4732 (4327 to 5166) 4693 (4289 to 5127) 4628 (4226 to 5057) 4550 (4156 to 4982)
T7 5282 (4866 to 5787) 5064 (4656 to 5544) 4851 (4446 to 5296) 4694 (4290 to 5131) 5339 (4918 to 5846) 5194 (4780 to 5682) 4987 (4578 to 5455) 4787 (4387 to 5214)
T8 5045 (4638 to 5495) 4967 (4565 to 5413) 4803 (4394 to 5240) 4671 (4268 to 5108) 5045 (4638 to 5495) 4967 (4565 to 5413) 4803 (4394 to 5240) 4671 (4268 to 5108)
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Strategy
Costs by substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
T9 5339 (4920 to 5843) 5196 (4788 to 5691) 4954 (4550 to 5417) 4760 (4358 to 5192) 5354 (4936 to 5866) 5237 (4827 to 5734) 5008 (4601 to 5478) 4798 (4400 to 5227)
P1 a,b b b b b b b b
P2 5502 (5095 to 5962) b b b b b b b
P3 4888 (4489 to 5334) b b b b b b b
P4 5968 (5550 to 6490) b b b b b b b
P5 5442 (5039 to 5900) 5066 (4649 to 5507) 4805 (4382 to 5244) 4651 (4247 to 5092) 5548 (5151 to 6011) 5268 (4853 to 5718) 4946 (4531 to 5388) 4736 (4331 to 5181)
P6 4874 (4475 to 5316) 4759 (4362 to 5193) 4637 (4241 to 5059) 4540 (4145 to 4967) 4903 (4504 to 5345) 4830 (4429 to 5273) 4719 (4322 to 5150) 4597 (4200 to 5024)
P7 5894 (5479 to 6409) 5402 (4982 to 5899) 5019 (4614 to 5470) 4769 (4363 to 5203) 6028 (5612 to 6555) 5675 (5266 to 6207) 5242 (4837 to 5708) 4910 (4512 to 5343)
P8 5591 (5187 to 6053) 5381 (4975 to 5832) 4986 (4566 to 5428) 4753 (4345 to 5192) 5591 (5187 to 6053) 5381 (4975 to 5832) 4986 (4566 to 5428) 4753 (4345 to 5192)
P9 6058 (5651 to 6575) 5750 (5338 to 6261) 5211 (4807 to 5671) 4871 (4469 to 5306) 6077 (5666 to 6599) 5801 (5391 to 6320) 5285 (4877 to 5758) 4926 (4529 to 5358)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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Appendix 4 Modelling approach for long-term
outcomes
The following figures show the digitised curves for all-cause death (Figure 48) and death attributable toprostate cancer (Figure 49) from PIVOT8 for the men allocated to watchful waiting.
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FIGURE 48 Digitised curves for all-cause death for men allocated to watchful waiting in PIVOT (Wilt et al., 2012).8
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FIGURE 49 Digitised curves for death attributable to prostate cancer for men allocated to watchful waiting in
PIVOT (Wilt et al., 2012).8
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Parametric models were fitted to these data in order to extrapolate the probability of survival being the
follow-up of PIVOT. Broadly, two options were examined:
1. parametric model for all-cause death using either Weibull or exponential regression
2. parametric model for death attributable to prostate cancer using Weibull, exponential or linear
regression, in addition to all-cause death from the UK general population.
Figures 50–52 show the performance of the two approaches. Using a parametric model for all-cause death
has better face validity than using death attributable to prostate cancer added to all-cause death from the
general population. The decrease in probability close to year 35 is because the models assume a probability
of death of 1 after the age of 100 years. The Weibull curve has a better fit and statistical goodness of fit
(not shown) over the three subgroups and, therefore, it was selected.
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FIGURE 50 Curve fitting for men with low-risk cancer allocated to watchful waiting in PIVOT (Wilt et al., 2012).8
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FIGURE 51 Curve fitting for men with intermediate-risk cancer allocated to watchful waiting in PIVOT (Wilt et al., 2012).8
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Figures 53–55 show the modelled life expectancy obtained by combining the hazard rate for death
predicted by the Weibull model and the hazard rate for death of the general population. These estimates
are used in the calibration model in step 2 (above) to obtain transition probabilities.
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FIGURE 52 Curve fitting for men with high-risk cancer allocated to watchful waiting in PIVOT (Wilt et al., 2012).8
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FIGURE 53 Life expectancy for men with low-risk cancer allocated to watchful waiting in PIVOT (Wilt et al., 2012)8
predicted with step 1 (above).
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FIGURE 54 Life expectancy for men with intermediate-risk cancer allocated to watchful waiting in PIVOT (Wilt et al.,
2012)8 predicted with step 1 (above).
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FIGURE 55 Life expectancy for men with high-risk cancer allocated to watchful waiting in PIVOT (Wilt et al., 2012)8
predicted with step 1 (above).
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Appendix 5 Transectal ultrasound-guided biopsy
There were concerns that TRUS-guided biopsy may be associated with a small risk of death as a result ofsepsis, which is not included in the base-case model. Therefore, the Loeb et al.23 systematic review on the
complications of prostate biopsy was examined for studies on the risk of death from TRUS-guided biopsy.
Loeb et al.23 identified 10 studies on the risk of death following TRUS-guided biopsy: Loeb et al.149 (2011),
Nam et al.,150 Carmignani et al.,151 Simsir et al.,152 Loeb et al.153 (2012), Hasegawa et al.,154 Kumagai
et al.,155 Gallina et al.,156 Carlsson et al.157 and Wu et al.158 Of these, Hasegawa et al.154 and Kumagai et al.155
are individual case reports of a death following transrectal biopsy in Japan and are reported in Japanese;
hence, they were not examined further. It was not possible to obtain the full text of Wu et al.,158 although
Loeb et al.23 reported that no deaths had occurred in this study. It was also not possible to obtain the full
text of Simsir et al.,152 a retrospective cohort study set in Turkey. The remaining six studies have been
reviewed in detail and are summarised in Table 57. One study found that biopsied men had an increased
risk of death compared with non-biopsied men.156 However, this study has limitations in that a limited range
of variables were available to make the biopsied group and control group more comparable; specifically, a
measure of comorbidities was not available for the control group.
TABLE 57 Summary of studies examining the risk of death from TRUS-guided biopsy
Study Methods Results Comments
Carlsson et al.157 (BJU
Int 2011;107:1912–7)
(various northern
European countries)
Death associated with
prostate biopsy among
participants of the European
Randomized Study of
Screening for Prostate Cancer.
Compared cohort of screen-
positive men (biopsied) with
cohort of screen-negative
men (no biopsy)
l n= 12,959 biopsied men
l n= 37,235 controls
l No statistically significant
difference in cumulative
120-day other-cause
mortality between the two
groups of men: 0.24%
(95% CI 0.17% to 0.34%)
for screening-positive men
compared with 0.24%
(95% CI 0.20% to 0.30%)
for screening-negative
men (p= 0.96)
l Only 14/31 (45%) of the
screening-positive men
who died within 120 days
were biopsied and none
died as an obvious
complication of the biopsy
No evidence that prostate
biopsy is associated with
increased risk of death
Carmignani et al.151
(Int Urol Nephrol
2012;44:1055–63)
(Italy)
Monitoring of major septic
complications after biopsy at
3 days, 7 days and 1 month
after transrectal biopsy
l n= 463
l Three cases of septic shock
l No deaths
No deaths occurred
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TABLE 57 Summary of studies examining the risk of death from TRUS-guided biopsy (continued )
Study Methods Results Comments
Gallina et al.156
(Int J Cancer
2008;123:647–52)
(Canada)
120-day death rate after
prostate biopsy and in a
convenience sample of
participants who did not
undergo biopsy
l Deaths:
¢ 279/22,175 biopsied
men (1.3%)
¢ 6/1778 controls (0.3%)
l Death rate in individuals
aged ≤ 85 years (maximum
age in control group):
1.1% in the cohort of men
exposed to prostate biopsy
compared with 0.3% in
the control group
(p < 0.0018)
l Biopsied men had an
increased risk of death
compared with controls
l Limitations: data not
available to match
samples or adjust for
comorbidities; samples
not comparable in age
Loeb et al.149
(2011) (J Urol
2011;186:1830–4)
(USA)
30-day hospitalisation rates
and primary diagnosis for
hospital admissions between
men who underwent biopsy
and random sample of
controls. Adjusted for
predictors of serious infections
and non-infectious
complications
l Deaths within 30 days:
¢ 55/17,475 biopsied
men (0.31%)
¢ 1474/134,977 controls
(1.03%)
l Adjusted OR 0.29 (95% CI
0.22 to 0.38); biopsied
men at reduced risk
of death
l Biopsied men had a
reduced risk of death
l Limitations: very small
number of deaths
among biopsied men
l May be affected
by unobserved
confounding by health
status (healthier men
may be more likely to
have a biopsy)
Loeb et al.153
(2012) (Eur Urol
2012;61:1110–4)
(the Netherlands)
Complications following
prostate biopsy reported in
the European Randomized
Study of Screening for
Prostate Cancer (Rotterdam
section)
l n= 9241
l Two men required
admission to the intensive
care unit
l No deaths
No deaths occurred
Nam et al.150 J Urol
2013;189(Suppl 1):
S12–17 (Canada)
30-day hospital admission and
mortality attributable to
urological complications
l n= 75,190 biopsied men
l Deaths within 30 days:
¢ 64/75,190 biopsied
men (0.09%)
l Only presents death
rates following biopsy
l Limitations: no control
group; hence, unclear
whether or not death is
caused by TRUS-guided
biopsy
l Presents unadjusted
mortality rates
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Appendix 6 Scenario analysis using the payment-
by-results tariff
Whereas the NHS reference costs reflect the average current cost across all health-care providers, thePbR tariff reflects the charge to primary care commissioners, who refer men to secondary care for
testing. The reference costs are used to set prices, such as the PbR tariff, for services. Given that the
perspective of the analysis is the NHS, the unit costs should be obtained from the NHS reference costs.
However, these may not reflect the costs to commissioners, who make the referral decision. Therefore,
sensitivity analysis is presented using PbR tariff unit costs.
Unit costs of tests
The costs used are shown in Table 58. The PbR tariff does not provide a cost for ‘LB76Z Transrectal
ultrasound guided biopsy of the prostate’, used in the base case for TRUS-guided biopsy; hence, the
Healthcare Resource Group code ‘LB27Z prostate or bladder neck minor endoscopic procedure male’ for an
outpatient appointment is used instead, with a cost of £339. This is similar to the approach taken for the
2014 NICE clinical guideline,13 although it used NHS reference costs and added the cost of histopathology.
Using this approach, the NHS reference cost for TRUS-guided biopsy would be £342 (£223 for the LB27Z
code for an outpatient appointment + £119 for histopathology). Similarly, the PbR tariff does not provide
the cost for ‘LB77Z Transperineal template biopsy of prostate’. The 2014 NICE clinical guideline used the
LB27Z code for a day case. Using NHS reference costs, the TPM-biopsy cost would be £830 (£533 for the
LB27Z code for a day case + £297 for histopathology). The PbR tariff does include the cost for LB27Z as an
ordinary elective spell at £931; therefore, this is used to represent the tariff for TPM-biopsy. The unit cost
for mpMRI is obtained from the code ‘RD03Z MRI scan of one area with pre- and post-contrast’, at £188
including reporting. The cost of a hospitalisation is the average tariff for a non-elective admission of £3173.
The cost of an A&E visit is the average tariff for type 1 and type 2 departments of £134. An outpatient
appointment is the cost of the code ‘WF02A first attendance single professional medical oncology’, at £91.
TABLE 58 Unit costs used for the PbR tariff scenario
Parameter Value (£) Source
Diagnostic tests
TRUS-guided biopsy 339.00 ‘LB27Z prostate or bladder neck minor endoscopic procedure male as
outpatient’110
TPM-biopsy 931.00 ‘LB27Z prostate or bladder neck minor endoscopic procedure male as
elective admission’110
mpMRI T2 DW DCE 188.00 ‘RD03Z MRI scan of one area with pre- and post-contrast’110
Management of AEs from testing
A&E admission 134.00 Average cost of admission in type 1 and type 2 departments110
Hospital admission 3173.00 Average cost of non-elective admission
Urology department nurse 91.00 ‘WF02A First attendance single professional Medical oncology’110
Other costs, common to both scenarios
GP 44.00 Equivalent to a GP appointment, with an average duration of 11.7 minutes112
Other health-care advice 7.90 Cost of nurse-led telephone triage112
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Results
Costs of testing using the payment-by-results tariff
Tables 59 and 60 show the costs of testing using the PbR tariff, presenting the average and 95% CI for
each substrategy. The costs of testing using the PbR tariff are similar to those using NHS reference costs
for the strategies involving mpMRI and TRUS-guided biopsy. The unit costs are similar, at £182 (NHS
reference cost) compared with £188 (PbR tariff) for mpMRI and £403 (NHS reference costs) compared with
£339 (PbR tariff) for TRUS-guided biopsy. There is a bigger difference, of up to £398, in the cost of
strategies involving TPM-biopsy. This is mainly because the NHS reference cost for TPM-biopsy is £1370,
£439 more than the PbR tariff. The costs of adverse effects from testing are smaller using NHS reference
costs than using the PbR tariff; however, the differences are small.
Diagnostic efficiency
Figure 56 shows the relationship between the proportion of CS cancers detected and the average cost
of testing using the PbR tariff. Table 61 shows the strategies forming the frontier in tabulated format.
There are small differences compared with using NHS reference costs in that some other strategies now
appear at the frontier. T1 2 —, in which all men receive TRUS-guided biopsy and no further testing at
the TRUS-guided biopsy definition 2; T7 222, and P1 —, in which all men receive TPM-biopsy and no
further testing.
The frontier is defined by 12 strategies at different definitions and cut-off points. The strategies in the
frontier in which all men receive mpMRI as the first test are:
l M1 – men whose mpMRI scan is suspicious of CS cancer receive a TRUS-guided biopsy. This strategy
is in the frontier at the TRUS-guided biopsy definition 2, mpMRI definition 1 and cut-off point 5.
l M3 – men whose mpMRI scan is suspicious of CS cancer receive a TRUS-guided biopsy; men in whom
CNS cancer was detected receive a second TRUS-guided biopsy to rule out CS cancer. This strategy
is in the frontier at the TRUS-guided biopsy definition 2, mpMRI definition 1 and 2 and cut-off
point 5.
l M4 – men whose mpMRI scan is suspicious of any cancer receive TRUS-guided biopsy; men in whom
the mpMRI showed suspected CS cancer but the TRUS-guided biopsy detected CNS cancer receive a
second TRUS-guided biopsy. This strategy is in the frontier at the TRUS-guided biopsy definition 2,
mpMRI definition 2 and cut-off point 5.
l M7 – men whose mpMRI scan is suspicious of CS cancer receive TRUS-guided biopsy; men in whom no
CS cancer was detected receive a second biopsy. This strategy is in the frontier at the TRUS-guided
biopsy definition 2, mpMRI definition 2 and cut-off points 2 and 5.
The strategies in the frontier in which all men receive a TRUS-guided biopsy as the first test are:
l T1 – all men receive TRUS-guided biopsy and no other tests. This strategy is in the frontier under
TRUS-guided biopsy definition 2.
l T6 – all men receive TRUS-guided biopsy; men in whom TRUS-guided biopsy detects CNS cancer have
mpMRI; men in whom the mpMRI scan is suspicious of CS cancer receive a second biopsy. This strategy
is in the frontier under TRUS-guided biopsy definition 2, mpMRI definition 2 and cut-off points 2 and 3.
l T7 – all men receive TRUS-guided biopsy; men in whom TRUS-guided biopsy does not detect CS cancer
have mpMRI; men in whom the mpMRI scan is suspicious of CS cancer receive a second biopsy. This
strategy is in the frontier under TRUS-guided biopsy definition 2, mpMRI definition 2 and cut-off points
2 and 3.
l P1 – all men receive TPM-biopsy and no other tests.
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TABLE 59 Costs of testing using the PbR tariff by strategy: TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Cost of testing per substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
M1 524 (505 to 545) 399 (381 to 418) 307 (291 to 323) 246 (235 to 258) 558 (539 to 581) 467 (446 to 489) 359 (342 to 377) 279 (265 to 294)
M2 572 (553 to 596) 504 (484 to 526) 373 (356 to 393) 285 (271 to 300) 572 (553 to 596) 504 (484 to 526) 373 (356 to 393) 285 (271 to 300)
M3 605 (576 to 636) 459 (433 to 486) 343 (322 to 366) 264 (248 to 280) 645 (617 to 676) 540 (513 to 571) 411 (387 to 436) 308 (289 to 328)
M4 654 (627 to 684) 564 (539 to 592) 410 (387 to 435) 303 (286 to 320) 659 (631 to 690) 578 (550 to 608) 426 (402 to 452) 314 (295 to 334)
M5 684 (650 to 719) 472 (446 to 502) 337 (317 to 357) 258 (244 to 273) 743 (708 to 781) 584 (551 to 618) 407 (385 to 433) 299 (282 to 316)
M6 769 (734 to 807) 649 (616 to 685) 428 (404 to 455) 307 (290 to 325) 769 (734 to 807) 649 (616 to 685) 428 (404 to 455) 307 (290 to 325)
M7 765 (726 to 807) 532 (501 to 566) 373 (348 to 399) 276 (258 to 294) 830 (789 to 872) 657 (619 to 697) 460 (431 to 491) 328 (306 to 350)
N1 1059 (1021 to 1100) 735 (693 to 782) 496 (458 to 536) 338 (309 to 369) 1149 (1118 to 1184) 912 (873 to 960) 631 (589 to 678) 425 (390 to 461)
N2 1185 (1159 to 1221) 1008 (970 to 1051) 668 (626 to 717) 440 (405 to 477) 1185 (1159 to 1221) 1008 (970 to 1051) 668 (626 to 717) 440 (405 to 477)
N3 735 (690 to 780) 555 (517 to 595) 402 (371 to 434) 292 (271 to 316) 783 (737 to 829) 657 (615 to 701) 495 (457 to 534) 354 (326 to 384)
N4 783 (741 to 826) 660 (625 to 699) 468 (437 to 502) 332 (308 to 355) 797 (753 to 844) 695 (654 to 738) 509 (473 to 548) 360 (333 to 389)
N5 939 (888 to 991) 590 (550 to 633) 385 (357 to 416) 277 (259 to 298) 1038 (987 to 1089) 770 (722 to 823) 485 (452 to 521) 330 (308 to 353)
N6 1082 (1030 to 1132) 879 (827 to 929) 516 (479 to 557) 341 (318 to 365) 1082 (1030 to 1132) 879 (827 to 929) 516 (479 to 557) 341 (318 to 365)
N7 1150 (1089 to 1210) 746 (694 to 800) 480 (439 to 523) 324 (297 to 353) 1263 (1201 to 1319) 960 (900 to 1022) 621 (574 to 670) 405 (370 to 441)
T1 386 (366 to 409) a a a a a a a
T2 582 (549 to 620) a a a a a a a
T3 493 (467 to 525) a a a a a a a
T4 689 (653 to 733) a a a a a a a
T5 642 (605 to 682) 558 (529 to 590) 514 (490 to 543) 495 (474 to 521) 666 (628 to 707) 601 (567 to 637) 534 (507 to 562) 504 (481 to 531)
T6 536 (505 to 568) 508 (481 to 539) 480 (455 to 507) 458 (436 to 484) 542 (512 to 577) 525 (496 to 557) 499 (472 to 529) 471 (448 to 497)
T7 792 (753 to 834) 681 (649 to 715) 609 (582 to 638) 568 (544 to 594) 823 (782 to 868) 740 (701 to 779) 647 (617 to 680) 589 (564 to 617)
T8 677 (638 to 720) 627 (593 to 664) 540 (513 to 570) 506 (483 to 534) 677 (638 to 720) 627 (593 to 664) 540 (513 to 570) 506 (483 to 534)
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TABLE 59 Costs of testing using the PbR tariff by strategy: TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5 (continued )
Strategy
Cost of testing per substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
T9 827 (788 to 872) 750 (713 to 789) 635 (605 to 666) 579 (555 to 606) 834 (794 to 879) 766 (729 to 807) 653 (622 to 687) 591 (566 to 619)
P1 1001 (974 to 1036) a a a a a a a
P2 895 (845 to 943) a a a a a a a
P3 664 (621 to 705) a a a a a a a
P4 1174 (1130 to 1220) a a a a a a a
P5 899 (845 to 947) 681 (642 to 722) 567 (539 to 600) 518 (494 to 545) 962 (906 to 1012) 791 (743 to 837) 617 (583 to 651) 540 (515 to 569)
P6 691 (645 to 736) 620 (582 to 659) 547 (514 to 580) 490 (465 to 517) 709 (661 to 755) 663 (619 to 706) 595 (559 to 632) 523 (494 to 554)
P7 1204 (1154 to 1255) 915 (871 to 962) 728 (693 to 767) 622 (595 to 651) 1285 (1235 to 1335) 1068 (1018 to 1120) 827 (788 to 870) 678 (646 to 713)
P8 990 (932 to 1043) 860 (811 to 908) 634 (598 to 669) 545 (519 to 574) 990 (932 to 1043) 860 (811 to 908) 634 (598 to 669) 545 (519 to 574)
P9 1306 (1257 to 1355) 1117 (1071 to 1166) 804 (766 to 844) 651 (622 to 684) 1317 (1269 to 1366) 1146 (1098 to 1197) 847 (807 to 891) 683 (650 to 719)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 60 Costs of testing using the PbR tariff by strategy: TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Cost of testing per substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
M1 524 (505 to 545) 399 (381 to 418) 307 (291 to 323) 246 (235 to 258) 558 (539 to 581) 467 (446 to 489) 359 (342 to 377) 279 (265 to 294)
M2 572 (553 to 596) 504 (484 to 526) 373 (356 to 393) 285 (271 to 300) 572 (553 to 596) 504 (484 to 526) 373 (356 to 393) 285 (271 to 300)
M3 555 (531 to 581) 419 (399 to 442) 319 (301 to 337) 251 (239 to 265) 592 (567 to 619) 494 (471 to 519) 376 (356 to 397) 288 (273 to 304)
M4 603 (580 to 630) 525 (503 to 549) 385 (366 to 406) 291 (276 to 306) 606 (581 to 634) 531 (507 to 556) 390 (371 to 413) 294 (279 to 310)
M5 675 (640 to 711) 465 (439 to 495) 332 (313 to 353) 256 (242 to 270) 734 (697 to 772) 575 (542 to 610) 401 (378 to 426) 295 (279 to 313)
M6 759 (723 to 798) 640 (607 to 677) 422 (398 to 449) 303 (286 to 321) 759 (723 to 798) 640 (607 to 677) 422 (398 to 449) 303 (286 to 321)
M7 706 (664 to 747) 486 (455 to 518) 344 (323 to 368) 261 (246 to 278) 768 (725 to 808) 602 (565 to 641) 418 (392 to 446) 304 (285 to 324)
N1 a a a a a a a a
N2 a a a a a a a a
N3 605 (570 to 642) 452 (424 to 482) 337 (316 to 360) 260 (245 to 276) 646 (609 to 683) 536 (503 to 571) 404 (378 to 432) 302 (282 to 322)
N4 653 (618 to 689) 558 (528 to 589) 404 (381 to 429) 299 (282 to 317) 660 (623 to 698) 573 (539 to 608) 418 (392 to 447) 308 (289 to 328)
N5 916 (860 to 974) 571 (528 to 617) 373 (345 to 405) 271 (253 to 291) 1014 (958 to 1067) 748 (694 to 803) 469 (432 to 507) 321 (298 to 345)
N6 1058 (1003 to 1112) 856 (801 to 913) 499 (462 to 542) 331 (308 to 356) 1058 (1003 to 1112) 856 (801 to 913) 499 (462 to 542) 331 (308 to 356)
N7 997 (929 to 1062) 625 (569 to 682) 404 (369 to 443) 285 (263 to 308) 1102 (1031 to 1166) 817 (752 to 883) 514 (468 to 561) 344 (314 to 374)
T1 386 (366 to 409) b b b b b b b
T2 582 (549 to 620) b b b b b b b
T3 442 (418 to 469) b b b b b b b
T4 638 (603 to 680) b b b b b b b
T5 642 (605 to 682) 558 (529 to 590) 514 (490 to 543) 495 (474 to 521) 666 (628 to 707) 601 (567 to 637) 534 (507 to 562) 504 (481 to 531)
T6 463 (437 to 491) 446 (422 to 472) 432 (410 to 456) 421 (401 to 445) 467 (441 to 497) 456 (431 to 483) 440 (418 to 466) 427 (406 to 451)
T7 720 (681 to 761) 618 (588 to 653) 560 (534 to 589) 531 (508 to 558) 748 (708 to 791) 670 (634 to 710) 588 (560 to 619) 545 (521 to 573)
T8 677 (638 to 720) 627 (593 to 664) 540 (513 to 570) 506 (483 to 534) 677 (638 to 720) 627 (593 to 664) 540 (513 to 570) 506 (483 to 534)
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TABLE 60 Costs of testing using the PbR tariff by strategy: TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5 (continued )
Strategy
Cost of testing per substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
T9 755 (714 to 797) 687 (651 to 727) 586 (558 to 616) 542 (518 to 570) 759 (718 to 801) 697 (659 to 738) 595 (566 to 627) 547 (523 to 576)
P1 a,b b b b b b b b
P2 895 (845 to 943) b b b b b b b
P3 532 (496 to 569) b b b b b b b
P4 1042 (991 to 1089) b b b b b b b
P5 899 (845 to 947) 681 (642 to 722) 567 (539 to 600) 518 (494 to 545) 962 (906 to 1012) 791 (743 to 837) 617 (583 to 651) 540 (515 to 569)
P6 542 (505 to 581) 497 (467 to 529) 461 (435 to 488) 435 (412 to 459) 554 (514 to 595) 523 (489 to 558) 484 (455 to 513) 448 (424 to 474)
P7 1056 (1001 to 1106) 793 (750 to 837) 642 (609 to 681) 567 (541 to 595) 1130 (1075 to 1183) 928 (876 to 980) 715 (676 to 756) 603 (574 to 638)
P8 990 (932 to 1043) 860 (811 to 908) 634 (598 to 669) 545 (519 to 574) 990 (932 to 1043) 860 (811 to 908) 634 (598 to 669) 545 (519 to 574)
P9 1158 (1103 to 1210) 994 (943 to 1043) 718 (680 to 757) 595 (568 to 628) 1162 (1106 to 1213) 1006 (955 to 1056) 735 (695 to 777) 608 (579 to 642)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
A
P
P
E
N
D
IX
6
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
6
4
0.0
0
250
500
750
1000
1250
1500
0.2 0.4
C
o
st
 o
f 
te
st
in
g
 p
e
r 
m
a
n
 r
e
fe
rr
e
d
 (
£
)
0.6
Proportion of CS cancers detected
0.8 1.0
M1 215 M3 215
M3 225
M4 225
M7 225
T1 2—
T6 223
T6 222
T7 223
T7 222
M7 222
P1—
FIGURE 56 Efficiency plane using the PbR tariff for unit costs.
TABLE 61 Diagnostic strategies in the efficiency frontier using the PbR tariff
Strategy
Definition
mpMRI
cut-off
point
Detection of
CS cancers,
average
(95% CI)
Cost of
testing,
average
(95% CI) (£)
TRUS-guided
biopsy mpMRI
M1: mpMRI for all men and TRUS-guided biopsy
in men suspicious of CS cancer
2 1 5 0.22
(0.17 to 0.27)
246
(235 to 258)
M3: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; men with
CNS cancer on the first biopsy receive a second
TRUS-guided biopsy
2 1 5 0.24
(0.20 to 0.29)
251
(239 to 265)
2 2 5 0.35
(0.30 to 0.41)
288
(273 to 304)
M4: mpMRI for all men and TRUS-guided in
men with suspicion of any cancer; men with
suspected CS cancer at mpMRI and in whom
CNS cancer was detected on the first biopsy
receive a second TRUS-guided biopsy
2 2 5 0.37
(0.32 to 0.43)
294
(279 to 310)
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS
cancer was not detected
2 2 5 0.40
(0.35 to 0.46)
304
(285 to 324)
T1: TRUS-guided biopsy in all men and no
further testing
2 N/A N/A 0.61
(0.56 to 0.66)
386
(366 to 409)
T6: TRUS-guided biopsy for all men; men
classified as CNS cancer receive MRI; men with
suspected CS cancer receive a second
TRUS-guided biopsy
2 2 3 0.74
(0.69 to 0.78)
456
(431 to 483)
2 2 2 0.75
(0.71 to 0.79)
467
(441 to 497)
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Lifetime costs
Figure 57 shows the lifetime costs using a diagnostic strategy that uses the PbR tariff for the unit costs;
95% CIs are not shown to improve readability. Tables 62 and 63 show the results in tabulated format,
including 95% CIs. The costs vary between £3500 and close to £6000 per man referred for testing.
The substrategy with the lowest cost is M1 115, at £3499 (95% CI £3008 to £4113), which is also the
substrategy that achieves the fewest health benefits. The substrategy with the greatest costs is P9 122,
at £5950 (95% CI £5521 to £6478).
TABLE 61 Diagnostic strategies in the efficiency frontier using the PbR tariff (continued )
Strategy
Definition
mpMRI
cut-off
point
Detection of
CS cancers,
average
(95% CI)
Cost of
testing,
average
(95% CI) (£)
TRUS-guided
biopsy mpMRI
T7: TRUS-guided biopsy for all men; men
classified as NC or CNS cancer receive mpMRI;
men with suspected CS cancer receive a second
TRUS-guided biopsy
2 2 3 0.91
(0.86 to 0.94)
670
(634 to 710)
2 2 2 0.95
(0.90 to 0.98)
748
(708 to 791)
M7: mpMRI for all men and TRUS-guided biopsy
in men with suspected CS cancer; rebiopsy with
TRUS-guided biopsy for those in whom CS
cancer was not detected
2 2 2 0.95
(0.92 to 0.98)
768
(725 to 808)
P1: TPM-biopsy in all men N/A N/A N/A 1.00
(1.00 to 1.00)
1001
(974 to 1036)
N/A, not applicable; NC, no cancer.
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FIGURE 57 Scenario results: costs of each diagnostic strategy using the PbR tariff.
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TABLE 62 Scenario using the PbR tariff: overall costs by strategy – TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Lifetime costs per substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
M1 4240 (3800 to 4743) 3985 (3535 to 4502) 3711 (3234 to 4285) 3499 (3008 to 4113) 4307 (3877 to 4794) 4141 (3698 to 4648) 3890 (3436 to 4433) 3626 (3156 to 4218)
M2 4328 (3897 to 4811) 4209 (3771 to 4713) 3933 (3478 to 4464) 3650 (3183 to 4240) 4328 (3897 to 4811) 4209 (3771 to 4713) 3933 (3478 to 4464) 3650 (3183 to 4240)
M3 4791 (4383 to 5229) 4415 (4003 to 4845) 3979 (3536 to 4489) 3633 (3157 to 4210) 4887 (4482 to 5341) 4651 (4240 to 5085) 4271 (3851 to 4735) 3844 (3404 to 4366)
M4 4878 (4473 to 5323) 4639 (4231 to 5072) 4201 (3778 to 4690) 3785 (3333 to 4327) 4908 (4502 to 5360) 4719 (4304 to 5152) 4314 (3886 to 4765) 3868 (3429 to 4383)
M5 4646 (4237 to 5082) 4252 (3822 to 4723) 3862 (3400 to 4393) 3572 (3089 to 4173) 4751 (4340 to 5184) 4486 (4062 to 4931) 4111 (3677 to 4607) 3745 (3284 to 4300)
M6 4785 (4373 to 5223) 4595 (4173 to 5029) 4172 (3738 to 4652) 3777 (3331 to 4331) 4785 (4373 to 5223) 4595 (4173 to 5029) 4172 (3738 to 4652) 3777 (3331 to 4331)
M7 5197 (4768 to 5692) 4682 (4275 to 5125) 4130 (3695 to 4632) 3706 (3240 to 4264) 5331 (4908 to 5834) 4997 (4578 to 5474) 4492 (4073 to 4928) 3963 (3530 to 4451)
N1 5595 (5173 to 6117) 4967 (4551 to 5431) 4305 (3864 to 4800) 3795 (3322 to 4350) 5759 (5325 to 6289) 5348 (4927 to 5845) 4736 (4317 to 5175) 4101 (3671 to 4593)
N2 5811 (5373 to 6350) 5517 (5085 to 6017) 4840 (4425 to 5292) 4158 (3723 to 4656) 5811 (5373 to 6350) 5517 (5085 to 6017) 4840 (4425 to 5292) 4158 (3723 to 4656)
N3 4989 (4579 to 5440) 4565 (4159 to 4989) 4071 (3629 to 4587) 3679 (3204 to 4250) 5097 (4688 to 5566) 4832 (4434 to 5267) 4403 (3981 to 4859) 3918 (3483 to 4437)
N4 5076 (4668 to 5537) 4789 (4390 to 5218) 4293 (3872 to 4773) 3830 (3385 to 4370) 5118 (4711 to 5585) 4900 (4495 to 5342) 4446 (4021 to 4889) 3942 (3505 to 4458)
N5 4937 (4532 to 5374) 4398 (3966 to 4864) 3928 (3467 to 4450) 3600 (3119 to 4199) 5083 (4686 to 5510) 4706 (4288 to 5136) 4213 (3771 to 4705) 3791 (3330 to 4341)
N6 5137 (4739 to 5568) 4860 (4445 to 5297) 4286 (3852 to 4774) 3826 (3385 to 4371) 5137 (4739 to 5568) 4860 (4445 to 5297) 4286 (3852 to 4774) 3826 (3385 to 4371)
N7 5686 (5271 to 6200) 4978 (4571 to 5436) 4288 (3850 to 4770) 3780 (3313 to 4331) 5874 (5455 to 6401) 5397 (4981 to 5895) 4726 (4318 to 5170) 4082 (3658 to 4574)
T1 4009 (3566 to 4509) a a a a a a a
T2 4279 (3851 to 4752) a a a a a a a
T3 4279 (3837 to 4742) a a a a a a a
T4 4550 (4123 to 5002) a a a a a a a
T5 4565 (4157 to 4997) 4418 (4002 to 4863) 4286 (3867 to 4747) 4193 (3777 to 4672) 4605 (4195 to 5035) 4503 (4095 to 4940) 4367 (3950 to 4824) 4248 (3830 to 4714)
T6 4685 (4277 to 5115) 4547 (4146 to 4972) 4363 (3955 to 4815) 4213 (3803 to 4693) 4719 (4309 to 5156) 4638 (4237 to 5067) 4490 (4096 to 4922) 4306 (3902 to 4767)
T7 5242 (4818 to 5735) 4956 (4552 to 5414) 4640 (4233 to 5081) 4397 (3995 to 4855) 5316 (4886 to 5819) 5132 (4719 to 5619) 4848 (4447 to 5294) 4545 (4144 to 4978)
T8 4619 (4209 to 5048) 4545 (4133 to 4973) 4387 (3967 to 4838) 4258 (3837 to 4720) 4619 (4209 to 5048) 4545 (4133 to 4973) 4387 (3967 to 4838) 4258 (3837 to 4720)
T9 5296 (4865 to 5793) 5082 (4671 to 5543) 4742 (4331 to 5186) 4462 (4061 to 4907) 5330 (4899 to 5833) 5174 (4755 to 5664) 4869 (4464 to 5318) 4555 (4155 to 4988)
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TABLE 62 Scenario using the PbR tariff: overall costs by strategy – TRUS-guided biopsy definition 1, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5 (continued )
Strategy
Lifetime costs per substrategy, average (95% CI) (£)
112 113 114 115 122 123 124 125
P1 5637 (5197 to 6175) a a a a a a a
P2 4886 (4485 to 5306) a a a a a a a
P3 4933 (4527 to 5380) a a a a a a a
P4 5810 (5382 to 6352) a a a a a a a
P5 4866 (4457 to 5301) 4575 (4166 to 5014) 4360 (3938 to 4826) 4226 (3805 to 4703) 4946 (4546 to 5372) 4734 (4320 to 5157) 4481 (4068 to 4925) 4302 (3887 to 4770)
P6 4917 (4511 to 5362) 4719 (4317 to 5147) 4468 (4058 to 4910) 4264 (3854 to 4740) 4967 (4549 to 5409) 4848 (4446 to 5285) 4641 (4246 to 5075) 4389 (3991 to 4841)
P7 5774 (5360 to 6290) 5285 (4879 to 5759) 4819 (4418 to 5260) 4481 (4076 to 4940) 5904 (5485 to 6442) 5573 (5159 to 6082) 5113 (4710 to 5570) 4682 (4290 to 5107)
P8 4978 (4578 to 5400) 4820 (4423 to 5246) 4514 (4102 to 4951) 4316 (3900 to 4777) 4978 (4578 to 5400) 4820 (4423 to 5246) 4514 (4102 to 4951) 4316 (3900 to 4777)
P9 5898 (5480 to 6427) 5553 (5140 to 6038) 4981 (4587 to 5432) 4572 (4170 to 5015) 5940 (5521 to 6478) 5668 (5253 to 6169) 5148 (4749 to 5609) 4696 (4304 to 5123)
a These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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TABLE 63 Scenario using the PbR tariff: overall costs by strategy – TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5
Strategy
Lifetime costs per substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
M1 4686 (4259 to 5148) 4337 (3902 to 4799) 3931 (3477 to 4461) 3610 (3140 to 4192) 4776 (4346 to 5242) 4556 (4124 to 5028) 4202 (3770 to 4685) 3806 (3367 to 4335)
M2 4802 (4366 to 5274) 4646 (4228 to 5113) 4266 (3829 to 4734) 3842 (3399 to 4367) 4802 (4366 to 5274) 4646 (4228 to 5113) 4266 (3829 to 4734) 3842 (3399 to 4367)
M3 4856 (4450 to 5297) 4466 (4057 to 4901) 4011 (3569 to 4517) 3649 (3183 to 4219) 4956 (4545 to 5420) 4712 (4304 to 5155) 4317 (3907 to 4766) 3870 (3436 to 4377)
M4 4971 (4558 to 5439) 4776 (4366 to 5230) 4346 (3929 to 4791) 3882 (3443 to 4396) 4981 (4571 to 5449) 4802 (4394 to 5258) 4380 (3967 to 4820) 3907 (3472 to 4415)
M5 5024 (4620 to 5483) 4551 (4133 to 4991) 4049 (3612 to 4545) 3666 (3203 to 4238) 5149 (4726 to 5622) 4839 (4421 to 5295) 4375 (3957 to 4820) 3897 (3462 to 4398)
M6 5188 (4763 to 5665) 4966 (4563 to 5423) 4454 (4042 to 4894) 3940 (3508 to 4438) 5188 (4763 to 5665) 4966 (4563 to 5423) 4454 (4042 to 4894) 3940 (3508 to 4438)
M7 5194 (4793 to 5695) 4680 (4278 to 5124) 4129 (3710 to 4620) 3706 (3240 to 4260) 5328 (4904 to 5848) 4994 (4583 to 5475) 4490 (4075 to 4920) 3962 (3537 to 4455)
N1 a a a a a a a a
N2 a a a a a a a a
N3 4926 (4516 to 5385) 4515 (4112 to 4950) 4040 (3602 to 4542) 3663 (3191 to 4230) 5031 (4618 to 5504) 4773 (4369 to 5223) 4358 (3948 to 4806) 3893 (3456 to 4400)
N4 5041 (4632 to 5522) 4825 (4425 to 5280) 4375 (3961 to 4817) 3896 (3459 to 4408) 5056 (4647 to 5537) 4863 (4459 to 5318) 4422 (4010 to 4859) 3929 (3500 to 4433)
N5 5293 (4884 to 5768) 4678 (4262 to 5118) 4103 (3671 to 4597) 3688 (3226 to 4260) 5457 (5043 to 5935) 5037 (4623 to 5499) 4462 (4046 to 4900) 3934 (3502 to 4432)
N6 5515 (5096 to 5983) 5209 (4802 to 5660) 4552 (4139 to 4990) 3980 (3550 to 4470) 5515 (5096 to 5983) 5209 (4802 to 5660) 4552 (4139 to 4990) 3980 (3550 to 4470)
N7 5532 (5127 to 6041) 4857 (4458 to 5310) 4212 (3784 to 4686) 3742 (3279 to 4296) 5712 (5304 to 6237) 5254 (4849 to 5740) 4618 (4209 to 5046) 4020 (3601 to 4518)
T1 4393 (3983 to 4826) b b b b b b b
T2 4718 (4311 to 5159) b b b b b b b
T3 4514 (4108 to 4942) b b b b b b b
T4 4839 (4439 to 5273) b b b b b b b
T5 4950 (4549 to 5398) 4802 (4392 to 5253) 4670 (4262 to 5103) 4577 (4170 to 5019) 4990 (4581 to 5440) 4887 (4482 to 5334) 4751 (4340 to 5192) 4632 (4225 to 5073)
T6 4683 (4278 to 5118) 4621 (4227 to 5057) 4544 (4140 to 4981) 4482 (4076 to 4916) 4699 (4298 to 5134) 4661 (4262 to 5099) 4597 (4203 to 5032) 4520 (4117 to 4952)
T7 5240 (4821 to 5748) 5030 (4619 to 5509) 4821 (4409 to 5275) 4666 (4261 to 5105) 5295 (4873 to 5806) 5155 (4740 to 5655) 4955 (4547 to 5429) 4759 (4357 to 5200)
T8 5004 (4595 to 5457) 4929 (4524 to 5373) 4772 (4358 to 5212) 4643 (4233 to 5080) 5004 (4595 to 5457) 4929 (4524 to 5373) 4772 (4358 to 5212) 4643 (4233 to 5080)
T9 5294 (4876 to 5811) 5157 (4747 to 5650) 4923 (4519 to 5382) 4731 (4325 to 5169) 5309 (4888 to 5827) 5197 (4782 to 5696) 4975 (4569 to 5450) 4769 (4369 to 5212)
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TABLE 63 Scenario using the PbR tariff: overall costs by strategy – TRUS-guided biopsy definition 2, mpMRI definitions 1 and 2 and mpMRI cut-off points 2–5 (continued )
Strategy
Lifetime costs per substrategy, average (95% CI) (£)
212 213 214 215 222 223 224 225
P1 a,b b b b b b b b
P2 5270 (4854 to 5730) b b b b b b b
P3 4801 (4398 to 5246) b b b b b b b
P4 5678 (5260 to 6208) b b b b b b b
P5 5250 (4842 to 5698) 4960 (4540 to 5407) 4744 (4325 to 5190) 4611 (4200 to 5052) 5331 (4920 to 5790) 5118 (4712 to 5581) 4865 (4454 to 5315) 4686 (4279 to 5130)
P6 4794 (4390 to 5235) 4697 (4302 to 5132) 4589 (4184 to 5022) 4503 (4095 to 4942) 4818 (4414 to 5263) 4758 (4360 to 5199) 4662 (4269 to 5098) 4554 (4156 to 4977)
P7 5651 (5238 to 6181) 5264 (4856 to 5764) 4940 (4542 to 5388) 4720 (4311 to 5152) 5756 (5340 to 6293) 5483 (5067 to 5999) 5134 (4727 to 5601) 4847 (4446 to 5287)
P8 5363 (4943 to 5821) 5204 (4800 to 5655) 4898 (4483 to 5350) 4701 (4293 to 5142) 5363 (4943 to 5821) 5204 (4800 to 5655) 4898 (4483 to 5350) 4701 (4293 to 5142)
P9 5775 (5359 to 6300) 5531 (5116 to 6047) 5102 (4690 to 5559) 4811 (4410 to 5253) 5792 (5378 to 6319) 5578 (5161 to 6098) 5170 (4761 to 5643) 4861 (4462 to 5301)
a These strategies do not include TRUS-guided biopsy and, therefore, the results do not vary by TRUS-guided biopsy definition.
b These strategies do not include mpMRI and, therefore, the results do not vary by mpMRI definition and cut-off point.
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Cost-effectiveness using payment-by-results tariff
Figure 58 shows the cost-effectiveness plane for the scenario using the PbR tariff as the source of unit
costs for the tests and related complications. Table 64 shows the results in tabulated format for the
strategies in the cost-effectiveness frontier. The strategies in the cost-effectiveness frontier are similar to
those in the cost-effectiveness frontier in the base case. Four strategies forming the frontier start with
mpMRI: M1, M3, M4 and M7; five strategies start with biopsy: T1, T6, T7, P4 and P1. The cost-effective
strategy depends on the value of health opportunity cost. At £13,000 per QALY, the cost-effective
substrategy is M7 222. On average, M7 222 achieves the highest net health at 8.307 QALYs. At £20,000
and £30,000 per QALY gained, the cost-effective strategy is P4 2––. However, the difference between
P4 2–– and P1, the next best strategy, is small at 0.001 QALYs.
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FIGURE 58 Cost-effectiveness plane for the scenario using the PbR tariff.
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TABLE 64 Diagnostic strategies in the cost-effectiveness frontier using the PbR tariff
Strategy
Definition
mpMRI
cut-off
point
QALYs,
average
(95% CI)
Costs, average
(95% CI) (£) ICER (£)
Net health at
TRUS-guided
biopsy mpMRI
£13,000
per QALY
£20,000
per QALY
£30,000
per QALY
M1: mpMRI for all men and TRUS-guided
biopsy in men suspicious of CS cancer
1 1 5 8.29
(7.94 to 8.68)
3499
(3008 to 4113)
8.023 8.118 8.176
2 1 5 8.33
(7.99 to 8.69)
3610
(3140 to 4192)
3081 8.051 8.148 8.208
M3: mpMRI for all men and TRUS-guided
biopsy in men with suspected CS cancer;
men with CNS cancer on the first biopsy
receive a second TRUS-guided biopsy
2 1 5 8.34
(8.01 to 8.70)
3649
(3183 to 4219)
3588 8.059 8.157 8.218
M4: mpMRI for all men and TRUS-guided
in men with suspicion of any cancer; men
with suspected CS cancer at mpMRI and in
whom CNS cancer was detected on the first
biopsy receive a second TRUS-guided biopsy
2 2 5 8.41
(8.11 to 8.74)
3907
(3472 to 4415)
3691 8.109 8.214 8.279
T1: TRUS-guided biopsy in all men and no
further testing
2 N/A N/A 8.54
(8.25 to 8.83)
4393
(3983 to 4826)
3793 8.200 8.318 8.391
T6: TRUS-guided biopsy for all men; men
classified as CNS cancer receive MRI; men
with suspected CS cancer receive a second
TRUS-guided biopsy
2 2 3 8.60
(8.31 to 8.90)
4661
(4262 to 5099)
4184 8.243 8.369 8.446
2 2 2 8.61
(8.32 to 8.91)
4699
(4298 to 5134)
4524 8.249 8.375 8.453
T7: TRUS-guided biopsy for all men; men
classified as NC or CNS cancer receive
mpMRI; men with suspected CS cancer
receive a second TRUS-guided biopsy
2 2 3 8.69
(8.38 to 9.00)
5155
(4740 to 5655)
5539 8.296 8.435 8.521
2 2 2 8.71
(8.40 to 9.03)
5295
(4873 to 5806)
6954 8.305 8.448 8.536
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Threshold sensitivity analysis
Table 65 shows the results of the sensitivity analysis for the scenario using PbR tariff costs for the unit cost
of tests and resource use associated with testing. In summary:
l A relative sensitivity of < 1.15 for MRI-targeted TRUS-guided biopsy (‘W’biopsy) changes the cost-
effective strategy at the health opportunity cost of £13,000 per QALY gained from M7 222 to T7 222.
A relative sensitivity of > 1.30 (sensitivity > 0.80) changes the cost-effective strategy at £20,000 per
QALY gained from P4 2–– to M7 222. Changes of > 1.43 (sensitivity > 0.88) change the cost-effective
strategy at £30,000 from P4 2–– to M7 222. The implication is that the cost-effectiveness of M7 222 is
improved if the sensitivity of MRI-targeted TRUS-guided biopsy is improved.
l Increasing the sensitivity of MRI-targeted second TRUS-guided biopsy in men with a prior negative
biopsy (‘Z’ biopsy) to 0.90 changes the cost-effective substrategy at £20,000 per QALY gained from
P4 2— to M7 222. Increasing it further to 0.91 changes the cost-effective substrategy at £13,000 per
QALY from M7 222 to T7 222. Further increases change the cost-effective substrategy to T9 222. In
T9, all men receive TRUS-guided biopsy; men in whom the biopsy did not detect CS cancer receive
mpMRI. Men in whom the first TRUS-guided biopsy had not detected cancer but the mpMRI indicates
that cancer is present receive a second TRUS-guided biopsy. Men in whom the first TRUS-guided biopsy
had detected CNS cancer but the mpMRI indicates CS cancer receive a second TRUS-guided biopsy.
l A lower proportion of intermediate-risk cancer changes the cost-effective strategy to P1—, depending
on the cost-effectiveness thresholds. A proportion between 0.35 and 0.43 changes the cost-effective
strategy to M7 222 at £20,000 per QALY gained.
l Increasing the proportion of men with no cancer to 0.41 and 0.53 changes the cost-effective strategy
at £20,000 per QALY gained to P1 and M7 222, respectively. At £30,000 per QALY gained, the
cost-effective strategy changes to P1.
l There are no changes in the cost-effective strategy for risk of death between 0.0001% and 0.005%,
that is, between 1 and 50 in 1,000,000 men who have a biopsy die from biopsy-related complications.
A risk of death from biopsy of 0.01% (i.e. 100 in 1,000,000 men who have a biopsy die from biopsy-
related complications) changes the cost-effective strategy at £20,000 from P4 2–– to P1. Increasing the
risk further to 0.05% (i.e. 500 in 1,000,000 men die) changes the cost-effective strategy at £30,000
from P4 2–– to P1. From a risk of 0.05% to 0.5% (i.e. 500 to 5000 in 1,000,000 men die), the cost-
effective strategy across the range of values of health opportunity cost is P1. A risk of 2% (i.e. 20,000
in 1,000,000 men die) changes the cost-effective strategy at £13,000 per QALY to N1 123; in this
strategy, all men receive mpMRI and men in whom the mpMRI scan is suspicious of CS cancer receive
TPM-biopsy.
l Changes in the cost-effective strategy at £13,000 per QALY gained occur when the health loss
from the incorrect classification is ≥ 0.02 QALYs. Reductions of < 0.2 QALYs do not change the
cost-effective strategy at £20,000 and £30,000 per QALY gained.
l The cost-effective strategy changes to less-costly and less-sensitive strategies if the clinical effectiveness
of RP is reduced.
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TABLE 65 Results of the sensitivity analysis using the PbR tariff
Analysis
Cost-effective substrategy at the health opportunity cost of
£13,000 per QALY £20,000 per QALY £30,000 per QALY
Base case M7 222 P4 2–– P4 2––
SA1: changes in relative sensitivity of MRI-targeted TRUS-guided biopsy (‘W’) in detecting CS cancer; sensitivity in base
case = 1.2
1–1.15 T7 222 P4 2–– P4 2––
1.16–1.25 M7 222 P4 2–– P4 2––
1.30–1.42 M7 222 M7 222 P4 2––
1.43–1.50 M7 222 M7 222 M7 222
SA2: changes in the sensitivity of MRI-targeted second TRUS-guided biopsy (‘Z’) in detecting CS cancer; sensitivity in base
case = 0.87
0.90 M7 222 M7 222 P4 2––
0.91 T7 222 M7 222 P4 2––
0.92–0.93 T7 222 T9 222 P4 2––
0.94–1.00 T9 222 T9 222 T9 222
SA3: prevalence of intermediate-risk vs. low-risk cancer; base case = 0.53
0.49–0.52 M7 222 P1 — P4 2––
0.44–0.48 M7 222 P1 — P1 —
0.35–0.43 M7 222 M7 222 P1 —
SA4: probability of NC; base case = 0.28
0.30–0.33 M7 222 P1 — P4 2––
0.34–0.41 M7 222 P1 — P1 —
0.42–0.53 M7 222 M7 222 P1 —
SA5: risk of death from biopsy
0.01% M7 222 P1 — P4 2––
0.05% M7 222 P1 — P1 —
0.5% P1 — P1 — P1 —
2% N1 123 P1 — P1 —
SA6: reduced quality-adjusted survival from incorrect classification as NC
QALY reduction 0.02–0.06 P1 — P4 2–– P4 2––
SA7: reduced effectiveness of RP
5% M7 222 M7 222 P4 2––
10% T7 222 M7 222 M7 222
15% M1 215 T7 223 M7 222
20–30% M1 115 M1 115 T6 222
NC, no cancer; SA, sensitivity analysis.
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